Melanin concentrating hormone receptor antagonist

ABSTRACT

Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula I 
                         
wherein A, W, X, Z, R 1 -R 3 , and R 8  are as defined in the specification, are provided. Also provided are methods of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of Formula I.

BACKGROUND OF THE INVENTION

In 1999, 61% of adults, 13% of children aged 6 to 11 years and 14% ofadolescents aged 12 to 19 years in the United States were overweight.Increases in occurrence of overweight and obesity has been seen in allage, racial and ethnic groups, and in both men and women.

Epidemiological studies show an increase in mortality associated withoverweight and obesity. Individuals who are obese (body mass index(“BMI”)>30) have a 50-100% increased risk of premature death from allcauses compared to individuals with a BMI in the range of 20 to 25. BMIis calculated according to the formula:

${BMI} = {\frac{{Weight}\mspace{14mu}{in}\mspace{14mu}{pounds}}{\left( {{Height}\mspace{14mu}{in}\mspace{14mu}{inches}} \right)^{2}} \times 703}$

An estimated 300,000 deaths a year in the United States may beattributable to obesity. Overweight and obesity are associated with anincreased risk for coronary heart disease; type 2 diabetes; endometrial,colon, postmenopausal breast, and other cancers; and certainmusculoskeletal disorders, such as knee osteoarthritis.

Both modest and large weight gains are associated with significantlyincreased risk of disease. For example, a weight gain of 11 to 18 poundsincreases a person's risk of developing type 2 diabetes to twice that ofindividuals who have not gained weight, while those who gain 44 poundsor more have four times the risk of type 2 diabetes. A gain ofapproximately 10 to 20 pounds results in an increased risk of coronaryheart disease (nonfatal myocardial infarction and death) of 1.25 timesin women and 1.6 times in men. Higher levels of body weight gain of 22pounds in men and 44 pounds in women result in an increased coronaryheart disease risk of 1.75 and 2.65, respectively. In women with a BMIof 34 or greater, the risk of developing endometrial cancer is increasedby more than six times. Overweight and obesity are also known toexacerbate many chronic conditions such as hypertension and elevatedcholesterol. Overweight and obese individuals also may suffer fromsocial stigmatization, discrimination, and poor body image. Althoughobesity-associated morbidities occur most frequently in adults,important consequences of excess weight as well as antecedents of adultdisease occur in overweight children and adolescents. Overweightchildren and adolescents are more likely to become overweight or obeseadults; this concern is greatest among adolescents. Type 2 diabetes,high blood lipids, and hypertension as well as early maturation andorthopedic problems also occur with increased frequency in overweightyouth. A common consequence of childhood overweight ispsychosocial-specifically discrimination. See The Surgeon General's CallTo Action To Prevent and Decrease Overweight and Obesity, U.S. Dept. ofHealth and Human Services, 2001. Thus, the need exists for methods ofcontrolling weight and treating obesity.

Melanin-concentrating hormone (MCH) is a cyclic, 19-amino acidhypothalamic neuropeptide derived from a larger pro-hormone precursor ofMCH, Pmch. Pmch-deficient mice are lean, hypophagic, and have anincreased metabolic rate. Transgenic mice over-expressing Pmch arehyperphagic and develop mild obesity. Consequently, MCH has beenimplicated in the regulation of energy homeostasis, through actions onmotor activity, metabolism, food intake and neuroendocrine function.

Two receptors have been identified in MCH, and are designated MCH 1receptor and MCH 2 receptor. The MCH 1 and MCH 2 receptors are Gprotein-coupled receptors (GPCRs) believed to be responsible for theactions of MCH. G proteins are heterotrimeric proteins that controlcellular responses to stimuli by cycling between a GTP-bound activestate, which regulates the activity of a number of effector proteins,and a GDP-bound inactive state. GPCRs accelerate activation of the Gprotein by increasing the GDP/GTP exchange rate.

MCH 1 receptor-deficient mice have normal body weights, yet are lean andhave reduced fat mass. Surprisingly, MCH 1 receptor-deficient mice arehyperphagic when maintained on regular chow, and their leanness is aconsequence of hyperactivity and altered metabolism. Consistent with thehyperactivity, MCH 1 receptor-deficient mice are less susceptible todiet-induced obesity. Importantly, chronic central infusions of MCHinduce hyperphagia and mild obesity in wild-type mice, but not in MCH 1receptor-deficient mice. Marsh et al., Proc. Nat. Acad. Sci., 99(5),3241 (2002).

Because MCH has been shown to be an important regulator of food intakeand energy balance, compounds capable of modulating the activity of MCHreceptors, particularly MCH 1 receptors, are highly desirable for thetreatment of eating disorders and metabolic disorders.

PCT Publication No. WO 02/04433 describes phenylcycloalkylmethylaminoand phenylalkenylamino derivatives as modulators of MCH 1 receptorsuseful in the treatment of certain metabolic, feeding and sexualdisorders.

U.S. Pat. No. 6,472,394 describes the use of amide derivatives of1,4-disubstituted piperidine as MCH antagonists for the treatment ofobesity and diabetes.

SUMMARY OF THE INVENTION

Among the several objects of certain embodiments of the presentinvention, therefore, may be noted the provision of melaninconcentrating hormone receptor antagonists; the provision ofpharmaceutical compositions comprising melanin concentrating hormonereceptor antagonists; the provision of methods of treating, preventing,or otherwise ameliorating melanin concentrating hormone-mediateddisorders in a subject; the provision of methods for treating,preventing or otherwise ameliorating obesity in a subject; and theprovision of methods of achieving sustained body weight loss in asubject.

Briefly therefore, the present invention is directed to a melaninconcentrating hormone receptor antagonist of Formula I as definedherein.

The present invention is also directed to pharmaceutical compositionscomprising a compound of Formula I, as defined herein, and apharmaceutically acceptable carrier, adjuvant, or diluent.

The present invention is also directed to a method of inhibiting a GPCR,comprising contacting a compound of Formula I, as defined herein, with aGPCR, wherein the compound of Formula I is present at a concentrationsufficient to inhibit the binding of a GPCR ligand in vitro. This methodincludes inhibiting a GPCR in vivo, e.g., in a subject given an amountof a compound of Formula I that would be sufficient to inhibit thebinding of a ligand to the GCPR in vitro. Examples of GPCRs which may beinhibited according to the present invention include, but are notlimited to the following GPCR families: Acetylcholine muscarinic,Adenosine, adrenergic, adrenergic, alpha-adrenergic, angiotensin, AR,Cannabinoid, DA, dopamine, His, imidazoline, Leukotriene, mAch, MCH,Opioid, serotonergic, serotonin, and Somatostatin.

Inhibition of the binding of a GPCR ligand to GPCRs is useful in thetreatment of numerous disorders, including digestive tract disorders;mucolytic asthma; arrhythmia; ischemia; reperfusion injury; bronchospasmassociated with asthma, emphysema and chronic bronchitis; acute andchronic respiratory diseases, including cystic fibrosis;cardiostimulant; chronic bronchitis; neurological depression; heartfailure; benign prostate hypertrophy; diabetes; muscle spasm; myocardialinfarction; stroke; Alzheimer's disease; anorexia; cachexia; multiplesclerosis; hyperprolactinemia; psychotropism; mydriasis in ocularexamination and surgery; deficitary and productive schizophrenia,psychasthenia and non-endogenous depression; kidney disease;vasodilation; chronic gastritis; glaucoma; depression; rhinitis,including allergic rhinitis; pain, including cancer pain,musculoskeletal pain, post-operative pain; eye disease; dyspepsia;cough; ulcer, including gastrointestinal, gastric and esophageal ulcers;helicobacter pylori prophylaxis infection; oesophagitis; allergies,including non-asthma allergies; cold; asthma; conjuctivitis; urticaria;diarrhea; Creutzfeldt-Jakob disease; dysmenorrhoea; drug addiction anddrug overdose; septic shock treatment; cerebral ischaemia; drugposoning; head trauma; inflammation; pruritus; tardive dyskinesia;emesis; anxiety; motility dysfunction; cluster headaches; hypertension;cancer; irritable bowel syndrome; hemotherapy-induced nausea andvomiting; thrombosis; dementia; opiate-induced nausea and vomiting;bipolar depression; migraine; sleep disorders; traumatic shock;gastritis; gastro-oesophageal reflux; psychosis; Parkinson disease;Dependence treatment; Pre-eclampsia; Raynaud's disease; Vasospasm;haemostasis; nausea and vomiting; spasms; post-operative nausea andvomiting; alcoholism, alcohol addiction; bulimia; nicotine addiction;obsessive-compulsive disorder; panic disorder; post-traumatic stressdisorder; premenstrual syndrome; and dermatitis, including allergicdermatitis.

The present invention is also directed to methods of inhibiting thebinding of MCH to MCH receptors comprising contacting a compound ofFormula I with cells expressing MCH receptors, wherein the compound ispresent at a concentration sufficient to inhibit MCH binding to MCHreceptors in vitro. This method includes inhibiting the binding of MCHto MCH receptors in vivo, e.g., in a subject given an amount of acompound of Formula I that would be sufficient to inhibit the binding ofMCH to the MCH receptors in vitro. The amount of a compound of Formula Ithat would be sufficient to inhibit the binding of MCH to the MCHreceptor in vitro may be readily determined via a MCH receptor bindingassay, such as the assay described hereinbelow in Example 7.

The present invention is also directed to methods for altering thesignal-transducing activity of MCH receptors, particularly the MCHreceptor-mediated release of intracellular calcium, said methodcomprising exposing cells expressing such receptors to an effectiveamount of a compound of the invention. This method includes altering thesignal-transducing activity of MCH receptors in vivo, e.g., in a subjectgiven an amount of a compound of Formula I that would be sufficient toalter the signal-transducing activity of MCH receptors in vitro. Theamount of a compound that would be sufficient to alter thesignal-transducing activity of MCH receptors may be determined via a MCHreceptor signal transduction assay, such as the calcium mobilizationassay described hereinbelow in Example 6.

The present invention is also directed to methods of using compounds ofFormula I and appropriately labeled derivatives thereof as standards andreagents in determining the ability of a potential pharmaceutical tobind to MCH receptor.

The present invention is also directed to methods of treating,preventing, or otherwise ameliorating melanin concentratinghormone-mediated disorders in a subject, the method comprisingadministering a compound of Formula I or a pharmaceutical compositioncomprising a compound of Formula I and a pharmaceutically-acceptablecarrier, adjuvant, or diluent to said subject.

The present invention is also directed to methods of treating orpreventing obesity in a subject, the method comprising administering acompound of Formula I or a pharmaceutical composition comprising acompound of Formula I and a pharmaceutically-acceptable carrier,adjuvant, or diluent to said subject.

The present invention is also directed to methods of treating orpreventing conditions such as feeding disorders, including obesity,bulimia and bulimia nervosa; sexual or reproductive disorders;depression and anxiety; epileptic seizure; hypertension; cerebralhemorrhage; congestive heart failure; sleep disturbances; or anycondition in which antagonism of an MCH receptor is beneficial.

The present invention is also directed to methods of treating eatingdisorders, particularly obesity and bulimia nervosa, comprisingadministering to a subject in need of such treatment a compound ofFormula I in combination with leptin, a leptin receptor agonist, or amelanocortin receptor 4 (MC4) agonist.

The present invention is also directed to methods of using compounds ofFormula I as positive controls in assays for activity of GPCRs,particularly MCH.

The present invention is also directed to methods of using appropriatelylabeled compounds of Formula I as probes for the localization of GPCRs,particularly MCH, in tissue sections.

Other objects and features will be in part apparent and in part pointedout hereinafter.

Abbreviations and Definitions

The term “alkyl”, where used alone or within other terms such as“haloalkyl”, “alkylsulfonyl”, “alkoxyalkyl” and “hydroxyalkyl”, is alinear or branched radical having one to twenty carbon atoms or,preferably, one to twelve carbon atoms. More preferred alkyl radicalsare “lower alkyl” radicals having one to ten carbon atoms. Mostpreferred are lower alkyl radicals having one to six carbon atoms.Examples of such radicals include methyl, ethyl, propyl (e.g., n-propyland isopropyl), butyl (e.g., n-butyl, isobutyl, sec-butyl, andtert-butyl), pentyl (e.g., n-pentyl and iso-amyl), hexyl, and the like.

The term “cycloalkyl” is a saturated carbocyclic radical having three totwelve carbon atoms. The cycloalkyl radical may be mono-, bi-, ortricyclic. More preferred cycloalkyl radicals are “lower cycloalkyl”radicals having three to eight carbon atoms. Examples of such radicalsinclude cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term “alkenyl” is a linear or branched radical having at least onecarbon-carbon double bond and having two to twenty carbon atoms or,preferably, two to twelve carbon atoms. More preferred alkyl radicalsare “lower alkenyl” radicals having two to six carbon atoms. Examples ofalkenyl radicals include ethenyl, propenyl, allyl, butenyl and4-methylbutenyl. The terms “alkenyl” and “lower alkenyl” also areradicals having “cis” and “trans” orientations, or alternatively, “E”and “Z” orientations.

The term “cycloalkenyl” is a partially unsaturated carbocyclic radicalhaving three to twelve carbon atoms. The cycloalkenyl radicals may bemono-, bi-, or tricyclic. More preferred cycloalkenyl radicals are“lower cycloalkenyl” radicals having four to eight carbon atoms.Examples of such radicals include cyclobutenyl, cyclopentenyl,cyclopentadienyl, and cyclohexenyl.

The term “alkynyl” is a linear or branched radical having at least onecarbon-carbon triple bond and having two to twenty carbon atoms or,preferably, two to twelve carbon atoms. More preferred alkynyl radicalsare “lower alkynyl” radicals having two to ten carbon atoms. Mostpreferred are lower alkynyl radicals having two to six carbon atoms.Examples of such radicals include propargyl, butynyl, and the like.

The terms “carboxy” or “carboxyl”, whether used alone or with otherterms, such as “carboxyalkyl”, is —CO₂H.

The term “carboxyalkyl” is an alkyl radical as defined above substitutedwith a carboxy radical. More preferred are “lower carboxyalkyl”radicals, which are lower alkyl radicals as defined above substitutedwith a carboxy radical, and may be additionally substituted on the alkylradical with halo. Examples of such lower carboxyalkyl radicals includecarboxymethyl, carboxyethyl and carboxypropyl.

The term “halo” is a halogen such as fluorine, chlorine, bromine oriodine.

The term “haloalkyl” is an alkyl radical as defined above wherein anyone or more of the carbon atoms is substituted with halo as definedabove. Specifically included are monohaloalkyl, dihaloalkyl andpolyhaloalkyl radicals. A monohaloalkyl radical, for one example, mayhave either an iodo, bromo, chloro or fluoro atom within the radical.Dihalo and polyhaloalkyl radicals may have two or more of the same haloatoms or a combination of different halo radicals. More preferredhaloalkyl radicals are “lower haloalkyl” having one to six carbon atoms.Examples of lower haloalkyl radicals include fluoromethyl,difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl,difluorochloromethyl, dichlorofluoromethyl, difluoroethyl,difluoropropyl, dichloroethyl and dichloropropyl.

The terms “alkoxy” and “alkyloxy” are linear or branched oxy-containingradicals each having alkyl portions of one to ten carbon atoms. Morepreferred alkoxy radicals are “lower alkoxy” radicals having one to sixcarbon atoms. Examples of such radicals include methoxy, ethoxy,propoxy, butoxy and tert-butoxy. The “alkoxy” radicals may be furthersubstituted with one or more halo atoms, such as fluoro, chloro orbromo, to provide haloalkoxy radicals. More preferred haloalkoxyradicals are “lower haloalkoxy” radicals having one to six carbon atomsand one or more halo radicals. Examples of such radicals includefluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy,fluoroethoxy and fluoropropoxy.

The term “alkoxyalkyl” is an alkyl radical having one or more alkoxyradicals attached to the alkyl radical, that is, to form monoalkoxyalkyland polyalkoxyalkyl radicals. More preferred alkoxyalkyl radicals are“lower alkoxyalkyl” radicals having two to twelve carbon atoms. Examplesof such radicals include methoxymethyl, methoxyethyl, methoxypropyl,ethoxymethyl, ethoxyethyl, ethoxypropyl, dimethoxymethyl,dimethoxyethyl, methoxy(ethoxy)ethyl, dimethoxypropyl, andmethoxy(ethoxy)propyl.

The term “alkoxycarbonyl” is a radical containing an alkoxy radical, asdefined above, attached via an oxygen atom to a carbonyl radical, i.e.,an ester radical. More preferred are “lower alkoxycarbonyl” radicalswith alkyl portions having one to six carbons. Examples of such loweralkoxycarbonyl radicals include substituted or unsubstitutedmethoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl andhexyloxycarbonyl.

The term “hydroxyalkyl” is a linear or branched alkyl radical having oneto ten carbon atoms, any one of which may be substituted with one ormore hydroxyl radicals. More preferred hydroxyalkyl radicals are “lowerhydroxyalkyl” radicals having one to six carbon atoms and one or morehydroxyl radicals. Examples of such radicals include hydroxymethyl,hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl.

The term “alkylamino” is an amino group that has been substituted withone or two alkyl radicals. Preferred are “lower N-alkylamino” radicalshaving alkyl portions having one to six carbon atoms. Suitable loweralkylamino may be mono- or dialkylamino, such as N-methylamino,N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like.

The term “alkylaminoalky” is a radical having one or more alkyl radicalsattached to the nitrogen atom of an aminoalkyl radical.

The term “alkylaminocarbonyl” is an aminocarbonyl group that has beensubstituted with one or two alkyl radicals on the amino nitrogen atom.Preferred are “N-alkylaminocarbonyl” “N,N-dialkylaminocarbonyl”radicals. More preferred are “lower N-alkylaminocarbonyl” and “lowerN,N-dialkylaminocarbonyl” radicals with lower alkyl portions as definedabove.

The term “alkylthio” is a radical containing an alkyl radical of one toten carbon atoms attached to a divalent sulfur atom. More preferredalkylthio radicals are “lower alkylthio” radicals having alkyl radicalsof one to six carbon atoms. Examples of such lower alkylthio radicalsare methylthio, ethylthio, propylthio, butylthio and hexylthio.

The term “alkylthioalkyl” is a radical containing an alkylthio radicalattached through the divalent sulfur atom to an alkyl radical of one toabout ten carbon atoms. More preferred alkylthioalkyl radicals are“lower alkylthioalkyl” radicals having alkyl radicals of one to sixcarbon atoms. Examples of such lower alkylthioalkyl radicals includemethylthiomethyl, methylthioethyl, ethylthioethyl, and ethylthiopropyl.

The term “alkylsulfinyl” is a radical containing a linear or branchedalkyl radical, of one to ten carbon atoms, attached to a divalent—S(═O)— radical. More preferred alkylsulfinyl radicals are “loweralkylsulfinyl” radicals having alkyl radicals of one to six carbonatoms. Examples of such lower alkylsulfinyl radicals includemethylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl.

The term “aminoalkyl” is an alkyl radical substituted with one or moreamino radicals. More preferred are “lower aminoalkyl” radicals of one tosix carbon atoms. Examples of such radicals include aminomethyl,aminoethyl, and the like.

The term “aminocarbonyl” is an amide group of the formula —C(═O)NH₂.

The term “carbonyl”, whether used alone or with other terms, such as“alkoxycarbonyl”, is —(C═O)—.

The term “aryl”, alone or in combination, is a carbocyclic aromaticsystem containing one, two or three rings wherein such rings may beattached together in a pendent manner or may be fused, and wherein atleast one of the rings is aromatic. The term “aryl” includes aromaticradicals such as phenyl, naphthyl, tetrahydronaphthyl, indane andbiphenyl. Aryl moieties may also be substituted at a substitutableposition with one or more substituents selected independently fromalkyl, alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl,aminocarbonylalkyl, alkoxy, aralkoxy, hydroxyl, amino, halo, nitro,alkylamino, acyl, cyano, carboxy, aminocarbonyl, alkoxycarbonyl andaralkoxycarbonyl.

The terms “heterocyclyl” and “heterocyclo” are saturated or partiallyunsaturated heteroatom-containing ring-shaped radicals having one, two,or three rings wherein such rings may be attached together in a pendentmanner or may be fused, where the heteroatoms may be selected fromnitrogen, sulfur and oxygen. Examples of saturated heterocyclyl andheterocyclo radicals include saturated 3- to 6-membered heteromonocylicradicals containing one to four nitrogen atoms (e.g., pyrrolidinyl,imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3- to6-membered heteromonocyclic group containing one to two oxygen atoms andone to three nitrogen atoms (e.g., morpholinyl, etc.); saturated 3- to6-membered heteromonocyclic group containing one to two sulfur atoms andone to three nitrogen atoms (e.g., thiazolidinyl, etc.). Examples ofpartially unsaturated heterocyclyl and heterocyclo radicals includedihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole.

The term “heteroaryl” is an aromatic heteroatom-containing ring-shapedradical having one, two, or three rings wherein at least one ring isaromatic. Examples of heteroaryl radicals include unsaturated 3- to6-membered heteromonocyclic group containing one to four nitrogen atoms,e.g., pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl,pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl,1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g.1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensedheterocyclyl group containing one to five nitrogen atoms, e.g., indolyl,isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl,indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g.,tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3- to 6-memberedheteromonocyclic group containing an oxygen atom, e.g., pyranyl, furyl,etc.; unsaturated 3- to 6-membered heteromonocyclic group containing asulfur atom, e.g., thienyl, etc.; unsaturated 3- to 6-memberedheteromonocyclic group containing one to two oxygen atoms and one tothree nitrogen atoms, e.g., oxazolyl, isoxazolyl, oxadiazolyl (e.g.,1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.;unsaturated condensed heterocyclyl group containing one to two oxygenatoms and one to three nitrogen atoms (e.g., benzoxazolyl,benzoxadiazolyl, etc.); unsaturated 3- to 6-membered heteromonocyclicgroup containing one to two sulfur atoms and one to three nitrogenatoms, e.g., thiazolyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl,1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturatedcondensed heterocyclyl group containing one to two sulfur atoms and oneto three nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.)and the like. The term “heteroaryl” also includes radicals whereheteroaryl radicals are fused with aryl radicals. Examples of such fusedbicyclic radicals include benzofuran, benzothiophene, and the like. Saidheterocyclyl group may be substituted at a substitutable position withone or more substituents selected independently from alkyl, hydroxyl,halo, alkoxy, oxo, amino and alkylamino.

The terms “heterocyclylalkyl” and “heterocycloalkyl” are saturated andpartially unsaturated heterocyclyl-substituted alkyl radicals, such aspyrrolidinylmethyl, and heteroaryl-substituted alkyl radicals, such aspyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, andquinolylethyl. The heteroaryl in said heteroaralkyl may be additionallysubstituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.

The term “acyl” is a radical provided by the residue after removal ofhydroxyl from an organic acid. Examples of such acyl radicals includealkanoyl and aroyl radicals.

The term “alkanoyl” or “alkylcarbonyl” are alkyl radicals as definedherein attached to a carbonyl radical. Examples of such alkanoylradicals include formyl, acetyl, propionyl, butyryl, isobutyryl,valeryl, isovaleryl, pivaloyl, hexanoyl, and trifluoroacetyl.

The terms “arylcarbonyl” (also called “aroyl”) and “aralkylcarbonyl”include radicals having aryl or aralkyl radicals, as defined herein,attached to a carbonyl radical. Examples of such radicals includesubstituted or unsubstituted phenylcarbonyl, naththoyl, andbenzylcarbonyl. The aryl in said aroyl and aralkylcarbonyl radicals maybe additionally substituted.

The term “aralkoxy” is an aralkyl radical as defined herein attachedthrough an oxygen atom to other radicals.

The term “aralkoxyalkyl” is an aralkoxy radical as defined hereinattached through an oxygen atom to an alkyl radical.

The terms “aralkyl” and “arylalkyl” are aryl-substituted alkyl radicalssuch as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, anddiphenylethyl. The aryl in said aralkyl may be additionally substitutedwith halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. The terms benzyland phenylmethyl are interchangeable.

The term “aralkylamino” is an aralkyl radical as defined herein attachedthrough an amino nitrogen atom to other radicals. The terms“N-arylaminoalkyl” and “N-aryl-N-alkyl-aminoalkyl” are amino groupswhich have been substituted with one aryl radical or one aryl and onealkyl radical, respectively, and having the amino group attached to analkyl radical. Examples of such radicals include N-phenylaminomethyl andN-phenyl-N-methylaminomethyl.

The term “aralkylthio” is an aralkyl radical attached to a sulfur atom.

The term “aralkylthioalkyl” is an aralkylthio radical attached through asulfur atom to an alkyl radical.

The term “arylamino” is an amino group that has been substituted withone or two aryl radicals. An example of such arylamino radicals isN-phenylamino. The “arylamino” radicals may be further substituted onthe aryl ring portion of the radical.

The term “aryloxyalkyl” is a radical having an aryl radical attached toan alkyl radical through a divalent oxygen atom.

The term “arylthioalkyl” is a radical having an aryl radical attached toan alkyl radical through a divalent sulfur atom.

The term “sulfonyl”, whether used alone or linked to other terms such asalkylsulfonyl, is a divalent —SO₂— radical.

The term “alkylsulfonyl” is an alkyl radical attached to a sulfonylradical, where alkyl is defined as above. More preferred alkylsulfonylradicals are “lower alkylsulfonyl” radicals having one to six carbonatoms. Examples of such lower alkylsulfonyl radicals includemethylsulfonyl, ethylsulfonyl and propylsulfonyl. The “alkylsulfonyl”radicals may be further substituted with one or more halo atoms, such asfluoro, chloro or bromo, to provide haloalkylsulfonyl radicals.

The terms “sulfamyl”, “aminosulfonyl” and “sulfonamidyl” are —SO₂NH₂.

The term “pharmaceutically acceptable” is used adjectivally herein tomean that the modified noun is appropriate for use in a pharmaceuticalproduct; that is the “pharmaceutically-acceptable” material isrelatively safe and/or non-toxic, though not necessarily providing aseparable therapeutic benefit by itself. Pharmaceutically-acceptablecations include metallic ions and organic ions. More preferred metallicions include, but are not limited to, appropriate alkali metal salts,alkaline earth metal salts and other physiologically-acceptable metalions. Exemplary ions include aluminum, calcium, lithium, magnesium,potassium, sodium and zinc, in their usual valences. Preferred organicions include protonated tertiary amines and quaternary ammonium cations,including in part, trimethylamine, diethylamine,N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine,ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplarypharmaceutically acceptable acids include without limitationhydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid,methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleicacid, malic acid, citric acid, isocitric acid, succinic acid, lacticacid, gluconic acid, glucuronic acid, pyruvic acid, oxalacetic acid,fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoicacid, and the like.

The term “prodrug” refers to a chemical compound that can be convertedinto a therapeutic compound by metabolic or simple chemical processeswithin the body of the subject.

The term “subject” for purposes of treatment or prevention includes anyhuman or animal subject who is in need of treatment. The subject can bea domestic livestock species, a laboratory animal species, a zoo animalor a companion animal. In one embodiment, the subject is a mammal. Inanother embodiment, the mammal is a human being.

The term “PBS” stands for phosphate buffered saline.

The term “HEPES” stands forN-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid.

The term “BSA” stands for bovine serum albumin.

The term “STI” stands for soybean trypsin inhibitor.

The term “Pefabloc” stands for (4-(2-aminoethyl)benzenesulfonylfluoride,HCl salt.

The term “Phosphoramidon” stands forN-α-L-rhamnopyranosyloxy(hydroxyphosphinyl)-L-leucyl-L-tryptophan.

The term “FCC” stands for flash column chromatography.

The term “K_(i)” stands for inhibitory rate constant.

The term “FLIPR” stands for fluorometric imaging plate reader.

The term “HEK 293” stands for the human embryonic kidney 293 cell line.

The term “Boc” stands for tert-butoxycarbonyl.

The term “DIC” stands for diisopropylcarbodiimide.

The term “DCM” stands for dichloromethane.

The term “DBU” stands for 1,8-diazabicyclo[5.4.0]undec-7-ene.

The term “phosgene” stands for COCl₂.

The term “DCE” stands for dichloroethane.

The term “DMF” stands for dimethylformamide.

The term “EtOAc” stands for ethyl acetate.

The term “HOBt” stands for 1-Hydroxybenzotriazole hydrate.

The term “MeOH” stands for methanol.

The term “TFA” stands for trifluoroacetic acid.

The MCH receptor antagonists employed in the present invention can existin tautomeric, geometric or stereoisomeric forms. The present inventioncontemplates all such compounds, including cis- and trans-geometricisomers, E- and Z-geometric isomers, R- and S-enantiomers,diastereomers, d- and l-isomers, the racemic mixtures thereof and othermixtures thereof. Pharmaceutically acceptable salts of such tautomeric,geometric or stereoisomeric forms are also included within theinvention. The terms “cis” and “trans”, as used herein, denote a form ofgeometric isomerism in which two carbon atoms connected by a double bondand each substituted by a hydrogen and another group, will each have ahydrogen atom on the same side of the double bond (“cis”) or on oppositesides of the double bond (“trans”). Some of the compounds describedherein contain alkenyl groups, and are meant to include both cis andtrans or “E” and “Z” geometric forms. Furthermore, some of the compoundsdescribed herein contain one or more stereocenters and are meant toinclude R, S, and mixtures or R and S forms for each stereocenterpresent.

The MCH receptor antagonists utilized in the present invention may be inthe form of free bases or pharmaceutically-acceptable acid additionsalts thereof. The term “pharmaceutically-acceptable salts” are saltscommonly used to form alkali metal salts and to form addition salts offree acids or free bases. The nature of the salt may vary, provided thatit is pharmaceutically acceptable. Suitable pharmaceutically-acceptableacid addition salts of compounds for use in the present methods may beprepared from an inorganic acid or from an organic acid. Examples ofsuch inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric,carbonic, sulfuric and phosphoric acid. Appropriate organic acids may beselected from aliphatic, cycloaliphatic, aromatic, araliphatic,heterocyclic, carboxylic and sulfonic classes of organic acids, examplesof which are formic, acetic, propionic, succinic, glycolic, gluconic,lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric,pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic,4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic),methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic,2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic,cyclohexylaminosulfonic, stearic, algenic, hydroxybutyric, salicylic,galactaric and galacturonic acid. Suitable pharmaceutically-acceptablebase addition salts of compounds of use in the present methods includemetallic salts made from aluminum, calcium, lithium, magnesium,potassium, sodium and zinc or organic salts made fromN,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine,ethylenediamine, meglumine (N-methylglucamine), and procaine. All ofthese salts may be prepared by conventional means from the correspondingcompound by reacting, for example, the appropriate acid or base with thecompound of any Formula set forth herein.

The MCH receptor antagonists useful in the practice of the presentinvention can be formulated into pharmaceutical compositions andadministered by any means that will deliver a therapeutically effectivedose. Such compositions can be administered orally, parenterally, byinhalation spray, rectally, intradermally, transdermally, or topically,in dosage unit formulations containing conventional nontoxicpharmaceutically-acceptable carriers, adjuvants, and vehicles asdesired. Topical administration may also involve the use of transdermaladministration such as transdermal patches or iontophoresis devices. Theterm parenteral as used herein includes subcutaneous, intravenous,intramuscular, or intrasternal injection, or infusion techniques.Formulation of drugs is discussed in, e.g., Hoover, Remington'sPharmaceutical Sciences, (1975), and Liberman & Lachman, Eds.,Pharmaceutical Dosage Forms, (1980).

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions, can be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation may also be a sterile injectable solutionor suspension in a nontoxic parenterally-acceptable diluent or solvent.Among the acceptable vehicles and solvents that may be employed arewater, Ringer's solution, and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose, any bland fixed oil may beemployed, including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid are useful in the preparation of injectables.Dimethyl acetamide, surfactants including ionic and non-ionicdetergents, and polyethylene glycols can be used. Mixtures of solventsand wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the compounds discussedherein can be prepared by mixing the active agent with a suitablenon-irritating excipient such as cocoa butter, synthetic mono-, di-, ortriglycerides, fatty acids, or polyethylene glycols, which are solid atordinary temperatures but liquid at the rectal temperature, and whichwill therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration may include capsules,tablets, pills, powders, and granules. In such solid dosage forms, thecompounds are ordinarily combined with one or more adjuvants appropriateto the indicated route of administration. If administered per os, thecompounds can be admixed with lactose, sucrose, starch powder, celluloseesters of alkanoic acids, cellulose alkyl esters, talc, stearic acid,magnesium stearate, magnesium oxide, sodium and calcium salts ofphosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate,polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted orencapsulated for convenient administration. Such capsules or tablets cancontain a controlled-release formulation as can be provided in adispersion of active compound in hydroxypropylmethyl cellulose. In thecase of capsules, tablets, and pills, the dosage forms can also comprisebuffering agents such as sodium citrate, or magnesium or calciumcarbonate or bicarbonate. Tablets and pills can additionally be preparedwith enteric coatings.

For therapeutic purposes, formulations for parenteral administration canbe in the form of aqueous or non-aqueous isotonic sterile injectionsolutions or suspensions. These solutions and suspensions can beprepared from sterile powders or granules having one or more of thecarriers or diluents mentioned for use in the formulations for oraladministration. The compounds can be dissolved in water, polyethyleneglycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil,sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.Other adjuvants and modes of administration are well and widely known inthe pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups, and elixirscontaining inert diluents commonly used in the art, such as water. Suchcompositions can also comprise adjuvants, such as wetting agents,emulsifying and suspending agents, and sweetening, flavoring, andperfuming agents.

The amount of active ingredient that can be combined with the carriermaterials to produce a single dosage of the MCH receptor antagonist willvary depending upon the patient and the particular mode ofadministration. In general, the pharmaceutical compositions may containan MCH receptor antagonist in the range of about 1 to about 250 mg, moretypically, in the range of about 10 to about 200 mg and still moretypically, between about 25 to about 150 mg. A daily dose of about 0.01to about 80 mg/kg body weight, or more typically, between about 0.5 toabout 50 mg/kg body weight and even more typically, from about 1 toabout 25 mg/kg body weight, may be appropriate. The daily dose can beadministered in one to about four doses per day.

The MCH receptor antagonists are administered in such an amount as willbe therapeutically effective in the treatment, control, or prevention ofthe disorder or condition being treated. It will be appreciated that theamount of active ingredients contained in an individual dose of eachdosage form need not in itself constitute an effective amount, as thenecessary effective amount could be reached by administration of anumber of individual doses. Those skilled in the art will appreciatethat the quantity of active MCH receptor antagonist to be administeredwill vary depending upon the age, sex, and body weight of the subject tobe treated, the type of disease, or syndrome to be treated, theparticular method and scheduling of administration, and what other MCHreceptor antagonist, if any, is co-administered. Dosage amounts for anindividual patient may thus be above or below the typical dosage ranges.Generally speaking, the MCH receptor antagonist can be employed in anyamount known to be effective at treating, preventing or controlling thedisorder or condition being treated. The doses may be single doses ormultiple doses per day, with the number of doses taken per day and thetime allowed between doses varying depending on the individual needs ofthe patient. Optimization of treatment, including dosage amount, methodand time of administration, is thus best determined by a skilledpractitioner through close monitoring of patients on an individualbasis. Those skilled in the art will appreciate that dosages may also bedetermined with guidance from Goodman & Goldman, The PharmacologicalBasis of Therapeutics, 9th Ed. (1996), App. II, pp. 1707-1711 and fromGoodman & Goldman, The Pharmacological Basis of Therapeutics, 10th Ed.(2001), App. II, pp. 475-493.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

In one embodiment of the present invention, the MCH receptor antagonistis a compound of Formula I, or a pharmaceutically-acceptable salt,tautomer or prodrug thereof, having the following structure:

wherein

A is selected from the group consisting of heteroaryl, —C(═O)—, and—C(═O)NH—;

W is selected from the group consisting of a bond, —C(═O)—, alkyl,alkenyl, aryl, aralkenyl and heterocyclo;

X is selected from the group consisting of XA:

Z is selected from the group consisting of a bond, alkyl, cycloalkyl,aryl, aralkyl, heteroaryl, and heterocyclo;

R¹ is selected from the group consisting of alkyl, aryl, aralkyl,alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and alkylphosphonate,wherein R¹ is optionally substituted by one or more substituentsselected from the group consisting of alkyl, hydroxy, carboxyl, halo,cyano and keto;

R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl,aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and aralkoxy, or R² andR⁸ together with the atom to which they are both attached form a 5- or6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkylor heterocyclo group formed with R⁸ is optionally substituted by one ormore substituents selected from the group consisting of alkoxy, aryloxy,haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl,haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy, hydroxyalkoxy,alkoxycarbonyl, alkylthio, N-(alkylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, aryl, alkoxy,aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³ is optionallysubstituted by one or more substituents selected from the groupconsisting of halo, aryl, haloaryl, alkoxy, alkyl, carboxyl, aryloxy,keto, and hydroxy;

R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the groupconsiting of hydrogen, alkyl, and halo; and

R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the atom towhich they are both attached form a 5- or 6-membered cycloalkyl orheterocyclo group;

provided that Z is not methyl when X is XB or XC, further provided thatW is not pyrrolidyl when X is XC, and further provided that R³ is notaryl- or haloaryl-substituted indolyl.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrugthereof, wherein A is selected from the group consisting of 5- or6-membered heteroaryl, —C(═O)—, and —C(═O)NH—;

W is selected from the group consisting of a bond, —C(═O)—, lower alkyl,lower alkenyl, aryl, aralkenyl and 3- to 10-membered heterocyclo;

Z is selected from the group consisting of a bond, lower alkyl, lowercycloalkyl, aryl, aralkyl and 3- to 10-membered heterocyclo;

R¹ is selected from the group consisting of lower alkyl, aryl, aralkyl,lower alkoxycarbonyl, 3- to 10-membered heterocyclo, aryloxy, 3- to10-membered heteroaryl, and lower alkylphosphonate, wherein R¹ isoptionally substituted by one or more substituents selected from thegroup consisting of lower alkyl, hydroxy, carboxyl, halo, cyano andketo;

R² is selected from the group consisting of hydrogen, lower alkyl, lowercycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered heterocyclo, 3- to10-membered heteroaryl, and aralkoxy, or R² and R⁸ together with theatom to which they are both attached form a 5- or 6-membered cycloalkylor heterocyclo group, wherein R² or the cycloalkyl or heterocyclo groupformed with R⁸ is optionally substituted by one or more substituentsselected from the group consisting of lower alkoxy, aryloxy, lowerhaloalkyl, halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl,haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano, hydroxy,lower hydroxyalkoxy, lower alkoxycarbonyl, lower alkylthio, N-(loweralkylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, aryl, loweralkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl,isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl,benzodioxolyl, and (3- to 10-membered heterocyclo)carbonyl, wherein R³is optionally substituted by one or more substituents selected from thegroup consisting of halo, aryl, haloaryl, lower alkoxy, lower alkyl,carboxyl, aryloxy, keto, and hydroxy;

R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the groupconsiting of hydrogen, lower alkyl, and halo; and

R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the atom towhich they are both attached form a 5- or 6-membered cycloalkyl orheterocyclo group.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrugthereof, wherein A is selected from the group consisting of furyl,thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—;

W is selected from the group consisting of a bond, —C(═O)—, methyl,ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl,pentenyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenylethenyl,phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl,pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,dihydrothiazolyl, and tetrahydrofuryl;

Z is selected from the group consisting of a bond, methyl, ethyl,propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl,diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,dihydrothiazolyl, and tetrahydrofuryl;

R¹ is selected from the group consisting of methyl, ethyl, propyl,butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,pentyloxycarbonyl, hexyloxycarbonyl, pyrrolidinyl, imidazolidinyl,piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,dihydropyranyl, dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl,phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, furyl,thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, monomethylphosphonate,dimethylphosphonate, monoethylphosphonate, diethylphosphonate,monopropylphosphonate, and dipropylphosphonate, wherein R¹ is optionallysubstituted by one or more substituents selected from the groupconsisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy,carboxyl, fluoro, chloro, bromo, iodo, cyano and keto;

R² is selected from the group consisting of hydrogen, methyl, ethyl,propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl,diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,phenylcarbonyl, naphthylcarbonyl, tetrahydronaphthylcarbonyl,biphenylcarbonyl, pyrrolidinyl, imidazolidinyl, piperidinyl,piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl,dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl, furyl, thienyl,pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl,indolyl, benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, phenylmethoxy, phenylethoxy,phenylpropoxy, phenylbutoxy, phenylpentyloxy, and phenylhexyloxy, or R²and R⁸ together with the atom to which they are both attached form a 5-or 6-membered cycloalkyl or heterocyclo group selected from the groupconsisting of cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl,piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl,wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ isoptionally substituted by one or more substituents selected from thegroup consisting of methoxy, ethoxy, propoxy, butoxy, pentyloxy,hexyloxy, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy,fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl,heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl,difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, fluoro,chloro, bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl,phenylpentenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl,diphenylethyl, methyl, ethyl, propyl, butyl, pentyl, hexyl,fluoromethylphenyl, difluoromethylphenyl, trifluoromethylphenyl,chloromethylphenyl, dichloromethylphenyl, trichloromethylphenyl,trichloromethylphenyl, bis(fluoromethyl)phenyl,bis(difluoromethyl)phenyl, bis(trifluoromethyl)phenyl,bis(chloromethyl)phenyl, bis(dichloromethyl)phenyl,bis(trichloromethyl)phenyl, bis(trichloromethyl)phenyl, chlorophenoxy,bromophenoxy, fluorophenoxy, dichlorophenoxy, dibromophenoxy,difluorophenoxy, chlorobromophenoxy, chlorofluorophenoxy,bromofluorophenoxy, methylphenoxy, ethylphenoxy, propylphenoxy,dimethylphenoxy, diethylphenoxy, dipropylphenoxy, methylnaphthyloxy,ethylnaphthyloxy, propylnaphthyloxy, dimethylnaphthyloxy,diethylnaphthyloxy, dipropylnaphthyloxy, methylbiphenylyloxy,ethylbiphenylyloxy, propylbiphenylyloxy, dimethylbiphenylyloxy,diethylbiphenylyloxy, dipropylbiphenylyloxy, furyl, thienyl, pyrrolyl,pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,tetrazolyl, benzodioxolyl, cyano, hydroxy, hydroxymethoxy,hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, hydroxypentyloxy,hydroxyhexyloxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, methylthio,ethylthio, propylthio, butylthio, pentylthio, hexylthio,N-(methylcarbonyl)amino, N-(ethylcarbonyl)amino,N-(propylcarbonyl)amino, N-(butylcarbonyl)amino,N-(pentylcarbonyl)amino, N-(hexylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, phenyl, naphthyl,tetrahydronaphthyl, biphenyl, methoxy, ethoxy, propoxy, butoxy,pentyloxy, hexyloxy, phenylmethoxy, phenylethoxy, phenylpropoxy,phenylbutoxy, phenylpentyloxy, phenylhexyloxy, furyl, thienyl, pyrrolyl,pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,tetrazolyl, benzodioxolyl, pyrrolidinylcarbonyl, imidazolidinylcarbonyl,piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl,thiazolidinylcarbonyl, dihydrothienylcarbonyl, dihydropyranylcarbonyl,dihydrofurylcarbonyl, dihydrothiazolylcarbonyl, andtetrahydrofurylcarbonyl, wherein R³ is optionally substituted by one ormore substituents selected from the group consisting of fluoro, chloro,bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dibromophenyl,difluorophenyl, chlorobromophenyl, chlorofluorophenyl,bromofluorophenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy,hexyloxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, carboxyl,phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, keto, andhydroxy;

R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the groupconsisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl,fluoro, chloro, bromo, and iodo; and

R⁸ is selected from the group consisting of hydrogen, methyl, ethyl,propyl, butyl, pentyl, and hexyl, or R² and R⁸ together with the atom towhich they are both attached form a 5- or 6-membered cycloalkyl orheterocyclo group selected from the group consisting of cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl,piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrugthereof, wherein A is selected from the group consisting of furyl,thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—;

W is selected from the group consisting of a bond, —C(═O)—, alkyl,alkenyl, aryl, aralkenyl and heterocyclo;

X is selected from the group consisting of XA:

Z is selected from the group consisting of a bond, alkyl, cycloalkyl,aryl, aralkyl, heteroaryl, and heterocyclo;

R¹ is selected from the group consisting of alkyl, aryl, aralkyl,alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and alkylphosphonate,wherein R¹ is optionally substituted by one or more substituentsselected from the group consisting of alkyl, hydroxy, carboxyl, halo,cyano and keto;

R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl,aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and aralkoxy, or R² andR⁸ together with the atom to which they are both attached form a 5- or6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkylor heterocyclo group formed with R⁸ is optionally substituted by one ormore substituents selected from the group consisting of alkoxy, aryloxy,haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl,haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy, hydroxyalkoxy,alkoxycarbonyl, alkylthio, N-(alkylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, aryl, alkoxy,aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³ is optionallysubstituted by one or more substituents selected from the groupconsisting of halo, aryl, haloaryl, alkoxy, alkyl, carboxyl, aryloxy,keto, and hydroxy;

R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the groupconsiting of hydrogen, alkyl, and halo; and

R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to whichthey are both attached form a 5- or 6-membered cycloalkyl or heterocyclogroup;

provided that Z is not methyl when X is XB or XC, further provided thatW is not pyrrolidyl when X is XC, and further provided that R³ is notaryl- or haloaryl-substituted indolyl;

or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrugthereof, wherein A is selected from the group consisting of furyl,thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—;

W is selected from the group consisting of a bond, —C(═O)—, lower alkyl,lower alkenyl, aryl, aralkenyl and 3- to 10-membered heterocyclo;

Z is selected from the group consisting of a bond, lower alkyl, lowercycloalkyl, aryl, aralkyl and 3- to 10-membered heterocyclo;

R¹ is selected from the group consisting of lower alkyl, aryl, aralkyl,lower alkoxycarbonyl, 3- to 10-membered heterocyclo, aryloxy, 3- to10-membered heteroaryl, and lower alkylphosphonate, wherein R¹ isoptionally substituted by one or more substituents selected from thegroup consisting of lower alkyl, hydroxy, carboxyl, halo, cyano andketo;

R² is selected from the group consisting of hydrogen, lower alkyl, lowercycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered heterocyclo, 3- to10-membered heteroaryl, and aralkoxy, or R² and R⁸ together with theatom to which they are both attached form a 5- or 6-membered cycloalkylor heterocyclo group, wherein R² or the cycloalkyl or heterocyclo groupformed with R⁸ is optionally substituted by one or more substituentsselected from the group consisting of lower alkoxy, aryloxy, lowerhaloalkyl, halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl,haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano, hydroxy,lower hydroxyalkoxy, lower alkoxycarbonyl, lower alkylthio, N-(loweralkylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, aryl, loweralkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl,isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl,benzodioxolyl, and (3- to 10-membered heterocyclo)carbonyl, wherein R³is optionally substituted by one or more substituents selected from thegroup consisting of halo, aryl, haloaryl, lower alkoxy, lower alkyl,carboxyl, aryloxy, keto, and hydroxy;

R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the groupconsiting of hydrogen, lower alkyl, and halo; and

R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the atom towhich they are both attached form a 5- or 6-membered cycloalkyl orheterocyclo group.

In another embodiment, the MCH receptor antagonist is selected from asubclass of compounds of Formula I represented by Formula II:

wherein

A is selected from the group consisting of furyl, thienyl, pyrrolyl,pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—;

W is selected from the group consisting of a bond, —C(═O)—, alkyl,alkenyl, aryl, aralkenyl and heterocyclo;

Z is selected from the group consisting of a bond, alkyl, cycloalkyl,aryl, aralkyl, heteroaryl, and heterocyclo;

R¹ is selected from the group consisting of alkyl, aryl, aralkyl,alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and alkylphosphonate,wherein R¹ is optionally substituted by one or more substituentsselected from the group consisting of alkyl, hydroxy, carboxyl, halo,cyano and keto;

R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl,aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and aralkoxy, or R² andR⁸ together with the atom to which they are both attached form a 5- or6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkylor heterocyclo group formed with R⁸ is optionally substituted by one ormore substituents selected from the group consisting of alkoxy, aryloxy,haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl,haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy, hydroxyalkoxy,alkoxycarbonyl, alkylthio, N-(alkylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, aryl, alkoxy,aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³ is optionallysubstituted by one or more substituents selected from the groupconsisting of halo, aryl, haloaryl, alkoxy, alkyl, carboxyl, aryloxy,keto, and hydroxy;

R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consitingof hydrogen, alkyl, and halo; and

R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to whichthey are both attached form a 5- or 6-membered cycloalkyl or heterocyclogroup;

provided that R³ is not aryl- or haloaryl-substituted indolyl;

or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula II, or a pharmaceutically-acceptable salt, tautomer orprodrug thereof, wherein A is selected from the group consisting of 5-or 6-membered heteroaryl, —C(═O)—, and —C(═O)NH—;

W is selected from the group consisting of a bond, —C(═O)—, lower alkyl,lower alkenyl, aryl, aralkenyl and 3- to 10-membered heterocyclo;

Z is selected from the group consisting of a bond, lower alkyl, lowercycloalkyl, aryl, aralkyl and 3- to 10-membered heterocyclo;

R¹ is selected from the group consisting of lower alkyl, aryl, aralkyl,lower alkoxycarbonyl, 3- to 10-membered heterocyclo, aryloxy, 3- to10-membered heteroaryl, and lower alkylphosphonate, wherein R¹ isoptionally substituted by one or more substituents selected from thegroup consisting of lower alkyl, hydroxy, carboxyl, halo, cyano andketo;

R² is selected from the group consisting of hydrogen, lower alkyl, lowercycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered heterocyclo, 3- to10-membered heteroaryl, and aralkoxy, or R² and R⁸ together with theatom to which they are both attached form a 5- or 6-membered cycloalkylor heterocyclo group, wherein R² or the cycloalkyl or heterocyclo groupformed with R⁸ is optionally substituted by one or more substituentsselected from the group consisting of lower alkoxy, aryloxy, lowerhaloalkyl, halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl,haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano, hydroxy,lower hydroxyalkoxy, lower alkoxycarbonyl, lower alkylthio, N-(loweralkylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, aryl, loweralkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl,isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl,benzodioxolyl, and (3- to 10-membered heterocyclo)carbonyl, wherein R³is optionally substituted by one or more substituents selected from thegroup consisting of halo, aryl, haloaryl, lower alkoxy, lower alkyl,carboxyl, aryloxy, keto, and hydroxy;

R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consitingof hydrogen, lower alkyl, and halo; and

R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the atom towhich they are both attached form a 5- or 6-membered cycloalkyl orheterocyclo group.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula II, or a pharmaceutically-acceptable salt, tautomer orprodrug thereof, wherein A is selected from the group consisting offuryl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, —C(═O)—, and —C(═O)NH—;

W is selected from the group consisting of a bond, —C(═O)—, methyl,ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl,pentenyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenylethenyl,phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl,pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,dihydrothiazolyl, and tetrahydrofuryl;

Z is selected from the group consisting of a bond, methyl, ethyl,propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl,diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,dihydrothiazolyl, and tetrahydrofuryl;

R¹ is selected from the group consisting of methyl, ethyl, propyl,butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,pentyloxycarbonyl, hexyloxycarbonyl, pyrrolidinyl, imidazolidinyl,piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,dihydropyranyl, dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl,phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, furyl,thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, monomethylphosphonate,dimethylphosphonate, monoethylphosphonate, diethylphosphonate,monopropylphosphonate, and dipropylphosphonate, wherein R¹ is optionallysubstituted by one or more substituents selected from the groupconsisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy,carboxyl, fluoro, chloro, bromo, iodo, cyano and keto;

R² is selected from the group consisting of hydrogen, methyl, ethyl,propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl,diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,phenylcarbonyl, naphthylcarbonyl, tetrahydronaphthylcarbonyl,biphenylcarbonyl, pyrrolidinyl, imidazolidinyl, piperidinyl,piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl,dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl, furyl, thienyl,pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl,indolyl, benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, phenylmethoxy, phenylethoxy,phenylpropoxy, phenylbutoxy, phenylpentyloxy, and phenylhexyloxy, or R²and R⁸ together with the atom to which they are both attached form a 5-or 6-membered cycloalkyl or heterocyclo group selected from the groupconsisting of cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl,piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl,wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ isoptionally substituted by one or more substituents selected from thegroup consisting of methoxy, ethoxy, propoxy, butoxy, pentyloxy,hexyloxy, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy,fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl,heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl,difluoroethyl; difluoropropyl, dichloroethyl, dichloropropyl, fluoro,chloro, bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl,phenylpentenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl,diphenylethyl, methyl, ethyl, propyl, butyl, pentyl, hexyl,fluoromethylphenyl, difluoromethylphenyl, trifluoromethylphenyl,chloromethylphenyl, dichloromethylphenyl, trichloromethylphenyl,trichloromethylphenyl, bis(fluoromethyl)phenyl,bis(difluoromethyl)phenyl, bis(trifluoromethyl)phenyl,bis(chloromethyl)phenyl, bis(dichloromethyl)phenyl,bis(trichloromethyl)phenyl, bis(trichloromethyl)phenyl, chlorophenoxy,bromophenoxy, fluorophenoxy, dichlorophenoxy, dibromophenoxy,difluorophenoxy, chlorobromophenoxy, chlorofluorophenoxy,bromofluorophenoxy, methylphenoxy, ethylphenoxy, propylphenoxy,dimethylphenoxy, diethylphenoxy, dipropylphenoxy, methylnaphthyloxy,ethylnaphthyloxy, propylnaphthyloxy, dimethylnaphthyloxy,diethylnaphthyloxy, dipropylnaphthyloxy, methylbiphenylyloxy,ethylbiphenylyloxy, propylbiphenylyloxy, dimethylbiphenylyloxy,diethylbiphenylyloxy, dipropylbiphenylyloxy, furyl, thienyl, pyrrolyl,pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,tetrazolyl, benzodioxolyl, cyano, hydroxy, hydroxymethoxy,hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, hydroxypentyloxy,hydroxyhexyloxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, methylthio,ethylthio, propylthio, butylthio, pentylthio, hexylthio,N-(methylcarbonyl)amino, N-(ethylcarbonyl)amino,N-(propylcarbonyl)amino, N-(butylcarbonyl)amino,N-(pentylcarbonyl)amino, N-(hexylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, phenyl, naphthyl,tetrahydronaphthyl, biphenyl, methoxy, ethoxy, propoxy, butoxy,pentyloxy, hexyloxy, phenylmethoxy, phenylethoxy, phenylpropoxy,phenylbutoxy, phenylpentyloxy, phenylhexyloxy, furyl, thienyl, pyrrolyl,pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,tetrazolyl, benzodioxolyl, pyrrolidinylcarbonyl, imidazolidinylcarbonyl,piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl,thiazolidinylcarbonyl, dihydrothienylcarbonyl, dihydropyranylcarbonyl,dihydrofurylcarbonyl, dihydrothiazolylcarbonyl, andtetrahydrofurylcarbonyl, wherein R³ is optionally substituted by one ormore substituents selected from the group consisting of fluoro, chloro,bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dibromophenyl,difluorophenyl, chlorobromophenyl, chlorofluorophenyl,bromofluorophenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy,hexyloxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, carboxyl,phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, keto, andhydroxy;

R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consistingof hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, fluoro,chloro, bromo, and iodo; and

R⁸ is selected from the group consisting of hydrogen, methyl, ethyl,propyl, butyl, pentyl, and hexyl, or R² and R⁸ together with the atom towhich they are both attached form a 5- or 6-membered cycloalkyl orheterocyclo group selected from the group consisting of cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl,piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl.

In another embodiment, the MCH receptor antagonist is selected from asubclass of compounds of Formula I represented by Formula III:

wherein

W is selected from the group consisting of a bond, —C(═O)—, alkyl,alkenyl, aryl, aralkenyl and heterocyclo;

Z is selected from the group consisting of a bond, alkyl, cycloalkyl,aryl, aralkyl, heteroaryl, and heterocyclo;

R¹ is selected from the group consisting of alkyl, aryl, aralkyl,alkoxycarbonyl, heterocyclo, aryloxy, heteroaryl, and alkylphosphonate,wherein R¹ is optionally substituted by one or more substituentsselected from the group consisting of alkyl, hydroxy, carboxyl, halo,cyano and keto;

R² is selected from the group consisting of hydrogen, alkyl, cycloalkyl,aryl, aralkyl, aroyl, heterocyclo, heteroaryl, and aralkoxy, or R² andR⁸ together with the atom to which they are both attached form a 5- or6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkylor heterocyclo group formed with R⁸ is optionally substituted by one ormore substituents selected from the group consisting of alkoxy, aryloxy,haloalkyl, halo, aryl, aralkenyl, aralkyl, alkyl, haloalkylaryl,haloaryloxy, alkylaryloxy, heteroaryl, cyano, hydroxy, hydroxyalkoxy,alkoxycarbonyl, alkylthio, N-(alkylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, aryl, alkoxy,aralkoxy, heteroaryl and heterocyclocarbonyl, wherein R³ is optionallysubstituted by one or more substituents selected from the groupconsisting of halo, aryl, haloaryl, alkoxy, alkyl, carboxyl, aryloxy,keto, and hydroxy;

R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consitingof hydrogen, alkyl, and halo; and

R⁸ is hydrogen or alkyl, or R² and R⁸ together with the atom to whichthey are both attached form a 5- or 6-membered cycloalkyl or heterocyclogroup;

provided that R³ is not aryl- or haloaryl-substituted indolyl;

or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula III, or a pharmaceutically-acceptable salt, tautomer orprodrug thereof, wherein each of R⁴, R⁵, R⁶ and R⁷ are hydrogen.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula III, or a pharmaceutically-acceptable salt, tautomer orprodrug thereof, wherein each of R⁴, R⁵, R⁶ and R⁷ are hydrogen, andwherein W is selected from the group consisting of a bond, —C(═O)—,lower alkyl, lower alkenyl, aryl, aralkenyl and 3- to 10-memberedheterocyclo;

Z is selected from the group consisting of a bond, lower alkyl, lowercycloalkyl, aryl, aralkyl and 3- to 10-membered heterocyclo;

R¹ is selected from the group consisting of lower alkyl, aryl, aralkyl,lower alkoxycarbonyl, 3- to 10-membered heterocyclo, aryloxy, 3- to10-membered heteroaryl, and lower alkylphosphonate, wherein R¹ isoptionally substituted by one or more substituents selected from thegroup consisting of lower alkyl, hydroxy, carboxyl, halo, cyano andketo;

R² is selected from the group consisting of hydrogen, lower alkyl, lowercycloalkyl, aryl, aralkyl, aroyl, 3- to 10-membered heterocyclo, 3- to10-membered heteroaryl, and aralkoxy, or R² and R⁸ together with theatom to which they are both attached form a 5- or 6-membered cycloalkylor heterocyclo group, wherein R² or the cycloalkyl or heterocyclo groupformed with R⁸ is optionally substituted by one or more substituentsselected from the group consisting of lower alkoxy, aryloxy, lowerhaloalkyl, halo, aryl, aralkenyl, aralkyl, lower alkyl, haloalkylaryl,haloaryloxy, alkylaryloxy, 5- or 6-membered heteroaryl, cyano, hydroxy,lower hydroxyalkoxy, lower alkoxycarbonyl, lower alkylthio, N-(loweralkylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, aryl, loweralkoxy, aralkoxy, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,triazolyl, isoxazolyl, oxazolyl, indolyl, benzofuryl, thiazolyl,isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl,benzodioxolyl, and (3- to 10-membered heterocyclo)carbonyl, wherein R³is optionally substituted by one or more substituents selected from thegroup consisting of halo, aryl, haloaryl, lower alkoxy, lower alkyl,carboxyl, aryloxy, keto, and hydroxy;

R⁸ is hydrogen or lower alkyl, or R² and R⁸ together with the atom towhich they are both attached form a 5- or 6-membered cycloalkyl orheterocyclo group.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula III, or a pharmaceutically-acceptable salt, tautomer orprodrug thereof, wherein each of R⁴, R⁵, R⁶ and R⁷ are hydrogen, andwherein W is selected from the group consisting of a bond, —C(═O)—,methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl,butenyl, pentenyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl,phenylpentenyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl,morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl,dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl;

Z is selected from the group consisting of a bond, methyl, ethyl,propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl,diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl,thiazolidinyl, dihydrothienyl, dihydropyranyl, dihydrofuryl,dihydrothiazolyl, and tetrahydrofuryl;

R¹ is selected from the group consisting of methyl, ethyl, propyl,butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,pentyloxycarbonyl, hexyloxycarbonyl, pyrrolidinyl, imidazolidinyl,piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,dihydropyranyl, dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl,phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, furyl,thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl,oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, monomethylphosphonate,dimethylphosphonate, monoethylphosphonate, diethylphosphonate,monopropylphosphonate, and dipropylphosphonate, wherein R¹ is optionallysubstituted by one or more substituents selected from the groupconsisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy,carboxyl, fluoro, chloro, bromo, iodo, cyano and keto;

R² is selected from the group consisting of hydrogen, methyl, ethyl,propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl,diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl,phenylcarbonyl, naphthylcarbonyl, tetrahydronaphthylcarbonyl,biphenylcarbonyl, pyrrolidinyl, imidazolidinyl, piperidinyl,piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl, dihydropyranyl,dihydrofuryl, dihydrothiazolyl, tetrahydrofuryl, furyl, thienyl,pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl,indolyl, benzofuryl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl,dioxazole, tetrazolyl, benzodioxolyl, phenylmethoxy, phenylethoxy,phenylpropoxy, phenylbutoxy, phenylpentyloxy, and phenylhexyloxy, or R²and R⁸ together with the atom to which they are both attached form a 5-or 6-membered cycloalkyl or heterocyclo group selected from the groupconsisting of cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl,piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl,wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ isoptionally substituted by one or more substituents selected from thegroup consisting of methoxy, ethoxy, propoxy, butoxy, pentyloxy,hexyloxy, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy,fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl,heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl,difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, fluoro,chloro, bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl,phenylpentenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl,diphenylethyl, methyl, ethyl, propyl, butyl, pentyl, hexyl,fluoromethylphenyl, difluoromethylphenyl, trifluoromethylphenyl,chloromethylphenyl, dichloromethylphenyl, trichloromethylphenyl,trichloromethylphenyl, bis(fluoromethyl)phenyl,bis(difluoromethyl)phenyl, bis(trifluoromethyl)phenyl,bis(chloromethyl)phenyl, bis(dichloromethyl)phenyl,bis(trichloromethyl)phenyl, bis(trichloromethyl)phenyl, chlorophenoxy,bromophenoxy, fluorophenoxy, dichlorophenoxy, dibromophenoxy,difluorophenoxy, chlorobromophenoxy, chlorofluorophenoxy,bromofluorophenoxy, methylphenoxy, ethylphenoxy, propylphenoxy,dimethylphenoxy, diethylphenoxy, dipropylphenoxy, methylnaphthyloxy,ethylnaphthyloxy, propylnaphthyloxy, dimethylnaphthyloxy,diethylnaphthyloxy, dipropylnaphthyloxy, methylbiphenylyloxy,ethylbiphenylyloxy, propylbiphenylyloxy, dimethylbiphenylyloxy,diethylbiphenylyloxy, dipropylbiphenylyloxy, furyl, thienyl, pyrrolyl,pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,tetrazolyl, benzodioxolyl, cyano, hydroxy, hydroxymethoxy,hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, hydroxypentyloxy,hydroxyhexyloxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, methylthio,ethylthio, propylthio, butylthio, pentylthio, hexylthio,N-(methylcarbonyl)amino, N-(ethylcarbonyl)amino,N-(propylcarbonyl)amino, N-(butylcarbonyl)amino,N-(pentylcarbonyl)amino, N-(hexylcarbonyl)amino, and nitro;

R³ is selected from the group consisting of hydrogen, phenyl, naphthyl,tetrahydronaphthyl, biphenyl, methoxy, ethoxy, propoxy, butoxy,pentyloxy, hexyloxy, phenylmethoxy, phenylethoxy, phenylpropoxy,phenylbutoxy, phenylpentyloxy, phenylhexyloxy, furyl, thienyl, pyrrolyl,pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl,thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole,tetrazolyl, benzodioxolyl, pyrrolidinylcarbonyl, imidazolidinylcarbonyl,piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl,thiazolidinylcarbonyl, dihydrothienylcarbonyl, dihydropyranylcarbonyl,dihydrofurylcarbonyl, dihydrothiazolylcarbonyl, andtetrahydrofurylcarbonyl, wherein R³ is optionally substituted by one ormore substituents selected from the group consisting of fluoro, chloro,bromo, iodo, phenyl, naphthyl, tetrahydronaphthyl, biphenyl,chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dibromophenyl,difluorophenyl, chlorobromophenyl, chlorofluorophenyl,bromofluorophenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy,hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy,biphenylyloxy, keto, and hydroxy;

R⁸ is selected from the group consisting of hydrogen, methyl, ethyl,propyl, butyl, pentyl, and hexyl, or R² and R⁸ together with the atom towhich they are both attached form a 5- or 6-membered cycloalkyl orheterocyclo group selected from the group consisting of cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl,piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, dihydrothienyl,dihydropyranyl, dihydrofuryl, dihydrothiazolyl, and tetrahydrofuryl.

In another embodiment, the MCH receptor antagonist is selected from asubclass of compounds of Formula I represented by Formula IV:

wherein

Z is selected from the group consisting of a bond, alkyl, aryl, aralkyl,heteroaralkyl, and heterocyclo;

R¹ is selected from the group consisting of alkoxycarbonyl, alkyl,cycloalkyl, aralkyl, aryl, heteroaryl, and heterocyclo, wherein R¹ isoptionally substituted by one or more substituents selected from thegroup consisting of alkyl, halo, and keto;

R² is selected from the group consisting of alkyl, aryl, heterocyclo,and heteroaryl, or R² and R⁸ together with the atom to which they areboth attached form a 5- or 6-membered cycloalkyl or heterocyclo group,wherein R² or the cycloalkyl or heterocyclo group formed with R⁸ isoptionally substituted by one or more substituents selected from thegroup consisting of alkoxy, alkyl, alkylaryloxy, alkylthio, aralkenyl,aralkoxy, aralkyl, aryloxy, cyano, halo, haloalkyl, haloalkylaryl,haloaryloxy, heteroaryl, hydroxy, hydroxyalkoxy, N-(alkylcarbonyl)amino,and nitro;

R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consistingof hydrogen, alkyl and halo; and

R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independentlyselected from the group consisting of hydrogen, alkyl, hydroxy, andalkoxy;

or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula IV, or a pharmaceutically-acceptable salt, tautomer orprodrug thereof, wherein Z is selected from the group consisting of abond, lower alkyl, aryl, lower aralkyl, lower heteroaralkyl, and 3- to10-membered heterocyclo;

R¹ is selected from the group consisting of lower alkoxycarbonyl, loweralkyl, lower cycloalkyl, lower aralkyl, aryl, 3- to 10-memberedheteroaryl, and 3- to 10-membered heterocyclo, wherein R¹ is optionallysubstituted by one or more substituents selected from the groupconsisting of lower alkyl, halo, and keto;

R² is selected from the group consisting of lower alkyl, aryl, 3- to10-membered heterocyclo, and 3- to 10-membered heteroaryl, or R² and R⁸together with the atom to which they are both attached form a 5- or6-membered cycloalkyl or heterocyclo group, wherein R² or the cycloalkylor heterocyclo group formed with R⁸ is optionally substituted by one ormore substituents selected from the group consisting of lower alkoxy,lower alkyl, lower alkylaryloxy, lower alkylthio, lower aralkenyl, loweraralkoxy, lower aralkyl, aryloxy, cyano, halo, lower haloalkyl, lowerhaloalkylaryl, haloaryloxy, 3- to 10-membered heteroaryl, hydroxy, lowerhydroxyalkoxy, N-(lower alkylcarbonyl)amino, and nitro;

R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the groupconsiting of hydrogen, lower alkyl, and halo; and

R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independentlyselected from the group consisting of hydrogen, lower alkyl, hydroxy,and lower alkoxy.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula IV, or a pharmaceutically-acceptable salt, tautomer orprodrug thereof, wherein Z is selected from the group consisting of abond, methyl, ethyl, propyl, t-butyl, phenyl, tetrahydronaphthyl,biphenyl, naphthyl, phenylpropyl, indolylethyl, and piperidyl;

R¹ is selected from the group consisting of methoxycarbonyl,ethoxycarbonyl, t-butoxycarbonyl, isopropyl, n-butyl, t-butyl,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, phenyl,tetrahydronaphthyl, indolyl, tetrahydrofuryl, pyrrolidinyl, andmorpholinyl, wherein R¹ is optionally substituted by one or moresubstituents selected from the group consisting of methyl, ethyl,propyl, bromo, fluoro, chloro, and keto;

R² is selected from the group consisting of methyl, phenyl, biphenyl,naphthyl, tetrahydrofuryl, pyrrolidinyl, morpholinyl, piperidyl,thienyl, pyrrolyl, and pyridyl, or R² and R⁸ together with the atom towhich they are both attached form a piperidyl or cyclohexyl group,wherein R² or the piperidyl or cyclohexyl group formed with R⁸ isoptionally substituted by one or more substituents selected from thegroup consisting of methoxy, ethoxy, methyl, ethyl, isopropyl, isobutyl,methylphenoxy, methylthio, phenylethenyl, benzyloxy, phenylethoxy,benzyl, phenoxy, cyano, fluoro, chloro, bromo, trifluoromethyl,trifluoromethylphenyl, dichlorophenoxy, imidazole, benzodioxole,hydroxy, hydroxyethoxy, N-(methylcarbonyl)amino, and nitro;

R⁴, R⁵, R⁶, R⁷, and R⁹ are independently selected from the groupconsisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, fluoro,chloro, and bromo; and

R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independentlyselected from the group consisting of hydrogen, methyl, hydroxy, andmethoxy.

In another embodiment, the MCH receptor antagonist is selected from asubclass of compounds of Formula I represented by Formula V:

wherein

Z is selected from the group consisting of a bond, alkyl, aralkyl,heteroaralkyl, and heterocyclo;

R¹ is selected from the group consisting of alkoxycarbonyl, alkyl,aralkyl, aryl, heteroaryl, and heterocyclo, wherein R¹ is optionallysubstituted by one or more substituents selected from the groupconsisting of alkyl, halo, and keto;

R² is selected from the group consisting of alkyl, aryl, and heteroaryl,or R² and R⁸ together with the atom to which they are both attached forma 5- or 6-membered cycloalkyl or heterocyclo group, wherein R² or thecycloalkyl or heterocyclo group formed with R⁸ is optionally substitutedby one or more substituents selected from the group consisting ofalkoxy, alkyl, alkylaryloxy, alkylthio, aralkenyl, aralkoxy, aralkyl,aryloxy, cyano, halo, haloalkyl, haloalkylaryl, haloaryloxy, heteroaryl,hydroxy, hydroxyalkoxy, N-(alkylcarbonyl)amino, and nitro;

R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independentlyselected from the group consisting of hydrogen, alkyl, hydroxy, andalkoxy;

or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula V, or a pharmaceutically-acceptable salt, tautomer or prodrugthereof, wherein Z is selected from the group consisting of a bond,lower alkyl, lower aralkyl, lower heteroaralkyl, and 3- to 10-memberedheterocyclo;

R¹ is selected from the group consisting of lower alkoxycarbonyl, loweralkyl, lower aralkyl, aryl, 3- to 10-membered heteroaryl, and 3- to10-membered heterocyclo, wherein R¹ is optionally substituted by one ormore substituents selected from the group consisting of lower alkyl,halo, and keto;

R² is selected from the group consisting of lower alkyl, aryl, and 3- to10-membered heteroaryl, or R² and R⁸ together with the atom to whichthey are both attached form a 5- or 6-membered cycloalkyl or heterocyclogroup, wherein R² or the cycloalkyl or heterocyclo group formed with R⁸is optionally substituted by one or more substituents selected from thegroup consisting of lower alkoxy, lower alkyl, lower alkylaryloxy, loweralkylthio, lower aralkenyl, lower aralkoxy, lower aralkyl, aryloxy,cyano, halo, lower haloalkyl, lower haloalkylaryl, haloaryloxy, 3- to10-membered heteroaryl, hydroxy, lower hydroxyalkoxy, N-(loweralkylcarbonyl)amino, and nitro;

R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independentlyselected from the group consisting of hydrogen, lower alkyl, hydroxy,and lower alkoxy.

In another embodiment, the MCH receptor antagonist consists of compoundsof Formula V, or a pharmaceutically-acceptable salt, tautomer or prodrugthereof, wherein Z is selected from the group consisting of a bond,methyl, ethyl, propyl, t-butyl, phenylpropyl, indolylethyl, andpiperidyl;

R¹ is selected from the group consisting of methoxycarbonyl,ethoxycarbonyl, t-butoxycarbonyl, isopropyl, n-butyl, t-butyl, benzyl,phenyl, tetrahydronaphthyl, indolyl, tetrahydrofuryl, pyrrolidinyl, andmorpholinyl, wherein R¹ is optionally substituted by one or moresubstituents selected from the group consisting of methyl, chloro, andketo;

R² is selected from the group consisting of methyl, phenyl, biphenyl,naphthyl, thienyl, pyrrolyl, and pyridyl, or R² and R⁸ together with theatom to which they are both attached form a piperidyl or cyclohexylgroup, wherein R² or the piperidyl or cyclohexyl group formed with R⁸ isoptionally substituted by one or more substituents selected from thegroup consisting of methoxy, ethoxy, methyl, ethyl, isopropyl, isobutyl,methylphenoxy, methylthio, phenylethenyl, benzyloxy, phenylethoxy,benzyl, phenoxy, cyano, fluoro, chloro, bromo, trifluoromethyl,trifluoromethylphenyl, dichlorophenoxy, imidazole, benzodioxole,hydroxy, hydroxyethoxy, N-(methylcarbonyl)amino, and nitro;

R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e) are independentlyselected from the group consisting of hydrogen, methyl, hydroxy, andmethoxy.

In another embodiment, the compound of Formula I is selected from thegroup of compounds listed in Table 1.

TABLE 1 Com- pound No. Structure 1

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z repeat (M + H); MW464.62 4

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z repeat (M + H); MW464.62 11

1-{biphenyl-4-yl-[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z repeat (M + H);MW 540.2 12

1-[[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]-(3-phenoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 557.32 (M + H);MW 556.7 14

1-[(1-tert-butyl-1H-tetrazol-s-yl)phenylmethyl]-4-(3-phenylallyl)piperazine MS m/z 417.3 (M + H); MW 416.6 15

1-[(1-benzyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3- phenylallyl)piperazineMS m/z 451.28 (M + H); MW 450.6 16

(5-{phenyl-[4-(3-phenylallyl)piperazin-1- yl]methyl}tetrazol-1-yl)aceticacid methyl ester MS m/z 433.26 (M + H); MW 432.5 17

1-[(1-butyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3- phenylallyl)piperazineMS m/z 417.31 (M + H); MW 416.6 19

1-[(1-isopropyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine MS m/z 403.28 (M + H); MW 402.5 20

5-5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)-1H-indole MS m/z 276.28 (M + H); MW 475.6 21

(5-{phenyl-[4-(3-phenylallyl)piperazin-1- yl[methyl}tetrazol-1-yl)aceticacid ethyl ester MS m/z 447.29 (M + H); MW 446.6 22

1-(3-phenylallyl)-4-{phenyl-[1-(1,1,3,3-tetramethylbutyl)-1H-tetrazol-5- yl]methyl}piperazine MS m/z 473.37 (M +H); MW 472.7 24

(5-{phenyl-[4-(3-phenylallyl)piperazin-1- yl]methyl}tetrazol-1-yl)aceticacid tert-butyl ester MS m/z 475.3 (M + H); MW 474.6 26

3-phenyl-2-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1- yl)propionic acid methylester MS m/z 523.32 (M + H); MW 522.7 27

1-{[1-(3,3-diphenylpropyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z 555.4 (M + H); MW554.7 28

1-{[1-(1-benzylpiperidin-4-yl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z 534.37 (M+ H); MW533.7 29

3-[2-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)ethyl]-1H-indole MS m/z 504.33 (M + H); MW 503.730

1-{[1-(3,4-dichlorobenzyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine MS m/z 519.22 (M + H); MW519.5 31

3-(1H-indol-3-yl)-2-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1- yl)propionic acid methylester MS m/z 562.34 (M + H); MW 561.7 33

1-(3-phenylallyl)-4-{phenyl-[1-(tetrahydrofuran-2-ylmethyl)-1H-tetrazol-5-yl]methyl}piperazine MS m/z 445.31 (M + H); MW444.6 35

1-[(1-phenethyl-1H-tetrazol-5-yl)phenylmethyl]-4- (3-phenylallyl)piperazine MS m/z 465.29 (M + H); MW 464.6 36

1-[3-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)propyl]pyrrolidin-2-one MS m/z 486.34 (M + H);MW 485.6 37

1-({1-[2-(1-methyl-pyrrolidin-2-yl)ethyl]-1H-tetrazol-5-yl}phenylmethyl)-4-(3- phenylallyl)piperazine MS m/z 472.35(M + H); MW 471.6 38

1-(3-phenylallyl)-4-{phenyl-[1-(5,6,7,8-tetrahydronaphthalen-1-yl)-1H-tetrazol-5- yl]methyl}piperazine MS m/z491.33 (M + H); MW 490.7 39

1-({1-[2-(4-chlorophenyl)ethyl]-1H-tetrazol-5-yl}phenylmethyl)-4-(3-phenylallyl)piperazine MS m/z 499.27 (M + H); MW499.1 42

4-[3-5-{phenyl-[4-(3-phenylallyll)piperazin-1-yl]methyl}tetrazol-1-yl)propyl]morpholine MS m/z 488.35 (M + H); MW487.6 46

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]naphthalen-1-ylmethyl}-4-(3- phenylallyl)piperazine MS m/z 567.35(M + H); MW 566.7 48

1-[[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]-(3-fluorophenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 483.3 (M + H);MW 482.6 52

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-styrylphenyl)methyl]-4-(3-phenylallyl)piperazirie MS m/z 567.35 (M + H);MW 566.7 53

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5- yl]thiophen-2-ylmethyl}-4-(3-phenylallyl)piperazine MS m/z 471.25 (M + H); MW 470.6 55

1-{[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]-p-tolylmethyl]-4-(3-phenylallyl)piperazine MS m/z 479.32 (M + H); MW 478.656

1-[[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethyiphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 533.31(M + H); MW 532.6 57

1-{(4-chlorophenyl)-[1-(2,6-dimethyiphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 499.25 (M + H);MW 499.1 58

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-fluorophenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 483.3 (M + H);MW 482.6 60

1-{(3,4-dichlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 533.23 (M +H); MW 533.5 61

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-m-tolylmethyl}-4-(3-phenylallyl) piperazine MS m/z 479.33 (M + H); MW478.6 62

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]naphthalen-2-ylmethyl}-4-(3- phenylallyl)piperazine MS m/z 515.32(M + H); MW 514.7 63

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-trifluoromethylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 533.31(M + H); MW 532.6 64

1-{biphenyl-4-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 541.33 (M + H);MW 540.7 65

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(1-methyl-1H-pyrrol-2-yl)methyl]-4-(3- phenylallyl)piperazine MS m/z repeat(M + H); MW 467.6 66

1-{(2-benzyloxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 571.34 (M +H); MW 570.7 67

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(2-methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 495.31 (M + H);MW 494.6 68

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[5-(3-trifluoromethylphenyl)furan-2-yl]methyl}-4-(3- phenylallyl)piperazineMS m/z 599.32 (M + H); MW 598.7 69

1-{2-benzyloxy-1-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]ethyl}-4-(3-phenylallyl)piperazine MS m/z 509.3 (M + H);MW 508.7 70

1-{(4-benzyloxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 571.35 (M +H); MW 570.7 71

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(6-methylpyridin-2-yl)methyl]-4-(3- phenylallyl)piperazine MS m/z 480.31(M + H); MW 479.6 72

1-{[3-(3,4-dichlorophenoxy)phenyl]-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl) piperazineMS m/z 625.26 (M + H); MW 625.6 73

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-p-tolyloxyphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 571.3 (M +H); MW 570.7 74

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]pyridin-3-ylmethyl}-4-(3-phenylallyl)piperazine MS m/z 466.3 (M + H); MW 465.6 75

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]pyridin-2-ylmethyl}-4-(3-phenylallyl)piperazine MS m/z 466.3 (M + H); MW 465.6 76

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-phenoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 557.3 (M + H);MW 556.7 77

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 495.31 (M + H);MW 494.6 78

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-imidazol-1-ylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 531.3(M + H); MW 530.7 79

3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}benzonitrile MS m/z 490.28 (M + H);MW 489.6 80

2-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}benzonitrile MS m/z 490.31 (M + H);MW 489.6 81

1-{benzo[1,3]diaxol-4-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z repeat (M +H); MW 508 82

3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}phenol MS m/z 481.3 (M + H); MW480.6 83

1-{benzo[1,3]dioxol-5-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 509.3 (M +H); MW 508.6 84

2-(3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1- yl]methyl}phenoxy)ethanol MS m/z repeat(M + H); MW 524.67 85

1-{1-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-2-phenethyloxyethyl}-4-(3-phenylallyl)piperazine MS m/z 523.35 (M + H); MW522.7 86

1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5- yl]pyridin-4-ylmethyl}-4-(3-phenylallyl)piperazine MS m/z 466.31 (M + H); MW 465.6 87

1-{[3-(3,5-dichloro-phenoxy)-phenyl]-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MSm/z 625.25 (M + H); MW 625.6 91

1-{1-benzyl-4-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]piperidin-4-yl}-4-(3- phenylallyl)piperazine MS m/z xxxx(M + H); MW 547.7 92

1-{1-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]cyclohexyl)-4-(3-phenylallyl)piperazine MS m/z repeat (M + H); MW456.64 99

1-{4-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-1-methylpiperidin-4-yl}-4-(3-phenylallyl)piperazine MS m/z xxxx (M + H);MW 471.6 103

1-{(4-bromophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 543.2 (M + H);MW 543.5 116

1-{(4-bromophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 543.2 (M + H);MW 543.5 118

1-{(4-chiorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 499.27 (M + H);MW 499.1 119

1-(3-phenylallyl)-4-[phenyl-(1-phenyl-1H- tetrazol-5-yl)methyl]piperazine MS m/z 503.3 (M + H); MW 436.5 121

1-[(4-imidazol-1-ylphenyl)-(1-phenyl-1H-tetrazol-5-yl)methyl]-4-(3-phenylallyl)piperazine MS m/z 503.3 (M + H); MW 502.6122

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 495.31 (M + H);MW 494.6 123

1-{(3,4-dimethylphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 493.31 (M +H); MW 492.7 124

1-{(3,4-difluoraphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 501.27 (M +H); MW 500.6 125

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-isopropylphenyl)methyl}-4-(3- phenylallyl)piperazine MS m/z 507.34 (M +H); MW 506.7 126

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-methylsulfanylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 511.28(M + H); MW 510.7 127

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-ethylphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 493.32 (M + H);MW 492.7 128

1-{(3,4-dimethoxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 525.33 (M +H); MW 524.7 129

1-{(4-benzyloxy-3-methoxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MSm/z 601.35 (M + H); MW 600.8 130

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-isobutylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 521.35 (M +H); MW 520.7 131

n-(4-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1- yl]methyl}phenyl)acetamide MS m/z 522.31(M + H); MW 521.7 133

3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}benzonitrile MS m/z 490.300 (M +H); MW 489.6 134

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-imidazol-1-ylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 531.33(M + H); MW 530.7 135

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-imidazol-1-ylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 531.33(M + H); MW 530.7 136

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-ethoxyphenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 509.32 (M + H);MW 508.7 137

1-{(3,5-dichlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3- phenylallyl)piperazine MS m/z 533.23 (M +H); MW 533.5 138

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-nitrophenyl)methyl]-4-(3-phenylallyl)piperazine MS m/z 510.29 (M + H);MW 509.6 139

1-{(3-bromophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 543.22 (M + H);MW 543.5 140

1-{(3-chlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 500.26 (M + H);MW 499.1 142

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z 533.27(M + H); MW 532.6 143

1-{biphenyl-3-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine MS m/z 541.34 (M + H);MW 540.7 144

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3,3- diphenylallyl)piperazine MS m/z609.32 (M + H); MW 608.7 147

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-[3-(4- methoxyphenyl)allyl]piperazine MSm/z 563.29 (M + H); MW 562.6 148

2-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1-ylmethyl}-1-methyl-1H-indole MS m/z 560.32 (M + H); MW 559.6 150

3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1- ylmethyl}-1H-indole MS m/z417.23 (M + H); MW 545.6 151

2-(3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1- yl}propenyl)phenol MSm/z 549.30 (M + H); MW 548.6 154

1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3- phenylpropyl)piperazine MS m/z 535.3(M + H); MW 534.6 156

1-benzo[1,3]dioxol-5-ylmethyl-4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazine MS m/z 551.25 (M + H); MW 550.6162

(1-benzylpyrrolidin-3-yl)-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]ethylamine MS m/z 535.29 (M + H); MW 534.6163

4-(3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1-yl}propenyl)-2-methoxyphenol MS m/z 579.31 (M + H); MW 578.6 164

1-[[1-(2,6-dichlorophenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3- phenylallyl)piperazine MS m/z xxxx(M + H); MW 573.4

In another embodiment, the compound of Formula I is selected from thegroup of compounds of Formula V having the formula

wherein R^(1a), R^(1b), R^(2a), R^(2b), and R^(2c) are as defined inTable 2.

TABLE 2 Compound No. R^(1a) R^(1b) R^(2a) R^(2b) R^(2c) 200 H CH₃ CH₃ HH 201 H CH₃ CH₃ CH₃ H 202 H CH₃ CH₃ OCH₃ H 203 H CH₃ CH₃ Cl H 204 H CH₃CH₃ Br H 205 H CH₃ CH₃ F H 206 H CH₃ CH₃ H CH₃ 207 H CH₃ CH₃ CH₃ CH₃ 208H CH₃ CH₃ H OCH₃ 209 H CH₃ CH₃ CH₃ OCH₃ 210 H CH₃ CH₃ OCH₃ OCH₃ 211 HCH₃ CH₃ Cl OCH₃ 212 H CH₃ CH₃ Br OCH₃ 213 H CH₃ CH₃ F OCH₃ 214 H CH₃ CH₃H Cl 215 H CH₃ CH₃ CH₃ Cl 216 H CH₃ CH₃ OCH₃ Cl 217 H CH₃ CH₃ Cl Cl 218H CH₃ CH₃ Br Cl 219 H CH₃ CH₃ F Cl 220 H CH₃ CH₃ H Br 221 H CH₃ CH₃ CH₃Br 222 H CH₃ CH₃ OCH₃ Br 223 H CH₃ CH₃ Cl Br 224 H CH₃ CH₃ Br Br 225 HCH₃ CH₃ F Br 226 H CH₃ CH₃ H F 227 H CH₃ CH₃ CH₃ F 228 H CH₃ CH₃ OCH₃ F229 H CH₃ CH₃ Cl F 230 H CH₃ CH₃ Br F 231 H CH₃ CH₃ F F 232 H CH₃ OCH₃ HH 233 H CH₃ OCH₃ CH₃ H 234 H CH₃ OCH₃ OCH₃ H 235 H CH₃ OCH₃ Cl H 236 HCH₃ OCH₃ Br H 237 H CH₃ OCH₃ F H 238 H CH₃ OCH₃ H CH₃ 239 H CH₃ OCH₃ CH₃CH₃ 240 H CH₃ OCH₃ OCH₃ CH₃ 241 H CH₃ OCH₃ Cl CH₃ 242 H CH₃ OCH₃ Br CH₃243 H CH₃ OCH₃ F CH₃ 244 H CH₃ OCH₃ H OCH₃ 245 H CH₃ OCH₃ OCH₃ OCH₃ 246H CH₃ OCH₃ H Cl 247 H CH₃ OCH₃ CH₃ Cl 248 H CH₃ OCH₃ OCH₃ Cl 249 H CH₃OCH₃ Cl Cl 250 H CH₃ OCH₃ Br Cl 251 H CH₃ OCH₃ F Cl 252 H CH₃ OCH₃ H Br253 H CH₃ OCH₃ CH₃ Br 254 H CH₃ OCH₃ OCH₃ Br 255 H CH₃ OCH₃ Cl Br 256 HCH₃ OCH₃ Br Br 257 H CH₃ OCH₃ F Br 258 H CH₃ OCH₃ H F 259 H CH₃ OCH₃ CH₃F 260 H CH₃ OCH₃ OCH₃ F 261 H CH₃ OCH₃ Cl F 262 H CH₃ OCH₃ Br F 263 HCH₃ OCH₃ F F 264 H CH₃ Cl H H 265 H CH₃ Cl CH₃ H 266 H CH₃ Cl OCH₃ H 267H CH₃ Cl Cl H 268 H CH₃ Cl Br H 269 H CH₃ Cl F H 270 H CH₃ Cl H CH₃ 271H CH₃ Cl CH₃ CH₃ 272 H CH₃ Cl OCH₃ CH₃ 273 H CH₃ Cl Cl CH₃ 274 H CH₃ ClBr CH₃ 275 H CH₃ Cl F CH₃ 276 H CH₃ Cl H OCH₃ 277 H CH₃ Cl CH₃ OCH₃ 278H CH₃ Cl OCH₃ OCH₃ 279 H CH₃ Cl Cl OCH₃ 280 H CH₃ Cl Br OCH₃ 281 H CH₃Cl F OCH₃ 282 H CH₃ Cl H Cl 283 H CH₃ Cl Cl Cl 284 H CH₃ Cl H Br 285 HCH₃ Cl CH₃ Br 286 H CH₃ Cl OCH₃ Br 287 H CH₃ Cl Cl Br 288 H CH₃ Cl Br Br289 H CH₃ Cl F Br 290 H CH₃ Cl H F 291 H CH₃ Cl CH₃ F 292 H CH₃ Cl OCH₃F 293 H CH₃ Cl Cl F 294 H CH₃ Cl F F 295 H CH₃ Br H H 296 H CH₃ Br CH₃ H297 H CH₃ Br OCH₃ H 298 H CH₃ Br Cl H 299 H CH₃ Br Br H 300 H CH₃ Br F H301 H CH₃ Br H CH₃ 302 H CH₃ Br CH₃ CH₃ 303 H CH₃ Br OCH₃ CH₃ 304 H CH₃Br Cl CH₃ 305 H CH₃ Br Br CH₃ 306 H CH₃ Br F CH₃ 307 H CH₃ Br H OCH₃ 308H CH₃ Br CH₃ OCH₃ 309 H CH₃ Br OCH₃ OCH₃ 310 H CH₃ Br Cl OCH₃ 311 H CH₃Br Br OCH₃ 312 H CH₃ Br F OCH₃ 313 H CH₃ Br H Cl 314 H CH₃ Br CH₃ Cl 315H CH₃ Br OCH₃ Cl 316 H CH₃ Br Cl Cl 317 H CH₃ Br Br Cl 318 H CH₃ Br F Cl319 H CH₃ Br H Br 320 H CH₃ Br Br Br 321 H CH₃ Br H F 322 H CH₃ Br CH₃ F323 H CH₃ Br OCH₃ F 324 H CH₃ Br Cl F 325 H CH₃ Br Br F 326 H CH₃ Br F F327 H CH₃ F H H 328 H CH₃ F CH₃ H 329 H CH₃ F OCH₃ H 330 H CH₃ F Cl H331 H CH₃ F Br H 332 H CH₃ F F H 333 H CH₃ F H CH₃ 334 H CH₃ F CH₃ CH₃335 H CH₃ F OCH₃ CH₃ 336 H CH₃ F Cl CH₃ 337 H CH₃ F Br CH₃ 338 H CH₃ F FCH₃ 339 H CH₃ F H OCH₃ 340 H CH₃ F CH₃ OCH₃ 341 H CH₃ F OCH₃ OCH₃ 342 HCH₃ F Cl OCH₃ 343 H CH₃ F Br OCH₃ 344 H CH₃ F F OCH₃ 345 H CH₃ F H Cl346 H CH₃ F CH₃ Cl 347 H CH₃ F OCH₃ Cl 348 H CH₃ F Cl Cl 349 H CH₃ F BrCl 350 H CH₃ F F Cl 351 H CH₃ F H Br 352 H CH₃ F CH₃ Br 353 H CH₃ F OCH₃Br 354 H CH₃ F Cl Br 355 H CH₃ F Br Br 356 H CH₃ F F Br 357 H CH₃ F H F358 H CH₃ F F F 359 H OCH₃ CH₃ H H 360 H OCH₃ CH₃ H CH₃ 361 H OCH₃ CH₃ HOCH₃ 362 H OCH₃ CH₃ H Cl 363 H OCH₃ CH₃ H Br 364 H OCH₃ CH₃ H F 365 HOCH₃ CH₃ CH₃ H 366 H OCH₃ CH₃ CH₃ CH₃ 367 H OCH₃ CH₃ CH₃ OCH₃ 368 H OCH₃CH₃ CH₃ Cl 369 H OCH₃ CH₃ CH₃ Br 370 H OCH₃ CH₃ CH₃ F 371 H OCH₃ CH₃OCH₃ H 372 H OCH₃ CH₃ OCH₃ OCH₃ 373 H OCH₃ CH₃ OCH₃ Cl 374 H OCH₃ CH₃OCH₃ Br 375 H OCH₃ CH₃ OCH₃ F 376 H OCH₃ CH₃ Cl H 377 H OCH₃ CH₃ Cl OCH₃378 H OCH₃ CH₃ Cl Cl 379 H OCH₃ CH₃ Cl Br 380 H OCH₃ CH₃ Cl F 381 H OCH₃CH₃ Br H 382 H OCH₃ CH₃ Br OCH₃ 383 H OCH₃ CH₃ Br Cl 384 H OCH₃ CH₃ BrBr 385 H OCH₃ CH₃ Br F 386 H OCH₃ CH₃ F H 387 H OCH₃ CH₃ F OCH₃ 388 HOCH₃ CH₃ F Cl 389 H OCH₃ CH₃ F Br 390 H OCH₃ CH₃ F F 391 H OCH₃ OCH₃ H H392 H OCH₃ OCH₃ H CH₃ 393 H OCH₃ OCH₃ H OCH₃ 394 H OCH₃ OCH₃ H Cl 395 HOCH₃ OCH₃ H Br 396 H OCH₃ OCH₃ H F 397 H OCH₃ OCH₃ CH₃ H 398 H OCH₃ OCH₃CH₃ CH₃ 399 H OCH₃ OCH₃ CH₃ Cl 400 H OCH₃ OCH₃ CH₃ Br 401 H OCH₃ OCH₃CH₃ F 402 H OCH₃ OCH₃ OCH₃ H 403 H OCH₃ OCH₃ OCH₃ CH₃ 404 H OCH₃ OCH₃OCH₃ OCH₃ 405 H OCH₃ OCH₃ OCH₃ Cl 406 H OCH₃ OCH₃ OCH₃ Br 407 H OCH₃OCH₃ OCH₃ F 408 H OCH₃ OCH₃ Cl H 409 H OCH₃ OCH₃ Cl CH₃ 410 H OCH₃ OCH₃Cl Cl 411 H OCH₃ OCH₃ Cl Br 412 H OCH₃ OCH₃ Cl F 413 H OCH₃ OCH₃ Br H414 H OCH₃ OCH₃ Br CH₃ 415 H OCH₃ OCH₃ Br Cl 416 H OCH₃ OCH₃ Br Br 417 HOCH₃ OCH₃ Br F 418 H OCH₃ OCH₃ F H 419 H OCH₃ OCH₃ F CH₃ 420 H OCH₃ OCH₃F Cl 421 H OCH₃ OCH₃ F Br 422 H OCH₃ OCH₃ F F 423 H OCH₃ Cl H H 424 HOCH₃ Cl H CH₃ 425 H OCH₃ Cl H OCH₃ 426 H OCH₃ Cl H Cl 427 H OCH₃ Cl H Br428 H OCH₃ Cl H F 429 H OCH₃ Cl CH₃ H 430 H OCH₃ Cl CH₃ CH₃ 431 H OCH₃Cl CH₃ OCH₃ 432 H OCH₃ Cl CH₃ Br 433 H OCH₃ Cl CH₃ F 434 H OCH₃ Cl OCH₃H 435 H OCH₃ Cl OCH₃ CH₃ 436 H OCH₃ Cl OCH₃ OCH₃ 437 H OCH₃ Cl OCH₃ Br438 H OCH₃ Cl OCH₃ F 439 H OCH₃ Cl Cl H 440 H OCH₃ Cl Cl CH₃ 441 H OCH₃Cl Cl OCH₃ 442 H OCH₃ Cl Cl Cl 443 H OCH₃ Cl Cl Br 444 H OCH₃ Cl Cl F445 H OCH₃ Cl Br H 446 H OCH₃ Cl Br CH₃ 447 H OCH₃ Cl Br OCH₃ 448 H OCH₃Cl Br Br 449 H OCH₃ Cl F H 450 H OCH₃ Cl F CH₃ 451 H OCH₃ Cl F OCH₃ 452H OCH₃ Cl F Br 453 H OCH₃ Cl F F 454 H OCH₃ Br H H 455 H OCH₃ Br H CH₃456 H OCH₃ Br H OCH₃ 457 H OCH₃ Br H Cl 458 H OCH₃ Br H Br 459 H OCH₃ BrH F 460 H OCH₃ Br CH₃ H 461 H OCH₃ Br CH₃ CH₃ 462 H OCH₃ Br CH₃ OCH₃ 463H OCH₃ Br CH₃ Cl 464 H OCH₃ Br CH₃ F 465 H OCH₃ Br OCH₃ H 466 H OCH₃ BrOCH₃ CH₃ 467 H OCH₃ Br OCH₃ OCH₃ 468 H OCH₃ Br OCH₃ Cl 469 H OCH₃ BrOCH₃ F 470 H OCH₃ Br Cl H 471 H OCH₃ Br Cl CH₃ 472 H OCH₃ Br Cl OCH₃ 473H OCH₃ Br Cl Cl 474 H OCH₃ Br Cl F 475 H OCH₃ Br Br H 476 H OCH₃ Br BrCH₃ 477 H OCH₃ Br Br OCH₃ 478 H OCH₃ Br Br Cl 479 H OCH₃ Br Br Br 480 HOCH₃ Br Br F 481 H OCH₃ Br F H 482 H OCH₃ Br F CH₃ 483 H OCH₃ Br F OCH₃484 H OCH₃ Br F Cl 485 H OCH₃ Br F F 486 H OCH₃ F H H 487 H OCH₃ F H CH₃488 H OCH₃ F H OCH₃ 489 H OCH₃ F H Cl 490 H OCH₃ F H Br 491 H OCH₃ F H F492 H OCH₃ F CH₃ H 493 H OCH₃ F CH₃ CH₃ 494 H OCH₃ F CH₃ OCH₃ 495 H OCH₃F CH₃ Cl 496 H OCH₃ F CH₃ Br 497 H OCH₃ F OCH₃ H 498 H OCH₃ F OCH₃ CH₃499 H OCH₃ F OCH₃ OCH₃ 500 H OCH₃ F OCH₃ Cl 501 H OCH₃ F OCH₃ Br 502 HOCH₃ F Cl H 503 H OCH₃ F Cl CH₃ 504 H OCH₃ F Cl OCH₃ 505 H OCH₃ F Cl Cl506 H OCH₃ F Cl Br 507 H OCH₃ F Br H 508 H OCH₃ F Br CH₃ 509 H OCH₃ F BrOCH₃ 510 H OCH₃ F Br Cl 511 H OCH₃ F Br Br 512 H OCH₃ F F H 513 H OCH₃ FF CH₃ 514 H OCH₃ F F OCH₃ 515 H OCH₃ F F Cl 516 H OCH₃ F F Br 517 H OCH₃F F F 518 H Cl CH₃ H H 519 H Cl CH₃ H CH₃ 520 H Cl CH₃ H OCH₃ 521 H ClCH₃ H Cl 522 H Cl CH₃ H Br 523 H Cl CH₃ H F 524 H Cl CH₃ CH₃ H 525 H ClCH₃ CH₃ CH₃ 526 H Cl CH₃ CH₃ OCH₃ 527 H Cl CH₃ CH₃ Cl 528 H Cl CH₃ CH₃Br 529 H Cl CH₃ CH₃ F 530 H Cl CH₃ OCH₃ H 531 H Cl CH₃ OCH₃ OCH₃ 532 HCl CH₃ OCH₃ Cl 533 H Cl CH₃ OCH₃ Br 534 H Cl CH₃ OCH₃ F 535 H Cl CH₃ ClH 536 H Cl CH₃ Cl OCH₃ 537 H Cl CH₃ Cl Cl 538 H Cl CH₃ Cl Br 539 H ClCH₃ Cl F 540 H Cl CH₃ Br H 541 H Cl CH₃ Br OCH₃ 542 H Cl CH₃ Br Cl 543 HCl CH₃ Br Br 544 H Cl CH₃ Br F 545 H Cl CH₃ F H 546 H Cl CH₃ F OCH₃ 547H Cl CH₃ F Cl 548 H Cl CH₃ F Br 549 H Cl CH₃ F F 550 H Cl OCH₃ H H 551 HCl OCH₃ H CH₃ 552 H Cl OCH₃ H OCH₃ 553 H Cl OCH₃ H Cl 554 H Cl OCH₃ H Br555 H Cl OCH₃ H F 556 H Cl OCH₃ CH₃ H 557 H Cl OCH₃ CH₃ CH₃ 558 H ClOCH₃ CH₃ Cl 559 H Cl OCH₃ CH₃ Br 560 H Cl OCH₃ CH₃ F 561 H Cl OCH₃ OCH₃H 562 H Cl OCH₃ OCH₃ CH₃ 563 H Cl OCH₃ OCH₃ OCH₃ 564 H Cl OCH₃ OCH₃ Cl565 H Cl OCH₃ OCH₃ Br 566 H Cl OCH₃ OCH₃ F 567 H Cl OCH₃ Cl H 568 H ClOCH₃ Cl CH₃ 569 H Cl OCH₃ Cl Cl 570 H Cl OCH₃ Cl Br 571 H Cl OCH₃ Cl F572 H Cl OCH₃ Br H 573 H Cl OCH₃ Br CH₃ 574 H Cl OCH₃ Br Cl 575 H ClOCH₃ Br Br 576 H Cl OCH₃ Br F 577 H Cl OCH₃ F H 578 H Cl OCH₃ F CH₃ 579H Cl OCH₃ F Cl 580 H Cl OCH₃ F Br 581 H Cl OCH₃ F F 582 H Cl Cl H H 583H Cl Cl H CH₃ 584 H Cl Cl H OCH₃ 585 H Cl Cl H Cl 586 H Cl Cl H Br 587 HCl Cl H F 588 H Cl Cl CH₃ H 589 H Cl Cl CH₃ CH₃ 590 H Cl Cl CH₃ OCH₃ 591H Cl Cl CH₃ Br 592 H Cl Cl CH₃ F 593 H Cl Cl OCH₃ H 594 H Cl Cl OCH₃ CH₃595 H Cl Cl OCH₃ OCH₃ 596 H Cl Cl OCH₃ Br 597 H Cl Cl OCH₃ F 598 H Cl ClCl H 599 H Cl Cl Cl CH₃ 600 H Cl Cl Cl OCH₃ 601 H Cl Cl Cl Cl 602 H ClCl Cl Br 603 H Cl Cl Cl F 604 H Cl Cl Br H 605 H Cl Cl Br CH₃ 606 H ClCl Br OCH₃ 607 H Cl Cl Br Br 608 H Cl Cl F H 609 H Cl Cl F CH₃ 610 H ClCl F OCH₃ 611 H Cl Cl F Br 612 H Cl Cl F F 613 H Cl Br H H 614 H Cl Br HCH₃ 615 H Cl Br H OCH₃ 616 H Cl Br H Cl 617 H Cl Br H Br 618 H Cl Br H F619 H Cl Br CH₃ H 620 H Cl Br CH₃ CH₃ 621 H Cl Br CH₃ OCH₃ 622 H Cl BrCH₃ Cl 623 H Cl Br CH₃ F 624 H Cl Br OCH₃ H 625 H Cl Br OCH₃ CH₃ 626 HCl Br OCH₃ OCH₃ 627 H Cl Br OCH₃ Cl 628 H Cl Br OCH₃ F 629 H Cl Br Cl H630 H Cl Br Cl CH₃ 631 H Cl Br Cl OCH₃ 632 H Cl Br Cl Cl 633 H Cl Br ClF 634 H Cl Br Br H 635 H Cl Br Br CH₃ 636 H Cl Br Br OCH₃ 637 H Cl Br BrCl 638 H Cl Br Br Br 639 H Cl Br Br F 640 H Cl Br F H 641 H Cl Br F CH₃642 H Cl Br F OCH₃ 643 H Cl Br F Cl 644 H Cl Br F F 645 H Cl F H H 646 HCl F H CH₃ 647 H Cl F H OCH₃ 648 H Cl F H Cl 649 H Cl F H Br 650 H Cl FH F 651 H Cl F CH₃ H 652 H Cl F CH₃ CH₃ 653 H Cl F CH₃ OCH₃ 654 H Cl FCH₃ Cl 655 H Cl F CH₃ Br 656 H Cl F OCH₃ H 657 H Cl F OCH₃ CH₃ 658 H ClF OCH₃ OCH₃ 659 H Cl F OCH₃ Cl 660 H Cl F OCH₃ Br 661 H Cl F Cl H 662 HCl F Cl CH₃ 663 H Cl F Cl OCH₃ 664 H Cl F Cl Cl 665 H Cl F Cl Br 666 HCl F Br H 667 H Cl F Br CH₃ 668 H Cl F Br OCH₃ 669 H Cl F Br Cl 670 H ClF Br Br 671 H Cl F F H 672 H Cl F F CH₃ 673 H Cl F F OCH₃ 674 H Cl F FCl 675 H Cl F F Br 676 H Cl F F F 677 H Br CH₃ H H 678 H Br CH₃ H CH₃679 H Br CH₃ H OCH₃ 680 H Br CH₃ H Cl 681 H Br CH₃ H Br 682 H Br CH₃ H F683 H Br CH₃ CH₃ H 684 H Br CH₃ CH₃ CH₃ 685 H Br CH₃ CH₃ OCH₃ 686 H BrCH₃ CH₃ Cl 687 H Br CH₃ CH₃ Br 688 H Br CH₃ CH₃ F 689 H Br CH₃ OCH₃ H690 H Br CH₃ OCH₃ OCH₃ 691 H Br CH₃ OCH₃ Cl 692 H Br CH₃ OCH₃ Br 693 HBr CH₃ OCH₃ F 694 H Br CH₃ Cl H 695 H Br CH₃ Cl OCH₃ 696 H Br CH₃ Cl Cl697 H Br CH₃ Cl Br 698 H Br CH₃ Cl F 699 H Br CH₃ Br H 700 H Br CH₃ BrOCH₃ 701 H Br CH₃ Br Cl 702 H Br CH₃ Br Br 703 H Br CH₃ Br F 704 H BrCH₃ F H 705 H Br CH₃ F OCH₃ 706 H Br CH₃ F Cl 707 H Br CH₃ F Br 708 H BrCH₃ F F 709 H Br OCH₃ H H 710 H Br OCH₃ H CH₃ 711 H Br OCH₃ H OCH₃ 712 HBr OCH₃ H Cl 713 H Br OCH₃ H Br 714 H Br OCH₃ H F 715 H Br OCH₃ CH₃ H716 H Br OCH₃ CH₃ CH₃ 717 H Br OCH₃ CH₃ Cl 718 H Br OCH₃ CH₃ Br 719 H BrOCH₃ CH₃ F 720 H Br OCH₃ OCH₃ H 721 H Br OCH₃ OCH₃ CH₃ 722 H Br OCH₃OCH₃ OCH₃ 723 H Br OCH₃ OCH₃ Cl 724 H Br OCH₃ OCH₃ Br 725 H Br OCH₃ OCH₃F 726 H Br OCH₃ Cl H 727 H Br OCH₃ Cl CH₃ 728 H Br OCH₃ Cl Cl 729 H BrOCH₃ Cl Br 730 H Br OCH₃ Cl F 731 H Br OCH₃ Br H 732 H Br OCH₃ Br CH₃733 H Br OCH₃ Br Cl 734 H Br OCH₃ Br Br 735 H Br OCH₃ Br F 736 H Br OCH₃F H 737 H Br OCH₃ F CH₃ 738 H Br OCH₃ F Cl 739 H Br OCH₃ F Br 740 H BrOCH₃ F F 741 H Br Cl H H 742 H Br Cl H CH₃ 743 H Br Cl H OCH₃ 744 H BrCl H Cl 745 H Br Cl H Br 746 H Br Cl H F 747 H Br Cl CH₃ H 748 H Br ClCH₃ CH₃ 749 H Br Cl CH₃ OCH₃ 750 H Br Cl CH₃ Br 751 H Br Cl CH₃ F 752 HBr Cl OCH₃ H 753 H Br Cl OCH₃ CH₃ 754 H Br Cl OCH₃ OCH₃ 755 H Br Cl OCH₃Br 756 H Br Cl OCH₃ F 757 H Br Cl Cl H 758 H Br Cl Cl CH₃ 759 H Br Cl ClOCH₃ 760 H Br Cl Cl Cl 761 H Br Cl Cl Br 762 H Br Cl Cl F 763 H Br Cl BrH 764 H Br Cl Br CH₃ 765 H Br Cl Br OCH₃ 766 H Br Cl Br Br 767 H Br Cl FH 768 H Br Cl F CH₃ 769 H Br Cl F OCH₃ 770 H Br Cl F Br 771 H Br Cl F F772 H Br Br H H 773 H Br Br H CH₃ 774 H Br Br H OCH₃ 775 H Br Br H Cl776 H Br Br H Br 777 H Br Br H F 778 H Br Br CH₃ H 779 H Br Br CH₃ CH₃780 H Br Br CH₃ OCH₃ 781 H Br Br CH₃ Cl 782 H Br Br CH₃ F 783 H Br BrOCH₃ H 784 H Br Br OCH₃ CH₃ 785 H Br Br OCH₃ OCH₃ 786 H Br Br OCH₃ Cl787 H Br Br OCH₃ F 788 H Br Br Cl H 789 H Br Br Cl CH₃ 790 H Br Br ClOCH₃ 791 H Br Br Cl Cl 792 H Br Br Cl F 793 H Br Br Br H 794 H Br Br BrCH₃ 795 H Br Br Br OCH₃ 796 H Br Br Br Cl 797 H Br Br Br Br 798 H Br BrBr F 799 H Br Br F H 800 H Br Br F CH₃ 801 H Br Br F OCH₃ 802 H Br Br FCl 803 H Br Br F F 804 H Br F H H 805 H Br F H CH₃ 806 H Br F H OCH₃ 807H Br F H Cl 808 H Br F H Br 809 H Br F H F 810 H Br F CH₃ H 811 H Br FCH₃ CH₃ 812 H Br F CH₃ OCH₃ 813 H Br F CH₃ Cl 814 H Br F CH₃ Br 815 H BrF OCH₃ H 816 H Br F OCH₃ CH₃ 817 H Br F OCH₃ OCH₃ 818 H Br F OCH₃ Cl 819H Br F OCH₃ Br 820 H Br F Cl H 821 H Br F Cl CH₃ 822 H Br F Cl OCH₃ 823H Br F Cl Cl 824 H Br F Cl Br 825 H Br F Br H 826 H Br F Br CH₃ 827 H BrF Br OCH₃ 828 H Br F Br Cl 829 H Br F Br Br 830 H Br F F H 831 H Br F FCH₃ 832 H Br F F OCH₃ 833 H Br F F Cl 834 H Br F F Br 835 H Br F F F 836H F CH₃ H H 837 H F CH₃ H CH₃ 838 H F CH₃ H OCH₃ 839 H F CH₃ H Cl 840 HF CH₃ H Br 841 H F CH₃ H F 842 H F CH₃ CH₃ H 843 H F CH₃ CH₃ CH₃ 844 H FCH₃ CH₃ OCH₃ 845 H F CH₃ CH₃ Cl 846 H F CH₃ CH₃ Br 847 H F CH₃ CH₃ F 848H F CH₃ OCH₃ H 849 H F CH₃ OCH₃ OCH₃ 850 H F CH₃ OCH₃ Cl 851 H F CH₃OCH₃ Br 852 H F CH₃ OCH₃ F 853 H F CH₃ Cl H 854 H F CH₃ Cl OCH₃ 855 H FCH₃ Cl Cl 856 H F CH₃ Cl Br 857 H F CH₃ Cl F 858 H F CH₃ Br H 859 H FCH₃ Br OCH₃ 860 H F CH₃ Br Cl 861 H F CH₃ Br Br 862 H F CH₃ Br F 863 H FCH₃ F H 864 H F CH₃ F OCH₃ 865 H F CH₃ F Cl 866 H F CH₃ F Br 867 H F CH₃F F 868 H F OCH₃ H H 869 H F OCH₃ H CH₃ 870 H F OCH₃ H OCH₃ 871 H F OCH₃H Cl 872 H F OCH₃ H Br 873 H F OCH₃ H F 874 H F OCH₃ CH₃ H 875 H F OCH₃CH₃ CH₃ 876 H F OCH₃ CH₃ Cl 877 H F OCH₃ CH₃ Br 878 H F OCH₃ CH₃ F 879 HF OCH₃ OCH₃ H 880 H F OCH₃ OCH₃ CH₃ 881 H F OCH₃ OCH₃ OCH₃ 882 H F OCH₃OCH₃ Cl 883 H F OCH₃ OCH₃ Br 884 H F OCH₃ OCH₃ F 885 H F OCH₃ Cl H 886 HF OCH₃ Cl CH₃ 887 H F OCH₃ Cl Cl 888 H F OCH₃ Cl Br 889 H F OCH₃ Cl F890 H F OCH₃ Br H 891 H F OCH₃ Br CH₃ 892 H F OCH₃ Br Cl 893 H F OCH₃ BrBr 894 H F OCH₃ Br F 895 H F OCH₃ F H 896 H F OCH₃ F CH₃ 897 H F OCH₃ FCl 898 H F OCH₃ F Br 899 H F OCH₃ F F 900 H F Cl H H 901 H F Cl H CH₃902 H F Cl H OCH₃ 903 H F Cl H Cl 904 H F Cl H Br 905 H F Cl H F 906 H FCl CH₃ H 907 H F Cl CH₃ CH₃ 908 H F Cl CH₃ OCH₃ 909 H F Cl CH₃ Br 910 HF Cl CH₃ F 911 H F Cl OCH₃ H 912 H F Cl OCH₃ CH₃ 913 H F Cl OCH₃ OCH₃914 H F Cl OCH₃ Br 915 H F Cl OCH₃ F 916 H F Cl Cl H 917 H F Cl Cl CH₃918 H F Cl Cl OCH₃ 919 H F Cl Cl Cl 920 H F Cl Cl Br 921 H F Cl Cl F 922H F Cl Br H 923 H F Cl Br CH₃ 924 H F Cl Br OCH₃ 925 H F Cl Br Br 926 HF Cl F H 927 H F Cl F CH₃ 928 H F Cl F OCH₃ 929 H F Cl F Br 930 H F Cl FF 931 H F Br H H 932 H F Br H CH₃ 933 H F Br H OCH₃ 934 H F Br H Cl 935H F Br H Br 936 H F Br H F 937 H F Br CH₃ H 938 H F Br CH₃ CH₃ 939 H FBr CH₃ OCH₃ 940 H F Br CH₃ Cl 941 H F Br CH₃ F 942 H F Br OCH₃ H 943 H FBr OCH₃ CH₃ 944 H F Br OCH₃ OCH₃ 945 H F Br OCH₃ Cl 946 H F Br OCH₃ F947 H F Br Cl H 948 H F Br Cl CH₃ 949 H F Br Cl OCH₃ 950 H F Br Cl Cl951 H F Br Cl F 952 H F Br Br H 953 H F Br Br CH₃ 954 H F Br Br OCH₃ 955H F Br Br Cl 956 H F Br Br Br 957 H F Br Br F 958 H F Br F H 959 H F BrF CH₃ 960 H F Br F OCH₃ 961 H F Br F Cl 962 H F Br F F 963 H F F H H 964H F F H CH₃ 965 H F F H OCH₃ 966 H F F H Cl 967 H F F H Br 968 H F F H F969 H F F CH₃ H 970 H F F CH₃ CH₃ 971 H F F CH₃ OCH₃ 972 H F F CH₃ Cl973 H F F CH₃ Br 974 H F F OCH₃ H 975 H F F OCH₃ CH₃ 976 H F F OCH₃ OCH₃977 H F F OCH₃ Cl 978 H F F OCH₃ Br 979 H F F Cl H 980 H F F Cl CH₃ 981H F F Cl OCH₃ 982 H F F Cl Cl 983 H F F Cl Br 984 H F F Br H 985 H F FBr CH₃ 986 H F F Br OCH₃ 987 H F F Br Cl 988 H F F Br Br 989 H F F F H990 H F F F CH₃ 991 H F F F OCH₃ 992 H F F F Cl 993 H F F F Br 994 H F FF F 995 CH₃ CH₃ CH₃ H H 996 CH₃ CH₃ CH₃ CH₃ H 997 CH₃ CH₃ CH₃ OCH₃ H 998CH₃ CH₃ CH₃ Cl H 999 CH₃ CH₃ CH₃ Br H 1000 CH₃ CH₃ CH₃ F H 1001 CH₃ CH₃CH₃ H CH₃ 1002 CH₃ CH₃ CH₃ CH₃ CH₃ 1003 CH₃ CH₃ CH₃ H OCH₃ 1004 CH₃ CH₃CH₃ CH₃ OCH₃ 1005 CH₃ CH₃ CH₃ OCH₃ OCH₃ 1006 CH₃ CH₃ CH₃ Cl OCH₃ 1007CH₃ CH₃ CH₃ Br OCH₃ 1008 CH₃ CH₃ CH₃ F OCH₃ 1009 CH₃ CH₃ CH₃ H Cl 1010CH₃ CH₃ CH₃ CH₃ Cl 1011 CH₃ CH₃ CH₃ OCH₃ Cl 1012 CH₃ CH₃ CH₃ Cl Cl 1013CH₃ CH₃ CH₃ Br Cl 1014 CH₃ CH₃ CH₃ F Cl 1015 CH₃ CH₃ CH₃ H Br 1016 CH₃CH₃ CH₃ CH₃ Br 1017 CH₃ CH₃ CH₃ OCH₃ Br 1018 CH₃ CH₃ CH₃ Cl Br 1019 CH₃CH₃ CH₃ Br Br 1020 CH₃ CH₃ CH₃ F Br 1021 CH₃ CH₃ CH₃ H F 1022 CH₃ CH₃CH₃ CH₃ F 1023 CH₃ CH₃ CH₃ OCH₃ F 1024 CH₃ CH₃ CH₃ Cl F 1025 CH₃ CH₃ CH₃Br F 1026 CH₃ CH₃ CH₃ F F 1027 CH₃ CH₃ OCH₃ H H 1028 CH₃ CH₃ OCH₃ CH₃ H1029 CH₃ CH₃ OCH₃ OCH₃ H 1030 CH₃ CH₃ OCH₃ Cl H 1031 CH₃ CH₃ OCH₃ Br H1032 CH₃ CH₃ OCH₃ F H 1033 CH₃ CH₃ OCH₃ H CH₃ 1034 CH₃ CH₃ OCH₃ CH₃ CH₃1035 CH₃ CH₃ OCH₃ OCH₃ CH₃ 1036 CH₃ CH₃ OCH₃ Cl CH₃ 1037 CH₃ CH₃ OCH₃ BrCH₃ 1038 CH₃ CH₃ OCH₃ F CH₃ 1039 CH₃ CH₃ OCH₃ H OCH₃ 1040 CH₃ CH₃ OCH₃OCH₃ OCH₃ 1041 CH₃ CH₃ OCH₃ H Cl 1042 CH₃ CH₃ OCH₃ CH₃ Cl 1043 CH₃ CH₃OCH₃ OCH₃ Cl 1044 CH₃ CH₃ OCH₃ Cl Cl 1045 CH₃ CH₃ OCH₃ Br Cl 1046 CH₃CH₃ OCH₃ F Cl 1047 CH₃ CH₃ OCH₃ H Br 1048 CH₃ CH₃ OCH₃ CH₃ Br 1049 CH₃CH₃ OCH₃ OCH₃ Br 1050 CH₃ CH₃ OCH₃ Cl Br 1051 CH₃ CH₃ OCH₃ Br Br 1052CH₃ CH₃ OCH₃ F Br 1053 CH₃ CH₃ OCH₃ H F 1054 CH₃ CH₃ OCH₃ CH₃ F 1055 CH₃CH₃ OCH₃ OCH₃ F 1056 CH₃ CH₃ OCH₃ Cl F 1057 CH₃ CH₃ OCH₃ Br F 1058 CH₃CH₃ OCH₃ F F 1059 CH₃ CH₃ Cl H H 1060 CH₃ CH₃ Cl CH₃ H 1061 CH₃ CH₃ ClOCH₃ H 1062 CH₃ CH₃ Cl Cl H 1063 CH₃ CH₃ Cl Br H 1064 CH₃ CH₃ Cl F H1065 CH₃ CH₃ Cl H CH₃ 1066 CH₃ CH₃ Cl CH₃ CH₃ 1067 CH₃ CH₃ Cl OCH₃ CH₃1068 CH₃ CH₃ Cl Cl CH₃ 1069 CH₃ CH₃ Cl Br CH₃ 1070 CH₃ CH₃ Cl F CH₃ 1071CH₃ CH₃ Cl H OCH₃ 1072 CH₃ CH₃ Cl CH₃ OCH₃ 1073 CH₃ CH₃ Cl OCH₃ OCH₃1074 CH₃ CH₃ Cl Cl OCH₃ 1075 CH₃ CH₃ Cl Br OCH₃ 1076 CH₃ CH₃ Cl F OCH₃1077 CH₃ CH₃ Cl H Cl 1078 CH₃ CH₃ Cl Cl Cl 1079 CH₃ CH₃ Cl H Br 1080 CH₃CH₃ Cl CH₃ Br 1081 CH₃ CH₃ Cl OCH₃ Br 1082 CH₃ CH₃ Cl Cl Br 1083 CH₃ CH₃Cl Br Br 1084 CH₃ CH₃ Cl F Br 1085 CH₃ CH₃ Cl H F 1086 CH₃ CH₃ Cl CH₃ F1087 CH₃ CH₃ Cl OCH₃ F 1088 CH₃ CH₃ Cl Cl F 1089 CH₃ CH₃ Cl F F 1090 CH₃CH₃ Br H H 1091 CH₃ CH₃ Br CH₃ H 1092 CH₃ CH₃ Br OCH₃ H 1093 CH₃ CH₃ BrCl H 1094 CH₃ CH₃ Br Br H 1095 CH₃ CH₃ Br F H 1096 CH₃ CH₃ Br H CH₃ 1097CH₃ CH₃ Br CH₃ CH₃ 1098 CH₃ CH₃ Br OCH₃ CH₃ 1099 CH₃ CH₃ Br Cl CH₃ 1100CH₃ CH₃ Br Br CH₃ 1101 CH₃ CH₃ Br F CH₃ 1102 CH₃ CH₃ Br H OCH₃ 1103 CH₃CH₃ Br CH₃ OCH₃ 1104 CH₃ CH₃ Br OCH₃ OCH₃ 1105 CH₃ CH₃ Br Cl OCH₃ 1106CH₃ CH₃ Br Br OCH₃ 1107 CH₃ CH₃ Br F OCH₃ 1108 CH₃ CH₃ Br H Cl 1109 CH₃CH₃ Br CH₃ Cl 1110 CH₃ CH₃ Br OCH₃ Cl 1111 CH₃ CH₃ Br Cl Cl 1112 CH₃ CH₃Br Br Cl 1113 CH₃ CH₃ Br F Cl 1114 CH₃ CH₃ Br H Br 1115 CH₃ CH₃ Br Br Br1116 CH₃ CH₃ Br H F 1117 CH₃ CH₃ Br CH₃ F 1118 CH₃ CH₃ Br OCH₃ F 1119CH₃ CH₃ Br Cl F 1120 CH₃ CH₃ Br Br F 1121 CH₃ CH₃ Br F F 1122 CH₃ CH₃ FH H 1123 CH₃ CH₃ F CH₃ H 1124 CH₃ CH₃ F OCH₃ H 1125 CH₃ CH₃ F Cl H 1126CH₃ CH₃ F Br H 1127 CH₃ CH₃ F F H 1128 CH₃ CH₃ F H CH₃ 1129 CH₃ CH₃ FCH₃ CH₃ 1130 CH₃ CH₃ F OCH₃ CH₃ 1131 CH₃ CH₃ F Cl CH₃ 1132 CH₃ CH₃ F BrCH₃ 1133 CH₃ CH₃ F F CH₃ 1134 CH₃ CH₃ F H OCH₃ 1135 CH₃ CH₃ F CH₃ OCH₃1136 CH₃ CH₃ F OCH₃ OCH₃ 1137 CH₃ CH₃ F Cl OCH₃ 1138 CH₃ CH₃ F Br OCH₃1139 CH₃ CH₃ F F OCH₃ 1140 CH₃ CH₃ F H Cl 1141 CH₃ CH₃ F CH₃ Cl 1142 CH₃CH₃ F OCH₃ Cl 1143 CH₃ CH₃ F Cl Cl 1144 CH₃ CH₃ F Br Cl 1145 CH₃ CH₃ F FCl 1146 CH₃ CH₃ F H Br 1147 CH₃ CH₃ F CH₃ Br 1148 CH₃ CH₃ F OCH₃ Br 1149CH₃ CH₃ F Cl Br 1150 CH₃ CH₃ F Br Br 1151 CH₃ CH₃ F F Br 1152 CH₃ CH₃ FH F 1153 CH₃ CH₃ F F F 1154 CH₃ OCH₃ CH₃ H H 1155 CH₃ OCH₃ CH₃ H CH₃1156 CH₃ OCH₃ CH₃ H OCH₃ 1157 CH₃ OCH₃ CH₃ H Cl 1158 CH₃ OCH₃ CH₃ H Br1159 CH₃ OCH₃ CH₃ H F 1160 CH₃ OCH₃ CH₃ CH₃ H 1161 CH₃ OCH₃ CH₃ CH₃ CH₃1162 CH₃ OCH₃ CH₃ CH₃ OCH₃ 1163 CH₃ OCH₃ CH₃ CH₃ Cl 1164 CH₃ OCH₃ CH₃CH₃ Br 1165 CH₃ OCH₃ CH₃ CH₃ F 1166 CH₃ OCH₃ CH₃ OCH₃ H 1167 CH₃ OCH₃CH₃ OCH₃ OCH₃ 1168 CH₃ OCH₃ CH₃ OCH₃ Cl 1169 CH₃ OCH₃ CH₃ OCH₃ Br 1170CH₃ OCH₃ CH₃ OCH₃ F 1171 CH₃ OCH₃ CH₃ Cl H 1172 CH₃ OCH₃ CH₃ Cl OCH₃1173 CH₃ OCH₃ CH₃ Cl Cl 1174 CH₃ OCH₃ CH₃ Cl Br 1175 CH₃ OCH₃ CH₃ Cl F1176 CH₃ OCH₃ CH₃ Br H 1177 CH₃ OCH₃ CH₃ Br OCH₃ 1178 CH₃ OCH₃ CH₃ Br Cl1179 CH₃ OCH₃ CH₃ Br Br 1180 CH₃ OCH₃ CH₃ Br F 1181 CH₃ OCH₃ CH₃ F H1182 CH₃ OCH₃ CH₃ F OCH₃ 1183 CH₃ OCH₃ CH₃ F Cl 1184 CH₃ OCH₃ CH₃ F Br1185 CH₃ OCH₃ CH₃ F F 1186 CH₃ OCH₃ OCH₃ H H 1187 CH₃ OCH₃ OCH₃ H CH₃1188 CH₃ OCH₃ OCH₃ H OCH₃ 1189 CH₃ OCH₃ OCH₃ H Cl 1190 CH₃ OCH₃ OCH₃ HBr 1191 CH₃ OCH₃ OCH₃ H F 1192 CH₃ OCH₃ OCH₃ CH₃ H 1193 CH₃ OCH₃ OCH₃CH₃ CH₃ 1194 CH₃ OCH₃ OCH₃ CH₃ Cl 1195 CH₃ OCH₃ OCH₃ CH₃ Br 1196 CH₃OCH₃ OCH₃ CH₃ F 1197 CH₃ OCH₃ OCH₃ OCH₃ H 1198 CH₃ OCH₃ OCH₃ OCH₃ CH₃1199 CH₃ OCH₃ OCH₃ OCH₃ OCH₃ 1200 CH₃ OCH₃ OCH₃ OCH₃ Cl 1201 CH₃ OCH₃OCH₃ OCH₃ Br 1202 CH₃ OCH₃ OCH₃ OCH₃ F 1203 CH₃ OCH₃ OCH₃ Cl H 1204 CH₃OCH₃ OCH₃ Cl CH₃ 1205 CH₃ OCH₃ OCH₃ Cl Cl 1206 CH₃ OCH₃ OCH₃ Cl Br 1207CH₃ OCH₃ OCH₃ Cl F 1208 CH₃ OCH₃ OCH₃ Br H 1209 CH₃ OCH₃ OCH₃ Br CH₃1210 CH₃ OCH₃ OCH₃ Br Cl 1211 CH₃ OCH₃ OCH₃ Br Br 1212 CH₃ OCH₃ OCH₃ BrF 1213 CH₃ OCH₃ OCH₃ F H 1214 CH₃ OCH₃ OCH₃ F CH₃ 1215 CH₃ OCH₃ OCH₃ FCl 1216 CH₃ OCH₃ OCH₃ F Br 1217 CH₃ OCH₃ OCH₃ F F 1218 CH₃ OCH₃ Cl H H1219 CH₃ OCH₃ Cl H CH₃ 1220 CH₃ OCH₃ Cl H OCH₃ 1221 CH₃ OCH₃ Cl H Cl1222 CH₃ OCH₃ Cl H Br 1223 CH₃ OCH₃ Cl H F 1224 CH₃ OCH₃ Cl CH₃ H 1225CH₃ OCH₃ Cl CH₃ CH₃ 1226 CH₃ OCH₃ Cl CH₃ OCH₃ 1227 CH₃ OCH₃ Cl CH₃ Br1228 CH₃ OCH₃ Cl CH₃ F 1229 CH₃ OCH₃ Cl OCH₃ H 1230 CH₃ OCH₃ Cl OCH₃ CH₃1231 CH₃ OCH₃ Cl OCH₃ OCH₃ 1232 CH₃ OCH₃ Cl OCH₃ Br 1233 CH₃ OCH₃ ClOCH₃ F 1234 CH₃ OCH₃ Cl Cl H 1235 CH₃ OCH₃ Cl Cl CH₃ 1236 CH₃ OCH₃ Cl ClOCH₃ 1237 CH₃ OCH₃ Cl Cl Cl 1238 CH₃ OCH₃ Cl Cl Br 1239 CH₃ OCH₃ Cl Cl F1240 CH₃ OCH₃ Cl Br H 1241 CH₃ OCH₃ Cl Br CH₃ 1242 CH₃ OCH₃ Cl Br OCH₃1243 CH₃ OCH₃ Cl Br Br 1244 CH₃ OCH₃ Cl F H 1245 CH₃ OCH₃ Cl F CH₃ 1246CH₃ OCH₃ Cl F OCH₃ 1247 CH₃ OCH₃ Cl F Br 1248 CH₃ OCH₃ Cl F F 1249 CH₃OCH₃ Br H H 1250 CH₃ OCH₃ Br H CH₃ 1251 CH₃ OCH₃ Br H OCH₃ 1252 CH₃ OCH₃Br H Cl 1253 CH₃ OCH₃ Br H Br 1254 CH₃ OCH₃ Br H F 1255 CH₃ OCH₃ Br CH₃H 1256 CH₃ OCH₃ Br CH₃ CH₃ 1257 CH₃ OCH₃ Br CH₃ OCH₃ 1258 CH₃ OCH₃ BrCH₃ Cl 1259 CH₃ OCH₃ Br CH₃ F 1260 CH₃ OCH₃ Br OCH₃ H 1261 CH₃ OCH₃ BrOCH₃ CH₃ 1262 CH₃ OCH₃ Br OCH₃ OCH₃ 1263 CH₃ OCH₃ Br OCH₃ Cl 1264 CH₃OCH₃ Br OCH₃ F 1265 CH₃ OCH₃ Br Cl H 1266 CH₃ OCH₃ Br Cl CH₃ 1267 CH₃OCH₃ Br Cl OCH₃ 1268 CH₃ OCH₃ Br Cl Cl 1269 CH₃ OCH₃ Br Cl F 1270 CH₃OCH₃ Br Br H 1271 CH₃ OCH₃ Br Br CH₃ 1272 CH₃ OCH₃ Br Br OCH₃ 1273 CH₃OCH₃ Br Br Cl 1274 CH₃ OCH₃ Br Br Br 1275 CH₃ OCH₃ Br Br F 1276 CH₃ OCH₃Br F H 1277 CH₃ OCH₃ Br F CH₃ 1278 CH₃ OCH₃ Br F OCH₃ 1279 CH₃ OCH₃ Br FCl 1280 CH₃ OCH₃ Br F F 1281 CH₃ OCH₃ F H H 1282 CH₃ OCH₃ F H CH₃ 1283CH₃ OCH₃ F H OCH₃ 1284 CH₃ OCH₃ F H Cl 1285 CH₃ OCH₃ F H Br 1286 CH₃OCH₃ F H F 1287 CH₃ OCH₃ F CH₃ H 1288 CH₃ OCH₃ F CH₃ CH₃ 1289 CH₃ OCH₃ FCH₃ OCH₃ 1290 CH₃ OCH₃ F CH₃ Cl 1291 CH₃ OCH₃ F CH₃ Br 1292 CH₃ OCH₃ FOCH₃ H 1293 CH₃ OCH₃ F OCH₃ CH₃ 1294 CH₃ OCH₃ F OCH₃ OCH₃ 1295 CH₃ OCH₃F OCH₃ Cl 1296 CH₃ OCH₃ F OCH₃ Br 1297 CH₃ OCH₃ F Cl H 1298 CH₃ OCH₃ FCl CH₃ 1299 CH₃ OCH₃ F Cl OCH₃ 1300 CH₃ OCH₃ F Cl Cl 1301 CH₃ OCH₃ F ClBr 1302 CH₃ OCH₃ F Br H 1303 CH₃ OCH₃ F Br CH₃ 1304 CH₃ OCH₃ F Br OCH₃1305 CH₃ OCH₃ F Br Cl 1306 CH₃ OCH₃ F Br Br 1307 CH₃ OCH₃ F F H 1308 CH₃OCH₃ F F CH₃ 1309 CH₃ OCH₃ F F OCH₃ 1310 CH₃ OCH₃ F F Cl 1311 CH₃ OCH₃ FF Br 1312 CH₃ OCH₃ F F F 1313 CH₃ Cl CH₃ H H 1314 CH₃ Cl CH₃ H CH₃ 1315CH₃ Cl CH₃ H OCH₃ 1316 CH₃ Cl CH₃ H Cl 1317 CH₃ Cl CH₃ H Br 1318 CH₃ ClCH₃ H F 1319 CH₃ Cl CH₃ CH₃ H 1320 CH₃ Cl CH₃ CH₃ CH₃ 1321 CH₃ Cl CH₃CH₃ OCH₃ 1322 CH₃ Cl CH₃ CH₃ Cl 1323 CH₃ Cl CH₃ CH₃ Br 1324 CH₃ Cl CH₃CH₃ F 1325 CH₃ Cl CH₃ OCH₃ H 1326 CH₃ Cl CH₃ OCH₃ OCH₃ 1327 CH₃ Cl CH₃OCH₃ Cl 1328 CH₃ Cl CH₃ OCH₃ Br 1329 CH₃ Cl CH₃ OCH₃ F 1330 CH₃ Cl CH₃Cl H 1331 CH₃ Cl CH₃ Cl OCH₃ 1332 CH₃ Cl CH₃ Cl Cl 1333 CH₃ Cl CH₃ Cl Br1334 CH₃ Cl CH₃ Cl F 1335 CH₃ Cl CH₃ Br H 1336 CH₃ Cl CH₃ Br OCH₃ 1337CH₃ Cl CH₃ Br Cl 1338 CH₃ Cl CH₃ Br Br 1339 CH₃ Cl CH₃ Br F 1340 CH₃ ClCH₃ F H 1341 CH₃ Cl CH₃ F OCH₃ 1342 CH₃ Cl CH₃ F Cl 1343 CH₃ Cl CH₃ F Br1344 CH₃ Cl CH₃ F F 1345 CH₃ Cl OCH₃ H H 1346 CH₃ Cl OCH₃ H CH₃ 1347 CH₃Cl OCH₃ H OCH₃ 1348 CH₃ Cl OCH₃ H Cl 1349 CH₃ Cl OCH₃ H Br 1350 CH₃ ClOCH₃ H F 1351 CH₃ Cl OCH₃ CH₃ H 1352 CH₃ Cl OCH₃ CH₃ CH₃ 1353 CH₃ ClOCH₃ CH₃ Cl 1354 CH₃ Cl OCH₃ CH₃ Br 1355 CH₃ Cl OCH₃ CH₃ F 1356 CH₃ ClOCH₃ OCH₃ H 1357 CH₃ Cl OCH₃ OCH₃ CH₃ 1358 CH₃ Cl OCH₃ OCH₃ OCH₃ 1359CH₃ Cl OCH₃ OCH₃ Cl 1360 CH₃ Cl OCH₃ OCH₃ Br 1361 CH₃ Cl OCH₃ OCH₃ F1362 CH₃ Cl OCH₃ Cl H 1363 CH₃ Cl OCH₃ Cl CH₃ 1364 CH₃ Cl OCH₃ Cl Cl1365 CH₃ Cl OCH₃ Cl Br 1366 CH₃ Cl OCH₃ Cl F 1367 CH₃ Cl OCH₃ Br H 1368CH₃ Cl OCH₃ Br CH₃ 1369 CH₃ Cl OCH₃ Br Cl 1370 CH₃ Cl OCH₃ Br Br 1371CH₃ Cl OCH₃ Br F 1372 CH₃ Cl OCH₃ F H 1373 CH₃ Cl OCH₃ F CH₃ 1374 CH₃ ClOCH₃ F Cl 1375 CH₃ Cl OCH₃ F Br 1376 CH₃ Cl OCH₃ F F 1377 CH₃ Cl Cl H H1378 CH₃ Cl Cl H CH₃ 1379 CH₃ Cl Cl H OCH₃ 1380 CH₃ Cl Cl H Cl 1381 CH₃Cl Cl H Br 1382 CH₃ Cl Cl H F 1383 CH₃ Cl Cl CH₃ H 1384 CH₃ Cl Cl CH₃CH₃ 1385 CH₃ Cl Cl CH₃ OCH₃ 1386 CH₃ Cl Cl CH₃ Br 1387 CH₃ Cl Cl CH₃ F1388 CH₃ Cl Cl OCH₃ H 1389 CH₃ Cl Cl OCH₃ CH₃ 1390 CH₃ Cl Cl OCH₃ OCH₃1391 CH₃ Cl Cl OCH₃ Br 1392 CH₃ Cl Cl OCH₃ F 1393 CH₃ Cl Cl Cl H 1394CH₃ Cl Cl Cl CH₃ 1395 CH₃ Cl Cl Cl OCH₃ 1396 CH₃ Cl Cl Cl Cl 1397 CH₃ ClCl Cl Br 1398 CH₃ Cl Cl Cl F 1399 CH₃ Cl Cl Br H 1400 CH₃ Cl Cl Br CH₃1401 CH₃ Cl Cl Br OCH₃ 1402 CH₃ Cl Cl Br Br 1403 CH₃ Cl Cl F H 1404 CH₃Cl Cl F CH₃ 1405 CH₃ Cl Cl F OCH₃ 1406 CH₃ Cl Cl F Br 1407 CH₃ Cl Cl F F1408 CH₃ Cl Br H H 1409 CH₃ Cl Br H CH₃ 1410 CH₃ Cl Br H OCH₃ 1411 CH₃Cl Br H Cl 1412 CH₃ Cl Br H Br 1413 CH₃ Cl Br H F 1414 CH₃ Cl Br CH₃ H1415 CH₃ Cl Br CH₃ CH₃ 1416 CH₃ Cl Br CH₃ OCH₃ 1417 CH₃ Cl Br CH₃ Cl1418 CH₃ Cl Br CH₃ F 1419 CH₃ Cl Br OCH₃ H 1420 CH₃ Cl Br OCH₃ CH₃ 1421CH₃ Cl Br OCH₃ OCH₃ 1422 CH₃ Cl Br OCH₃ Cl 1423 CH₃ Cl Br OCH₃ F 1424CH₃ Cl Br Cl H 1425 CH₃ Cl Br Cl CH₃ 1426 CH₃ Cl Br Cl OCH₃ 1427 CH₃ ClBr Cl Cl 1428 CH₃ Cl Br Cl F 1429 CH₃ Cl Br Br H 1430 CH₃ Cl Br Br CH₃1431 CH₃ Cl Br Br OCH₃ 1432 CH₃ Cl Br Br Cl 1433 CH₃ Cl Br Br Br 1434CH₃ Cl Br Br F 1435 CH₃ Cl Br F H 1436 CH₃ Cl Br F CH₃ 1437 CH₃ Cl Br FOCH₃ 1438 CH₃ Cl Br F Cl 1439 CH₃ Cl Br F F 1440 CH₃ Cl F H H 1441 CH₃Cl F H CH₃ 1442 CH₃ Cl F H OCH₃ 1443 CH₃ Cl F H Cl 1444 CH₃ Cl F H Br1445 CH₃ Cl F H F 1446 CH₃ Cl F CH₃ H 1447 CH₃ Cl F CH₃ CH₃ 1448 CH₃ ClF CH₃ OCH₃ 1449 CH₃ Cl F CH₃ Cl 1450 CH₃ Cl F CH₃ Br 1451 CH₃ Cl F OCH₃H 1452 CH₃ Cl F OCH₃ CH₃ 1453 CH₃ Cl F OCH₃ OCH₃ 1454 CH₃ Cl F OCH₃ Cl1455 CH₃ Cl F OCH₃ Br 1456 CH₃ Cl F Cl H 1457 CH₃ Cl F Cl CH₃ 1458 CH₃Cl F Cl OCH₃ 1459 CH₃ Cl F Cl Cl 1460 CH₃ Cl F Cl Br 1461 CH₃ Cl F Br H1462 CH₃ Cl F Br CH₃ 1463 CH₃ Cl F Br OCH₃ 1464 CH₃ Cl F Br Cl 1465 CH₃Cl F Br Br 1466 CH₃ Cl F F H 1467 CH₃ Cl F F CH₃ 1468 CH₃ Cl F F OCH₃1469 CH₃ Cl F F Cl 1470 CH₃ Cl F F Br 1471 CH₃ Cl F F F 1472 CH₃ Br CH₃H H 1473 CH₃ Br CH₃ H CH₃ 1474 CH₃ Br CH₃ H OCH₃ 1475 CH₃ Br CH₃ H Cl1476 CH₃ Br CH₃ H Br 1477 CH₃ Br CH₃ H F 1478 CH₃ Br CH₃ CH₃ H 1479 CH₃Br CH₃ CH₃ CH₃ 1480 CH₃ Br CH₃ CH₃ OCH₃ 1481 CH₃ Br CH₃ CH₃ Cl 1482 CH₃Br CH₃ CH₃ Br 1483 CH₃ Br CH₃ CH₃ F 1484 CH₃ Br CH₃ OCH₃ H 1485 CH₃ BrCH₃ OCH₃ OCH₃ 1486 CH₃ Br CH₃ OCH₃ Cl 1487 CH₃ Br CH₃ OCH₃ Br 1488 CH₃Br CH₃ OCH₃ F 1489 CH₃ Br CH₃ Cl H 1490 CH₃ Br CH₃ Cl OCH₃ 1491 CH₃ BrCH₃ Cl Cl 1492 CH₃ Br CH₃ Cl Br 1493 CH₃ Br CH₃ Cl F 1494 CH₃ Br CH₃ BrH 1495 CH₃ Br CH₃ Br OCH₃ 1496 CH₃ Br CH₃ Br Cl 1497 CH₃ Br CH₃ Br Br1498 CH₃ Br CH₃ Br F 1499 CH₃ Br CH₃ F H 1500 CH₃ Br CH₃ F OCH₃ 1501 CH₃Br CH₃ F Cl 1502 CH₃ Br CH₃ F Br 1503 CH₃ Br CH₃ F F 1504 CH₃ Br OCH₃ HH 1505 CH₃ Br OCH₃ H CH₃ 1506 CH₃ Br OCH₃ H OCH₃ 1507 CH₃ Br OCH₃ H Cl1508 CH₃ Br OCH₃ H Br 1509 CH₃ Br OCH₃ H F 1510 CH₃ Br OCH₃ CH₃ H 1511CH₃ Br OCH₃ CH₃ CH₃ 1512 CH₃ Br OCH₃ CH₃ Cl 1513 CH₃ Br OCH₃ CH₃ Br 1514CH₃ Br OCH₃ CH₃ F 1515 CH₃ Br OCH₃ OCH₃ H 1516 CH₃ Br OCH₃ OCH₃ CH₃ 1517CH₃ Br OCH₃ OCH₃ OCH₃ 1518 CH₃ Br OCH₃ OCH₃ Cl 1519 CH₃ Br OCH₃ OCH₃ Br1520 CH₃ Br OCH₃ OCH₃ F 1521 CH₃ Br OCH₃ Cl H 1522 CH₃ Br OCH₃ Cl CH₃1523 CH₃ Br OCH₃ Cl Cl 1524 CH₃ Br OCH₃ Cl Br 1525 CH₃ Br OCH₃ Cl F 1526CH₃ Br OCH₃ Br H 1527 CH₃ Br OCH₃ Br CH₃ 1528 CH₃ Br OCH₃ Br Cl 1529 CH₃Br OCH₃ Br Br 1530 CH₃ Br OCH₃ Br F 1531 CH₃ Br OCH₃ F H 1532 CH₃ BrOCH₃ F CH₃ 1533 CH₃ Br OCH₃ F Cl 1534 CH₃ Br OCH₃ F Br 1535 CH₃ Br OCH₃F F 1536 CH₃ Br Cl H H 1537 CH₃ Br Cl H CH₃ 1538 CH₃ Br Cl H OCH₃ 1539CH₃ Br Cl H Cl 1540 CH₃ Br Cl H Br 1541 CH₃ Br Cl H F 1542 CH₃ Br Cl CH₃H 1543 CH₃ Br Cl CH₃ CH₃ 1544 CH₃ Br Cl CH₃ OCH₃ 1545 CH₃ Br Cl CH₃ Br1546 CH₃ Br Cl CH₃ F 1547 CH₃ Br Cl OCH₃ H 1548 CH₃ Br Cl OCH₃ CH₃ 1549CH₃ Br Cl OCH₃ OCH₃ 1550 CH₃ Br Cl OCH₃ Br 1551 CH₃ Br Cl OCH₃ F 1552CH₃ Br Cl Cl H 1553 CH₃ Br Cl Cl CH₃ 1554 CH₃ Br Cl Cl OCH₃ 1555 CH₃ BrCl Cl Cl 1556 CH₃ Br Cl Cl Br 1557 CH₃ Br Cl Cl F 1558 CH₃ Br Cl Br H1559 CH₃ Br Cl Br CH₃ 1560 CH₃ Br Cl Br OCH₃ 1561 CH₃ Br Cl Br Br 1562CH₃ Br Cl F H 1563 CH₃ Br Cl F CH₃ 1564 CH₃ Br Cl F OCH₃ 1565 CH₃ Br ClF Br 1566 CH₃ Br Cl F F 1567 CH₃ Br Br H H 1568 CH₃ Br Br H CH₃ 1569 CH₃Br Br H OCH₃ 1570 CH₃ Br Br H Cl 1571 CH₃ Br Br H Br 1572 CH₃ Br Br H F1573 CH₃ Br Br CH₃ H 1574 CH₃ Br Br CH₃ CH₃ 1575 CH₃ Br Br CH₃ OCH₃ 1576CH₃ Br Br CH₃ Cl 1577 CH₃ Br Br CH₃ F 1578 CH₃ Br Br OCH₃ H 1579 CH₃ BrBr OCH₃ CH₃ 1580 CH₃ Br Br OCH₃ OCH₃ 1581 CH₃ Br Br OCH₃ Cl 1582 CH₃ BrBr OCH₃ F 1583 CH₃ Br Br Cl H 1584 CH₃ Br Br Cl CH₃ 1585 CH₃ Br Br ClOCH₃ 1586 CH₃ Br Br Cl Cl 1587 CH₃ Br Br Cl F 1588 CH₃ Br Br Br H 1589CH₃ Br Br Br CH₃ 1590 CH₃ Br Br Br OCH₃ 1591 CH₃ Br Br Br Cl 1592 CH₃ BrBr Br Br 1593 CH₃ Br Br Br F 1594 CH₃ Br Br F H 1595 CH₃ Br Br F CH₃1596 CH₃ Br Br F OCH₃ 1597 CH₃ Br Br F Cl 1598 CH₃ Br Br F F 1599 CH₃ BrF H H 1600 CH₃ Br F H CH₃ 1601 CH₃ Br F H OCH₃ 1602 CH₃ Br F H Cl 1603CH₃ Br F H Br 1604 CH₃ Br F H F 1605 CH₃ Br F CH₃ H 1606 CH₃ Br F CH₃CH₃ 1607 CH₃ Br F CH₃ OCH₃ 1608 CH₃ Br F CH₃ Cl 1609 CH₃ Br F CH₃ Br1610 CH₃ Br F OCH₃ H 1611 CH₃ Br F OCH₃ CH₃ 1612 CH₃ Br F OCH₃ OCH₃ 1613CH₃ Br F OCH₃ Cl 1614 CH₃ Br F OCH₃ Br 1615 CH₃ Br F Cl H 1616 CH₃ Br FCl CH₃ 1617 CH₃ Br F Cl OCH₃ 1618 CH₃ Br F Cl Cl 1619 CH₃ Br F Cl Br1620 CH₃ Br F Br H 1621 CH₃ Br F Br CH₃ 1622 CH₃ Br F Br OCH₃ 1623 CH₃Br F Br Cl 1624 CH₃ Br F Br Br 1625 CH₃ Br F F H 1626 CH₃ Br F F CH₃1627 CH₃ Br F F OCH₃ 1628 CH₃ Br F F Cl 1629 CH₃ Br F F Br 1630 CH₃ Br FF F 1631 CH₃ F CH₃ H H 1632 CH₃ F CH₃ H CH₃ 1633 CH₃ F CH₃ H OCH₃ 1634CH₃ F CH₃ H Cl 1635 CH₃ F CH₃ H Br 1636 CH₃ F CH₃ H F 1637 CH₃ F CH₃ CH₃H 1638 CH₃ F CH₃ CH₃ CH₃ 1639 CH₃ F CH₃ CH₃ OCH₃ 1640 CH₃ F CH₃ CH₃ Cl1641 CH₃ F CH₃ CH₃ Br 1642 CH₃ F CH₃ CH₃ F 1643 CH₃ F CH₃ OCH₃ H 1644CH₃ F CH₃ OCH₃ OCH₃ 1645 CH₃ F CH₃ OCH₃ Cl 1646 CH₃ F CH₃ OCH₃ Br 1647CH₃ F CH₃ OCH₃ F 1648 CH₃ F CH₃ Cl H 1649 CH₃ F CH₃ Cl OCH₃ 1650 CH₃ FCH₃ Cl Cl 1651 CH₃ F CH₃ Cl Br 1652 CH₃ F CH₃ Cl F 1653 CH₃ F CH₃ Br H1654 CH₃ F CH₃ Br OCH₃ 1655 CH₃ F CH₃ Br Cl 1656 CH₃ F CH₃ Br Br 1657CH₃ F CH₃ Br F 1658 CH₃ F CH₃ F H 1659 CH₃ F CH₃ F OCH₃ 1660 CH₃ F CH₃ FCl 1661 CH₃ F CH₃ F Br 1662 CH₃ F CH₃ F F 1663 CH₃ F OCH₃ H H 1664 CH₃ FOCH₃ H CH₃ 1665 CH₃ F OCH₃ H OCH₃ 1666 CH₃ F OCH₃ H Cl 1667 CH₃ F OCH₃ HBr 1668 CH₃ F OCH₃ H F 1669 CH₃ F OCH₃ CH₃ H 1670 CH₃ F OCH₃ CH₃ CH₃1671 CH₃ F OCH₃ CH₃ Cl 1672 CH₃ F OCH₃ CH₃ Br 1673 CH₃ F OCH₃ CH₃ F 1674CH₃ F OCH₃ OCH₃ H 1675 CH₃ F OCH₃ OCH₃ CH₃ 1676 CH₃ F OCH₃ OCH₃ OCH₃1677 CH₃ F OCH₃ OCH₃ Cl 1678 CH₃ F OCH₃ OCH₃ Br 1679 CH₃ F OCH₃ OCH₃ F1680 CH₃ F OCH₃ Cl H 1681 CH₃ F OCH₃ Cl CH₃ 1682 CH₃ F OCH₃ Cl Cl 1683CH₃ F OCH₃ Cl Br 1684 CH₃ F OCH₃ Cl F 1685 CH₃ F OCH₃ Br H 1686 CH₃ FOCH₃ Br CH₃ 1687 CH₃ F OCH₃ Br Cl 1688 CH₃ F OCH₃ Br Br 1689 CH₃ F OCH₃Br F 1690 CH₃ F OCH₃ F H 1691 CH₃ F OCH₃ F CH₃ 1692 CH₃ F OCH₃ F Cl 1693CH₃ F OCH₃ F Br 1694 CH₃ F OCH₃ F F 1695 CH₃ F Cl H H 1696 CH₃ F Cl HCH₃ 1697 CH₃ F Cl H OCH₃ 1698 CH₃ F Cl H Cl 1699 CH₃ F Cl H Br 1700 CH₃F Cl H F 1701 CH₃ F Cl CH₃ H 1702 CH₃ F Cl CH₃ CH₃ 1703 CH₃ F Cl CH₃OCH₃ 1704 CH₃ F Cl CH₃ Br 1705 CH₃ F Cl CH₃ F 1706 CH₃ F Cl OCH₃ H 1707CH₃ F Cl OCH₃ CH₃ 1708 CH₃ F Cl OCH₃ OCH₃ 1709 CH₃ F Cl OCH₃ Br 1710 CH₃F Cl OCH₃ F 1711 CH₃ F Cl Cl H 1712 CH₃ F Cl Cl CH₃ 1713 CH₃ F Cl ClOCH₃ 1714 CH₃ F Cl Cl Cl 1715 CH₃ F Cl Cl Br 1716 CH₃ F Cl Cl F 1717 CH₃F Cl Br H 1718 CH₃ F Cl Br CH₃ 1719 CH₃ F Cl Br OCH₃ 1720 CH₃ F Cl Br Br1721 CH₃ F Cl F H 1722 CH₃ F Cl F CH₃ 1723 CH₃ F Cl F OCH₃ 1724 CH₃ F ClF Br 1725 CH₃ F Cl F F 1726 CH₃ F Br H H 1727 CH₃ F Br H CH₃ 1728 CH₃ FBr H OCH₃ 1729 CH₃ F Br H Cl 1730 CH₃ F Br H Br 1731 CH₃ F Br H F 1732CH₃ F Br CH₃ H 1733 CH₃ F Br CH₃ CH₃ 1734 CH₃ F Br CH₃ OCH₃ 1735 CH₃ FBr CH₃ Cl 1736 CH₃ F Br CH₃ F 1737 CH₃ F Br OCH₃ H 1738 CH₃ F Br OCH₃CH₃ 1739 CH₃ F Br OCH₃ OCH₃ 1740 CH₃ F Br OCH₃ Cl 1741 CH₃ F Br OCH₃ F1742 CH₃ F Br Cl H 1743 CH₃ F Br Cl CH₃ 1744 CH₃ F Br Cl OCH₃ 1745 CH₃ FBr Cl Cl 1746 CH₃ F Br Cl F 1747 CH₃ F Br Br H 1748 CH₃ F Br Br CH₃ 1749CH₃ F Br Br OCH₃ 1750 CH₃ F Br Br Cl 1751 CH₃ F Br Br Br 1752 CH₃ F BrBr F 1753 CH₃ F Br F H 1754 CH₃ F Br F CH₃ 1755 CH₃ F Br F OCH₃ 1756 CH₃F Br F Cl 1757 CH₃ F Br F F 1758 CH₃ F F H H 1759 CH₃ F F H CH₃ 1760 CH₃F F H OCH₃ 1761 CH₃ F F H Cl 1762 CH₃ F F H Br 1763 CH₃ F F H F 1764 CH₃F F CH₃ H 1765 CH₃ F F CH₃ CH₃ 1766 CH₃ F F CH₃ OCH₃ 1767 CH₃ F F CH₃ Cl1768 CH₃ F F CH₃ Br 1769 CH₃ F F OCH₃ H 1770 CH₃ F F OCH₃ CH₃ 1771 CH₃ FF OCH₃ OCH₃ 1772 CH₃ F F OCH₃ Cl 1773 CH₃ F F OCH₃ Br 1774 CH₃ F F Cl H1775 CH₃ F F Cl CH₃ 1776 CH₃ F F Cl OCH₃ 1777 CH₃ F F Cl Cl 1778 CH₃ F FCl Br 1779 CH₃ F F Br H 1780 CH₃ F F Br CH₃ 1781 CH₃ F F Br OCH₃ 1782CH₃ F F Br Cl 1783 CH₃ F F Br Br 1784 CH₃ F F F H 1785 CH₃ F F F CH₃1786 CH₃ F F F OCH₃ 1787 CH₃ F F F Cl 1788 CH₃ F F F Br 1789 CH₃ F F F F1790 OCH₃ CH₃ CH₃ H H 1791 OCH₃ CH₃ CH₃ CH₃ H 1792 OCH₃ CH₃ CH₃ OCH₃ H1793 OCH₃ CH₃ CH₃ Cl H 1794 OCH₃ CH₃ CH₃ Br H 1795 OCH₃ CH₃ CH₃ F H 1796OCH₃ CH₃ CH₃ H CH₃ 1797 OCH₃ CH₃ CH₃ CH₃ CH₃ 1798 OCH₃ CH₃ CH₃ H OCH₃1799 OCH₃ CH₃ CH₃ CH₃ OCH₃ 1800 OCH₃ CH₃ CH₃ OCH₃ OCH₃ 1801 OCH₃ CH₃ CH₃Cl OCH₃ 1802 OCH₃ CH₃ CH₃ Br OCH₃ 1803 OCH₃ CH₃ CH₃ F OCH₃ 1804 OCH₃ CH₃CH₃ H Cl 1805 OCH₃ CH₃ CH₃ CH₃ Cl 1806 OCH₃ CH₃ CH₃ OCH₃ Cl 1807 OCH₃CH₃ CH₃ Cl Cl 1808 OCH₃ CH₃ CH₃ Br Cl 1809 OCH₃ CH₃ CH₃ F Cl 1810 OCH₃CH₃ CH₃ H Br 1811 OCH₃ CH₃ CH₃ CH₃ Br 1812 OCH₃ CH₃ CH₃ OCH₃ Br 1813OCH₃ CH₃ CH₃ Cl Br 1814 OCH₃ CH₃ CH₃ Br Br 1815 OCH₃ CH₃ CH₃ F Br 1816OCH₃ CH₃ CH₃ H F 1817 OCH₃ CH₃ CH₃ CH₃ F 1818 OCH₃ CH₃ CH₃ OCH₃ F 1819OCH₃ CH₃ CH₃ Cl F 1820 OCH₃ CH₃ CH₃ Br F 1821 OCH₃ CH₃ CH₃ F F 1822 OCH₃CH₃ OCH₃ H H 1823 OCH₃ CH₃ OCH₃ CH₃ H 1824 OCH₃ CH₃ OCH₃ OCH₃ H 1825OCH₃ CH₃ OCH₃ Cl H 1826 OCH₃ CH₃ OCH₃ Br H 1827 OCH₃ CH₃ OCH₃ F H 1828OCH₃ CH₃ OCH₃ H CH₃ 1829 OCH₃ CH₃ OCH₃ CH₃ CH₃ 1830 OCH₃ CH₃ OCH₃ OCH₃CH₃ 1831 OCH₃ CH₃ OCH₃ Cl CH₃ 1832 OCH₃ CH₃ OCH₃ Br CH₃ 1833 OCH₃ CH₃OCH₃ F CH₃ 1834 OCH₃ CH₃ OCH₃ H OCH₃ 1835 OCH₃ CH₃ OCH₃ OCH₃ OCH₃ 1836OCH₃ CH₃ OCH₃ H Cl 1837 OCH₃ CH₃ OCH₃ CH₃ Cl 1838 OCH₃ CH₃ OCH₃ OCH₃ Cl1839 OCH₃ CH₃ OCH₃ Cl Cl 1840 OCH₃ CH₃ OCH₃ Br Cl 1841 OCH₃ CH₃ OCH₃ FCl 1842 OCH₃ CH₃ OCH₃ H Br 1843 OCH₃ CH₃ OCH₃ CH₃ Br 1844 OCH₃ CH₃ OCH₃OCH₃ Br 1845 OCH₃ CH₃ OCH₃ Cl Br 1846 OCH₃ CH₃ OCH₃ Br Br 1847 OCH₃ CH₃OCH₃ F Br 1848 OCH₃ CH₃ OCH₃ H F 1849 OCH₃ CH₃ OCH₃ CH₃ F 1850 OCH₃ CH₃OCH₃ OCH₃ F 1851 OCH₃ CH₃ OCH₃ Cl F 1852 OCH₃ CH₃ OCH₃ Br F 1853 OCH₃CH₃ OCH₃ F F 1854 OCH₃ CH₃ Cl H H 1855 OCH₃ CH₃ Cl CH₃ H 1856 OCH₃ CH₃Cl OCH₃ H 1857 OCH₃ CH₃ Cl Cl H 1858 OCH₃ CH₃ Cl Br H 1859 OCH₃ CH₃ Cl FH 1860 OCH₃ CH₃ Cl H CH₃ 1861 OCH₃ CH₃ Cl CH₃ CH₃ 1862 OCH₃ CH₃ Cl OCH₃CH₃ 1863 OCH₃ CH₃ Cl Cl CH₃ 1864 OCH₃ CH₃ Cl Br CH₃ 1865 OCH₃ CH₃ Cl FCH₃ 1866 OCH₃ CH₃ Cl H OCH₃ 1867 OCH₃ CH₃ Cl CH₃ OCH₃ 1868 OCH₃ CH₃ ClOCH₃ OCH₃ 1869 OCH₃ CH₃ Cl Cl OCH₃ 1870 OCH₃ CH₃ Cl Br OCH₃ 1871 OCH₃CH₃ Cl F OCH₃ 1872 OCH₃ CH₃ Cl H Cl 1873 OCH₃ CH₃ Cl Cl Cl 1874 OCH₃ CH₃Cl H Br 1875 OCH₃ CH₃ Cl CH₃ Br 1876 OCH₃ CH₃ Cl OCH₃ Br 1877 OCH₃ CH₃Cl Cl Br 1878 OCH₃ CH₃ Cl Br Br 1879 OCH₃ CH₃ Cl F Br 1880 OCH₃ CH₃ Cl HF 1881 OCH₃ CH₃ Cl CH₃ F 1882 OCH₃ CH₃ Cl OCH₃ F 1883 OCH₃ CH₃ Cl Cl F1884 OCH₃ CH₃ Cl F F 1885 OCH₃ CH₃ Br H H 1886 OCH₃ CH₃ Br CH₃ H 1887OCH₃ CH₃ Br OCH₃ H 1888 OCH₃ CH₃ Br Cl H 1889 OCH₃ CH₃ Br Br H 1890 OCH₃CH₃ Br F H 1891 OCH₃ CH₃ Br H CH₃ 1892 OCH₃ CH₃ Br CH₃ CH₃ 1893 OCH₃ CH₃Br OCH₃ CH₃ 1894 OCH₃ CH₃ Br Cl CH₃ 1895 OCH₃ CH₃ Br Br CH₃ 1896 OCH₃CH₃ Br F CH₃ 1897 OCH₃ CH₃ Br H OCH₃ 1898 OCH₃ CH₃ Br CH₃ OCH₃ 1899 OCH₃CH₃ Br OCH₃ OCH₃ 1900 OCH₃ CH₃ Br Cl OCH₃ 1901 OCH₃ CH₃ Br Br OCH₃ 1902OCH₃ CH₃ Br F OCH₃ 1903 OCH₃ CH₃ Br H Cl 1904 OCH₃ CH₃ Br CH₃ Cl 1905OCH₃ CH₃ Br OCH₃ Cl 1906 OCH₃ CH₃ Br Cl Cl 1907 OCH₃ CH₃ Br Br Cl 1908OCH₃ CH₃ Br F Cl 1909 OCH₃ CH₃ Br H Br 1910 OCH₃ CH₃ Br Br Br 1911 OCH₃CH₃ Br H F 1912 OCH₃ CH₃ Br CH₃ F 1913 OCH₃ CH₃ Br OCH₃ F 1914 OCH₃ CH₃Br Cl F 1915 OCH₃ CH₃ Br Br F 1916 OCH₃ CH₃ Br F F 1917 OCH₃ CH₃ F H H1918 OCH₃ CH₃ F CH₃ H 1919 OCH₃ CH₃ F OCH₃ H 1920 OCH₃ CH₃ F Cl H 1921OCH₃ CH₃ F Br H 1922 OCH₃ CH₃ F F H 1923 OCH₃ CH₃ F H CH₃ 1924 OCH₃ CH₃F CH₃ CH₃ 1925 OCH₃ CH₃ F OCH₃ CH₃ 1926 OCH₃ CH₃ F Cl CH₃ 1927 OCH₃ CH₃F Br CH₃ 1928 OCH₃ CH₃ F F CH₃ 1929 OCH₃ CH₃ F H OCH₃ 1930 OCH₃ CH₃ FCH₃ OCH₃ 1931 OCH₃ CH₃ F OCH₃ OCH₃ 1932 OCH₃ CH₃ F Cl OCH₃ 1933 OCH₃ CH₃F Br OCH₃ 1934 OCH₃ CH₃ F F OCH₃ 1935 OCH₃ CH₃ F H Cl 1936 OCH₃ CH₃ FCH₃ Cl 1937 OCH₃ CH₃ F OCH₃ Cl 1938 OCH₃ CH₃ F Cl Cl 1939 OCH₃ CH₃ F BrCl 1940 OCH₃ CH₃ F F Cl 1941 OCH₃ CH₃ F H Br 1942 OCH₃ CH₃ F CH₃ Br 1943OCH₃ CH₃ F OCH₃ Br 1944 OCH₃ CH₃ F Cl Br 1945 OCH₃ CH₃ F Br Br 1946 OCH₃CH₃ F F Br 1947 OCH₃ CH₃ F H F 1948 OCH₃ CH₃ F F F 1949 OCH₃ OCH₃ CH₃ HH 1950 OCH₃ OCH₃ CH₃ H CH₃ 1951 OCH₃ OCH₃ CH₃ H OCH₃ 1952 OCH₃ OCH₃ CH₃H Cl 1953 OCH₃ OCH₃ CH₃ H Br 1954 OCH₃ OCH₃ CH₃ H F 1955 OCH₃ OCH₃ CH₃CH₃ H 1956 OCH₃ OCH₃ CH₃ CH₃ CH₃ 1957 OCH₃ OCH₃ CH₃ CH₃ OCH₃ 1958 OCH₃OCH₃ CH₃ CH₃ Cl 1959 OCH₃ OCH₃ CH₃ CH₃ Br 1960 OCH₃ OCH₃ CH₃ CH₃ F 1961OCH₃ OCH₃ CH₃ OCH₃ H 1962 OCH₃ OCH₃ CH₃ OCH₃ OCH₃ 1963 OCH₃ OCH₃ CH₃OCH₃ Cl 1964 OCH₃ OCH₃ CH₃ OCH₃ Br 1965 OCH₃ OCH₃ CH₃ OCH₃ F 1966 OCH₃OCH₃ CH₃ Cl H 1967 OCH₃ OCH₃ CH₃ Cl OCH₃ 1968 OCH₃ OCH₃ CH₃ Cl Cl 1969OCH₃ OCH₃ CH₃ Cl Br 1970 OCH₃ OCH₃ CH₃ Cl F 1971 OCH₃ OCH₃ CH₃ Br H 1972OCH₃ OCH₃ CH₃ Br OCH₃ 1973 OCH₃ OCH₃ CH₃ Br Cl 1974 OCH₃ OCH₃ CH₃ Br Br1975 OCH₃ OCH₃ CH₃ Br F 1976 OCH₃ OCH₃ CH₃ F H 1977 OCH₃ OCH₃ CH₃ F OCH₃1978 OCH₃ OCH₃ CH₃ F Cl 1979 OCH₃ OCH₃ CH₃ F Br 1980 OCH₃ OCH₃ CH₃ F F1981 OCH₃ OCH₃ OCH₃ H H 1982 OCH₃ OCH₃ OCH₃ H CH₃ 1983 OCH₃ OCH₃ OCH₃ HOCH₃ 1984 OCH₃ OCH₃ OCH₃ H Cl 1985 OCH₃ OCH₃ OCH₃ H Br 1986 OCH₃ OCH₃OCH₃ H F 1987 OCH₃ OCH₃ OCH₃ CH₃ H 1988 OCH₃ OCH₃ OCH₃ CH₃ CH₃ 1989 OCH₃OCH₃ OCH₃ CH₃ Cl 1990 OCH₃ OCH₃ OCH₃ CH₃ Br 1991 OCH₃ OCH₃ OCH₃ CH₃ F1992 OCH₃ OCH₃ OCH₃ OCH₃ H 1993 OCH₃ OCH₃ OCH₃ OCH₃ CH₃ 1994 OCH₃ OCH₃OCH₃ OCH₃ OCH₃ 1995 OCH₃ OCH₃ OCH₃ OCH₃ Cl 1996 OCH₃ OCH₃ OCH₃ OCH₃ Br1997 OCH₃ OCH₃ OCH₃ OCH₃ F 1998 OCH₃ OCH₃ OCH₃ Cl H 1999 OCH₃ OCH₃ OCH₃Cl CH₃ 2000 OCH₃ OCH₃ OCH₃ Cl Cl 2001 OCH₃ OCH₃ OCH₃ Cl Br 2002 OCH₃OCH₃ OCH₃ Cl F 2003 OCH₃ OCH₃ OCH₃ Br H 2004 OCH₃ OCH₃ OCH₃ Br CH₃ 2005OCH₃ OCH₃ OCH₃ Br Cl 2006 OCH₃ OCH₃ OCH₃ Br Br 2007 OCH₃ OCH₃ OCH₃ Br F2008 OCH₃ OCH₃ OCH₃ F H 2009 OCH₃ OCH₃ OCH₃ F CH₃ 2010 OCH₃ OCH₃ OCH₃ FCl 2011 OCH₃ OCH₃ OCH₃ F Br 2012 OCH₃ OCH₃ OCH₃ F F 2013 OCH₃ OCH₃ Cl HH 2014 OCH₃ OCH₃ Cl H CH₃ 2015 OCH₃ OCH₃ Cl H OCH₃ 2016 OCH₃ OCH₃ Cl HCl 2017 OCH₃ OCH₃ Cl H Br 2018 OCH₃ OCH₃ Cl H F 2019 OCH₃ OCH₃ Cl CH₃ H2020 OCH₃ OCH₃ Cl CH₃ CH₃ 2021 OCH₃ OCH₃ Cl CH₃ OCH₃ 2022 OCH₃ OCH₃ ClCH₃ Br 2023 OCH₃ OCH₃ Cl CH₃ F 2024 OCH₃ OCH₃ Cl OCH₃ H 2025 OCH₃ OCH₃Cl OCH₃ CH₃ 2026 OCH₃ OCH₃ Cl OCH₃ OCH₃ 2027 OCH₃ OCH₃ Cl OCH₃ Br 2028OCH₃ OCH₃ Cl OCH₃ F 2029 OCH₃ OCH₃ Cl Cl H 2030 OCH₃ OCH₃ Cl Cl CH₃ 2031OCH₃ OCH₃ Cl Cl OCH₃ 2032 OCH₃ OCH₃ Cl Cl Cl 2033 OCH₃ OCH₃ Cl Cl Br2034 OCH₃ OCH₃ Cl Cl F 2035 OCH₃ OCH₃ Cl Br H 2036 OCH₃ OCH₃ Cl Br CH₃2037 OCH₃ OCH₃ Cl Br OCH₃ 2038 OCH₃ OCH₃ Cl Br Br 2039 OCH₃ OCH₃ Cl F H2040 OCH₃ OCH₃ Cl F CH₃ 2041 OCH₃ OCH₃ Cl F OCH₃ 2042 OCH₃ OCH₃ Cl F Br2043 OCH₃ OCH₃ Cl F F 2044 OCH₃ OCH₃ Br H H 2045 OCH₃ OCH₃ Br H CH₃ 2046OCH₃ OCH₃ Br H OCH₃ 2047 OCH₃ OCH₃ Br H Cl 2048 OCH₃ OCH₃ Br H Br 2049OCH₃ OCH₃ Br H F 2050 OCH₃ OCH₃ Br CH₃ H 2051 OCH₃ OCH₃ Br CH₃ CH₃ 2052OCH₃ OCH₃ Br CH₃ OCH₃ 2053 OCH₃ OCH₃ Br CH₃ Cl 2054 OCH₃ OCH₃ Br CH₃ F2055 OCH₃ OCH₃ Br OCH₃ H 2056 OCH₃ OCH₃ Br OCH₃ CH₃ 2057 OCH₃ OCH₃ BrOCH₃ OCH₃ 2058 OCH₃ OCH₃ Br OCH₃ Cl 2059 OCH₃ OCH₃ Br OCH₃ F 2060 OCH₃OCH₃ Br Cl H 2061 OCH₃ OCH₃ Br Cl CH₃ 2062 OCH₃ OCH₃ Br Cl OCH₃ 2063OCH₃ OCH₃ Br Cl Cl 2064 OCH₃ OCH₃ Br Cl F 2065 OCH₃ OCH₃ Br Br H 2066OCH₃ OCH₃ Br Br CH₃ 2067 OCH₃ OCH₃ Br Br OCH₃ 2068 OCH₃ OCH₃ Br Br Cl2069 OCH₃ OCH₃ Br Br Br 2070 OCH₃ OCH₃ Br Br F 2071 OCH₃ OCH₃ Br F H2072 OCH₃ OCH₃ Br F CH₃ 2073 OCH₃ OCH₃ Br F OCH₃ 2074 OCH₃ OCH₃ Br F Cl2075 OCH₃ OCH₃ Br F F 2076 OCH₃ OCH₃ F H H 2077 OCH₃ OCH₃ F H CH₃ 2078OCH₃ OCH₃ F H OCH₃ 2079 OCH₃ OCH₃ F H Cl 2080 OCH₃ OCH₃ F H Br 2081 OCH₃OCH₃ F H F 2082 OCH₃ OCH₃ F CH₃ H 2083 OCH₃ OCH₃ F CH₃ CH₃ 2084 OCH₃OCH₃ F CH₃ OCH₃ 2085 OCH₃ OCH₃ F CH₃ Cl 2086 OCH₃ OCH₃ F CH₃ Br 2087OCH₃ OCH₃ F OCH₃ H 2088 OCH₃ OCH₃ F OCH₃ CH₃ 2089 OCH₃ OCH₃ F OCH₃ OCH₃2090 OCH₃ OCH₃ F OCH₃ Cl 2091 OCH₃ OCH₃ F OCH₃ Br 2092 OCH₃ OCH₃ F Cl H2093 OCH₃ OCH₃ F Cl CH₃ 2094 OCH₃ OCH₃ F Cl OCH₃ 2095 OCH₃ OCH₃ F Cl Cl2096 OCH₃ OCH₃ F Cl Br 2097 OCH₃ OCH₃ F Br H 2098 OCH₃ OCH₃ F Br CH₃2099 OCH₃ OCH₃ F Br OCH₃ 2100 OCH₃ OCH₃ F Br Cl 2101 OCH₃ OCH₃ F Br Br2102 OCH₃ OCH₃ F F H 2103 OCH₃ OCH₃ F F CH₃ 2104 OCH₃ OCH₃ F F OCH₃ 2105OCH₃ OCH₃ F F Cl 2106 OCH₃ OCH₃ F F Br 2107 OCH₃ OCH₃ F F F 2108 OCH₃ ClCH₃ H H 2109 OCH₃ Cl CH₃ H CH₃ 2110 OCH₃ Cl CH₃ H OCH₃ 2111 OCH₃ Cl CH₃H Cl 2112 OCH₃ Cl CH₃ H Br 2113 OCH₃ Cl CH₃ H F 2114 OCH₃ Cl CH₃ CH₃ H2115 OCH₃ Cl CH₃ CH₃ CH₃ 2116 OCH₃ Cl CH₃ CH₃ OCH₃ 2117 OCH₃ Cl CH₃ CH₃Cl 2118 OCH₃ Cl CH₃ CH₃ Br 2119 OCH₃ Cl CH₃ CH₃ F 2120 OCH₃ Cl CH₃ OCH₃H 2121 OCH₃ Cl CH₃ OCH₃ OCH₃ 2122 OCH₃ Cl CH₃ OCH₃ Cl 2123 OCH₃ Cl CH₃OCH₃ Br 2124 OCH₃ Cl CH₃ OCH₃ F 2125 OCH₃ Cl CH₃ Cl H 2126 OCH₃ Cl CH₃Cl OCH₃ 2127 OCH₃ Cl CH₃ Cl Cl 2128 OCH₃ Cl CH₃ Cl Br 2129 OCH₃ Cl CH₃Cl F 2130 OCH₃ Cl CH₃ Br H 2131 OCH₃ Cl CH₃ Br OCH₃ 2132 OCH₃ Cl CH₃ BrCl 2133 OCH₃ Cl CH₃ Br Br 2134 OCH₃ Cl CH₃ Br F 2135 OCH₃ Cl CH₃ F H2136 OCH₃ Cl CH₃ F OCH₃ 2137 OCH₃ Cl CH₃ F Cl 2138 OCH₃ Cl CH₃ F Br 2139OCH₃ Cl CH₃ F F 2140 OCH₃ Cl OCH₃ H H 2141 OCH₃ Cl OCH₃ H CH₃ 2142 OCH₃Cl OCH₃ H OCH₃ 2143 OCH₃ Cl OCH₃ H Cl 2144 OCH₃ Cl OCH₃ H Br 2145 OCH₃Cl OCH₃ H F 2146 OCH₃ Cl OCH₃ CH₃ H 2147 OCH₃ Cl OCH₃ CH₃ CH₃ 2148 OCH₃Cl OCH₃ CH₃ Cl 2149 OCH₃ Cl OCH₃ CH₃ Br 2150 OCH₃ Cl OCH₃ CH₃ F 2151OCH₃ Cl OCH₃ OCH₃ H 2152 OCH₃ Cl OCH₃ OCH₃ CH₃ 2153 OCH₃ Cl OCH₃ OCH₃OCH₃ 2154 OCH₃ Cl OCH₃ OCH₃ Cl 2155 OCH₃ Cl OCH₃ OCH₃ Br 2156 OCH₃ ClOCH₃ OCH₃ F 2157 OCH₃ Cl OCH₃ Cl H 2158 OCH₃ Cl OCH₃ Cl CH₃ 2159 OCH₃ ClOCH₃ Cl Cl 2160 OCH₃ Cl OCH₃ Cl Br 2161 OCH₃ Cl OCH₃ Cl F 2162 OCH₃ ClOCH₃ Br H 2163 OCH₃ Cl OCH₃ Br CH₃ 2164 OCH₃ Cl OCH₃ Br Cl 2165 OCH₃ ClOCH₃ Br Br 2166 OCH₃ Cl OCH₃ Br F 2167 OCH₃ Cl OCH₃ F H 2168 OCH₃ ClOCH₃ F CH₃ 2169 OCH₃ Cl OCH₃ F Cl 2170 OCH₃ Cl OCH₃ F Br 2171 OCH₃ ClOCH₃ F F 2172 OCH₃ Cl Cl H H 2173 OCH₃ Cl Cl H CH₃ 2174 OCH₃ Cl Cl HOCH₃ 2175 OCH₃ Cl Cl H Cl 2176 OCH₃ Cl Cl H Br 2177 OCH₃ Cl Cl H F 2178OCH₃ Cl Cl CH₃ H 2179 OCH₃ Cl Cl CH₃ CH₃ 2180 OCH₃ Cl Cl CH₃ OCH₃ 2181OCH₃ Cl Cl CH₃ Br 2182 OCH₃ Cl Cl CH₃ F 2183 OCH₃ Cl Cl OCH₃ H 2184 OCH₃Cl Cl OCH₃ CH₃ 2185 OCH₃ Cl Cl OCH₃ OCH₃ 2186 OCH₃ Cl Cl OCH₃ Br 2187OCH₃ Cl Cl OCH₃ F 2188 OCH₃ Cl Cl Cl H 2189 OCH₃ Cl Cl Cl CH₃ 2190 OCH₃Cl Cl Cl OCH₃ 2191 OCH₃ Cl Cl Cl Cl 2192 OCH₃ Cl Cl Cl Br 2193 OCH₃ ClCl Cl F 2194 OCH₃ Cl Cl Br H 2195 OCH₃ Cl Cl Br CH₃ 2196 OCH₃ Cl Cl BrOCH₃ 2197 OCH₃ Cl Cl Br Br 2198 OCH₃ Cl Cl F H 2199 OCH₃ Cl Cl F CH₃2200 OCH₃ Cl Cl F OCH₃ 2201 OCH₃ Cl Cl F Br 2202 OCH₃ Cl Cl F F 2203OCH₃ Cl Br H H 2204 OCH₃ Cl Br H CH₃ 2205 OCH₃ Cl Br H OCH₃ 2206 OCH₃ ClBr H Cl 2207 OCH₃ Cl Br H Br 2208 OCH₃ Cl Br H F 2209 OCH₃ Cl Br CH₃ H2210 OCH₃ Cl Br CH₃ CH₃ 2211 OCH₃ Cl Br CH₃ OCH₃ 2212 OCH₃ Cl Br CH₃ Cl2213 OCH₃ Cl Br CH₃ F 2214 OCH₃ Cl Br OCH₃ H 2215 OCH₃ Cl Br OCH₃ CH₃2216 OCH₃ Cl Br OCH₃ OCH₃ 2217 OCH₃ Cl Br OCH₃ Cl 2218 OCH₃ Cl Br OCH₃ F2219 OCH₃ Cl Br Cl H 2220 OCH₃ Cl Br Cl CH₃ 2221 OCH₃ Cl Br Cl OCH₃ 2222OCH₃ Cl Br Cl Cl 2223 OCH₃ Cl Br Cl F 2224 OCH₃ Cl Br Br H 2225 OCH₃ ClBr Br CH₃ 2226 OCH₃ Cl Br Br OCH₃ 2227 OCH₃ Cl Br Br Cl 2228 OCH₃ Cl BrBr Br 2229 OCH₃ Cl Br Br F 2230 OCH₃ Cl Br F H 2231 OCH₃ Cl Br F CH₃2232 OCH₃ Cl Br F OCH₃ 2233 OCH₃ Cl Br F Cl 2234 OCH₃ Cl Br F F 2235OCH₃ Cl F H H 2236 OCH₃ Cl F H CH₃ 2237 OCH₃ Cl F H OCH₃ 2238 OCH₃ Cl FH Cl 2239 OCH₃ Cl F H Br 2240 OCH₃ Cl F H F 2241 OCH₃ Cl F CH₃ H 2242OCH₃ Cl F CH₃ CH₃ 2243 OCH₃ Cl F CH₃ OCH₃ 2244 OCH₃ Cl F CH₃ Cl 2245OCH₃ Cl F CH₃ Br 2246 OCH₃ Cl F OCH₃ H 2247 OCH₃ Cl F OCH₃ CH₃ 2248 OCH₃Cl F OCH₃ OCH₃ 2249 OCH₃ Cl F OCH₃ Cl 2250 OCH₃ Cl F OCH₃ Br 2251 OCH₃Cl F Cl H 2252 OCH₃ Cl F Cl CH₃ 2253 OCH₃ Cl F Cl OCH₃ 2254 OCH₃ Cl F ClCl 2255 OCH₃ Cl F Cl Br 2256 OCH₃ Cl F Br H 2257 OCH₃ Cl F Br CH₃ 2258OCH₃ Cl F Br OCH₃ 2259 OCH₃ Cl F Br Cl 2260 OCH₃ Cl F Br Br 2261 OCH₃ ClF F H 2262 OCH₃ Cl F F CH₃ 2263 OCH₃ Cl F F OCH₃ 2264 OCH₃ Cl F F Cl2265 OCH₃ Cl F F Br 2266 OCH₃ Cl F F F 2267 OCH₃ Br CH₃ H H 2268 OCH₃ BrCH₃ H CH₃ 2269 OCH₃ Br CH₃ H OCH₃ 2270 OCH₃ Br CH₃ H Cl 2271 OCH₃ Br CH₃H Br 2272 OCH₃ Br CH₃ H F 2273 OCH₃ Br CH₃ CH₃ H 2274 OCH₃ Br CH₃ CH₃CH₃ 2275 OCH₃ Br CH₃ CH₃ OCH₃ 2276 OCH₃ Br CH₃ CH₃ Cl 2277 OCH₃ Br CH₃CH₃ Br 2278 OCH₃ Br CH₃ CH₃ F 2279 OCH₃ Br CH₃ OCH₃ H 2280 OCH₃ Br CH₃OCH₃ OCH₃ 2281 OCH₃ Br CH₃ OCH₃ Cl 2282 OCH₃ Br CH₃ OCH₃ Br 2283 OCH₃ BrCH₃ OCH₃ F 2284 OCH₃ Br CH₃ Cl H 2285 OCH₃ Br CH₃ Cl OCH₃ 2286 OCH₃ BrCH₃ Cl Cl 2287 OCH₃ Br CH₃ Cl Br 2288 OCH₃ Br CH₃ Cl F 2289 OCH₃ Br CH₃Br H 2290 OCH₃ Br CH₃ Br OCH₃ 2291 OCH₃ Br CH₃ Br Cl 2292 OCH₃ Br CH₃ BrBr 2293 OCH₃ Br CH₃ Br F 2294 OCH₃ Br CH₃ F H 2295 OCH₃ Br CH₃ F OCH₃2296 OCH₃ Br CH₃ F Cl 2297 OCH₃ Br CH₃ F Br 2298 OCH₃ Br CH₃ F F 2299OCH₃ Br OCH₃ H H 2300 OCH₃ Br OCH₃ H CH₃ 2301 OCH₃ Br OCH₃ H OCH₃ 2302OCH₃ Br OCH₃ H Cl 2303 OCH₃ Br OCH₃ H Br 2304 OCH₃ Br OCH₃ H F 2305 OCH₃Br OCH₃ CH₃ H 2306 OCH₃ Br OCH₃ CH₃ CH₃ 2307 OCH₃ Br OCH₃ CH₃ Cl 2308OCH₃ Br OCH₃ CH₃ Br 2309 OCH₃ Br OCH₃ CH₃ F 2310 OCH₃ Br OCH₃ OCH₃ H2311 OCH₃ Br OCH₃ OCH₃ CH₃ 2312 OCH₃ Br OCH₃ OCH₃ OCH₃ 2313 OCH₃ Br OCH₃OCH₃ Cl 2314 OCH₃ Br OCH₃ OCH₃ Br 2315 OCH₃ Br OCH₃ OCH₃ F 2316 OCH₃ BrOCH₃ Cl H 2317 OCH₃ Br OCH₃ Cl CH₃ 2318 OCH₃ Br OCH₃ Cl Cl 2319 OCH₃ BrOCH₃ Cl Br 2320 OCH₃ Br OCH₃ Cl F 2321 OCH₃ Br OCH₃ Br H 2322 OCH₃ BrOCH₃ Br CH₃ 2323 OCH₃ Br OCH₃ Br Cl 2324 OCH₃ Br OCH₃ Br Br 2325 OCH₃ BrOCH₃ Br F 2326 OCH₃ Br OCH₃ F H 2327 OCH₃ Br OCH₃ F CH₃ 2328 OCH₃ BrOCH₃ F Cl 2329 OCH₃ Br OCH₃ F Br 2330 OCH₃ Br OCH₃ F F 2331 OCH₃ Br Cl HH 2332 OCH₃ Br Cl H CH₃ 2333 OCH₃ Br Cl H OCH₃ 2334 OCH₃ Br Cl H Cl 2335OCH₃ Br Cl H Br 2336 OCH₃ Br Cl H F 2337 OCH₃ Br Cl CH₃ H 2338 OCH₃ BrCl CH₃ CH₃ 2339 OCH₃ Br Cl CH₃ OCH₃ 2340 OCH₃ Br Cl CH₃ Br 2341 OCH₃ BrCl CH₃ F 2342 OCH₃ Br Cl OCH₃ H 2343 OCH₃ Br Cl OCH₃ CH₃ 2344 OCH₃ Br ClOCH₃ OCH₃ 2345 OCH₃ Br Cl OCH₃ Br 2346 OCH₃ Br Cl OCH₃ F 2347 OCH₃ Br ClCl H 2348 OCH₃ Br Cl Cl CH₃ 2349 OCH₃ Br Cl Cl OCH₃ 2350 OCH₃ Br Cl ClCl 2351 OCH₃ Br Cl Cl Br 2352 OCH₃ Br Cl Cl F 2353 OCH₃ Br Cl Br H 2354OCH₃ Br Cl Br CH₃ 2355 OCH₃ Br Cl Br OCH₃ 2356 OCH₃ Br Cl Br Br 2357OCH₃ Br Cl F H 2358 OCH₃ Br Cl F CH₃ 2359 OCH₃ Br Cl F OCH₃ 2360 OCH₃ BrCl F Br 2361 OCH₃ Br Cl F F 2362 OCH₃ Br Br H H 2363 OCH₃ Br Br H CH₃2364 OCH₃ Br Br H OCH₃ 2365 OCH₃ Br Br H Cl 2366 OCH₃ Br Br H Br 2367OCH₃ Br Br H F 2368 OCH₃ Br Br CH₃ H 2369 OCH₃ Br Br CH₃ CH₃ 2370 OCH₃Br Br CH₃ OCH₃ 2371 OCH₃ Br Br CH₃ Cl 2372 OCH₃ Br Br CH₃ F 2373 OCH₃ BrBr OCH₃ H 2374 OCH₃ Br Br OCH₃ CH₃ 2375 OCH₃ Br Br OCH₃ OCH₃ 2376 OCH₃Br Br OCH₃ Cl 2377 OCH₃ Br Br OCH₃ F 2378 OCH₃ Br Br Cl H 2379 OCH₃ BrBr Cl CH₃ 2380 OCH₃ Br Br Cl OCH₃ 2381 OCH₃ Br Br Cl Cl 2382 OCH₃ Br BrCl F 2383 OCH₃ Br Br Br H 2384 OCH₃ Br Br Br CH₃ 2385 OCH₃ Br Br Br OCH₃2386 OCH₃ Br Br Br Cl 2387 OCH₃ Br Br Br Br 2388 OCH₃ Br Br Br F 2389OCH₃ Br Br F H 2390 OCH₃ Br Br F CH₃ 2391 OCH₃ Br Br F OCH₃ 2392 OCH₃ BrBr F Cl 2393 OCH₃ Br Br F F 2394 OCH₃ Br F H H 2395 OCH₃ Br F H CH₃ 2396OCH₃ Br F H OCH₃ 2397 OCH₃ Br F H Cl 2398 OCH₃ Br F H Br 2399 OCH₃ Br FH F 2400 OCH₃ Br F CH₃ H 2401 OCH₃ Br F CH₃ CH₃ 2402 OCH₃ Br F CH₃ OCH₃2403 OCH₃ Br F CH₃ Cl 2404 OCH₃ Br F CH₃ Br 2405 OCH₃ Br F OCH₃ H 2406OCH₃ Br F OCH₃ CH₃ 2407 OCH₃ Br F OCH₃ OCH₃ 2408 OCH₃ Br F OCH₃ Cl 2409OCH₃ Br F OCH₃ Br 2410 OCH₃ Br F Cl H 2411 OCH₃ Br F Cl CH₃ 2412 OCH₃ BrF Cl OCH₃ 2413 OCH₃ Br F Cl Cl 2414 OCH₃ Br F Cl Br 2415 OCH₃ Br F Br H2416 OCH₃ Br F Br CH₃ 2417 OCH₃ Br F Br OCH₃ 2418 OCH₃ Br F Br Cl 2419OCH₃ Br F Br Br 2420 OCH₃ Br F F H 2421 OCH₃ Br F F CH₃ 2422 OCH₃ Br F FOCH₃ 2423 OCH₃ Br F F Cl 2424 OCH₃ Br F F Br 2425 OCH₃ Br F F F 2426OCH₃ F CH₃ H H 2427 OCH₃ F CH₃ H CH₃ 2428 OCH₃ F CH₃ H OCH₃ 2429 OCH₃ FCH₃ H Cl 2430 OCH₃ F CH₃ H Br 2431 OCH₃ F CH₃ H F 2432 OCH₃ F CH₃ CH₃ H2433 OCH₃ F CH₃ CH₃ CH₃ 2434 OCH₃ F CH₃ CH₃ OCH₃ 2435 OCH₃ F CH₃ CH₃ Cl2436 OCH₃ F CH₃ CH₃ Br 2437 OCH₃ F CH₃ CH₃ F 2438 OCH₃ F CH₃ OCH₃ H 2439OCH₃ F CH₃ OCH₃ OCH₃ 2440 OCH₃ F CH₃ OCH₃ Cl 2441 OCH₃ F CH₃ OCH₃ Br2442 OCH₃ F CH₃ OCH₃ F 2443 OCH₃ F CH₃ Cl H 2444 OCH₃ F CH₃ Cl OCH₃ 2445OCH₃ F CH₃ Cl Cl 2446 OCH₃ F CH₃ Cl Br 2447 OCH₃ F CH₃ Cl F 2448 OCH₃ FCH₃ Br H 2449 OCH₃ F CH₃ Br OCH₃ 2450 OCH₃ F CH₃ Br Cl 2451 OCH₃ F CH₃Br Br 2452 OCH₃ F CH₃ Br F 2453 OCH₃ F CH₃ F H 2454 OCH₃ F CH₃ F OCH₃2455 OCH₃ F CH₃ F Cl 2456 OCH₃ F CH₃ F Br 2457 OCH₃ F CH₃ F F 2458 OCH₃F OCH₃ H H 2459 OCH₃ F OCH₃ H CH₃ 2460 OCH₃ F OCH₃ H OCH₃ 2461 OCH₃ FOCH₃ H Cl 2462 OCH₃ F OCH₃ H Br 2463 OCH₃ F OCH₃ H F 2464 OCH₃ F OCH₃CH₃ H 2465 OCH₃ F OCH₃ CH₃ CH₃ 2466 OCH₃ F OCH₃ CH₃ Cl 2467 OCH₃ F OCH₃CH₃ Br 2468 OCH₃ F OCH₃ CH₃ F 2469 OCH₃ F OCH₃ OCH₃ H 2470 OCH₃ F OCH₃OCH₃ CH₃ 2471 OCH₃ F OCH₃ OCH₃ OCH₃ 2472 OCH₃ F OCH₃ OCH₃ Cl 2473 OCH₃ FOCH₃ OCH₃ Br 2474 OCH₃ F OCH₃ OCH₃ F 2475 OCH₃ F OCH₃ Cl H 2476 OCH₃ FOCH₃ Cl CH₃ 2477 OCH₃ F OCH₃ Cl Cl 2478 OCH₃ F OCH₃ Cl Br 2479 OCH₃ FOCH₃ Cl F 2480 OCH₃ F OCH₃ Br H 2481 OCH₃ F OCH₃ Br CH₃ 2482 OCH₃ F OCH₃Br Cl 2483 OCH₃ F OCH₃ Br Br 2484 OCH₃ F OCH₃ Br F 2485 OCH₃ F OCH₃ F H2486 OCH₃ F OCH₃ F CH₃ 2487 OCH₃ F OCH₃ F Cl 2488 OCH₃ F OCH₃ F Br 2489OCH₃ F OCH₃ F F 2490 OCH₃ F Cl H H 2491 OCH₃ F Cl H CH₃ 2492 OCH₃ F Cl HOCH₃ 2493 OCH₃ F Cl H Cl 2494 OCH₃ F Cl H Br 2495 OCH₃ F Cl H F 2496OCH₃ F Cl CH₃ H 2497 OCH₃ F Cl CH₃ CH₃ 2498 OCH₃ F Cl CH₃ OCH₃ 2499 OCH₃F Cl CH₃ Br 2500 OCH₃ F Cl CH₃ F 2501 OCH₃ F Cl OCH₃ H 2502 OCH₃ F ClOCH₃ CH₃ 2503 OCH₃ F Cl OCH₃ OCH₃ 2504 OCH₃ F Cl OCH₃ Br 2505 OCH₃ F ClOCH₃ F 2506 OCH₃ F Cl Cl H 2507 OCH₃ F Cl Cl CH₃ 2508 OCH₃ F Cl Cl OCH₃2509 OCH₃ F Cl Cl Cl 2510 OCH₃ F Cl Cl Br 2511 OCH₃ F Cl Cl F 2512 OCH₃F Cl Br H 2513 OCH₃ F Cl Br CH₃ 2514 OCH₃ F Cl Br OCH₃ 2515 OCH₃ F Cl BrBr 2516 OCH₃ F Cl F H 2517 OCH₃ F Cl F CH₃ 2518 OCH₃ F Cl F OCH₃ 2519OCH₃ F Cl F Br 2520 OCH₃ F Cl F F 2521 OCH₃ F Br H H 2522 OCH₃ F Br HCH₃ 2523 OCH₃ F Br H OCH₃ 2524 OCH₃ F Br H Cl 2525 OCH₃ F Br H Br 2526OCH₃ F Br H F 2527 OCH₃ F Br CH₃ H 2528 OCH₃ F Br CH₃ CH₃ 2529 OCH₃ F BrCH₃ OCH₃ 2530 OCH₃ F Br CH₃ Cl 2531 OCH₃ F Br CH₃ F 2532 OCH₃ F Br OCH₃H 2533 OCH₃ F Br OCH₃ CH₃ 2534 OCH₃ F Br OCH₃ OCH₃ 2535 OCH₃ F Br OCH₃Cl 2536 OCH₃ F Br OCH₃ F 2537 OCH₃ F Br Cl H 2538 OCH₃ F Br Cl CH₃ 2539OCH₃ F Br Cl OCH₃ 2540 OCH₃ F Br Cl Cl 2541 OCH₃ F Br Cl F 2542 OCH₃ FBr Br H 2543 OCH₃ F Br Br CH₃ 2544 OCH₃ F Br Br OCH₃ 2545 OCH₃ F Br BrCl 2546 OCH₃ F Br Br Br 2547 OCH₃ F Br Br F 2548 OCH₃ F Br F H 2549 OCH₃F Br F CH₃ 2550 OCH₃ F Br F OCH₃ 2551 OCH₃ F Br F Cl 2552 OCH₃ F Br F F2553 OCH₃ F F H H 2554 OCH₃ F F H CH₃ 2555 OCH₃ F F H OCH₃ 2556 OCH₃ F FH Cl 2557 OCH₃ F F H Br 2558 OCH₃ F F H F 2559 OCH₃ F F CH₃ H 2560 OCH₃F F CH₃ CH₃ 2561 OCH₃ F F CH₃ OCH₃ 2562 OCH₃ F F CH₃ Cl 2563 OCH₃ F FCH₃ Br 2564 OCH₃ F F OCH₃ H 2565 OCH₃ F F OCH₃ CH₃ 2566 OCH₃ F F OCH₃OCH₃ 2567 OCH₃ F F OCH₃ Cl 2568 OCH₃ F F OCH₃ Br 2569 OCH₃ F F Cl H 2570OCH₃ F F Cl CH₃ 2571 OCH₃ F F Cl OCH₃ 2572 OCH₃ F F Cl Cl 2573 OCH₃ F FCl Br 2574 OCH₃ F F Br H 2575 OCH₃ F F Br CH₃ 2576 OCH₃ F F Br OCH₃ 2577OCH₃ F F Br Cl 2578 OCH₃ F F Br Br 2579 OCH₃ F F F H 2580 OCH₃ F F F CH₃2581 OCH₃ F F F OCH₃ 2582 OCH₃ F F F Cl 2583 OCH₃ F F F Br 2584 OCH₃ F FF F 2585 Cl CH₃ CH₃ H H 2586 Cl CH₃ CH₃ CH₃ H 2587 Cl CH₃ CH₃ OCH₃ H2588 Cl CH₃ CH₃ Cl H 2589 Cl CH₃ CH₃ Br H 2590 Cl CH₃ CH₃ F H 2591 ClCH₃ CH₃ H CH₃ 2592 Cl CH₃ CH₃ CH₃ CH₃ 2593 Cl CH₃ CH₃ H OCH₃ 2594 Cl CH₃CH₃ CH₃ OCH₃ 2595 Cl CH₃ CH₃ OCH₃ OCH₃ 2596 Cl CH₃ CH₃ Cl OCH₃ 2597 ClCH₃ CH₃ Br OCH₃ 2598 Cl CH₃ CH₃ F OCH₃ 2599 Cl CH₃ CH₃ H Cl 2600 Cl CH₃CH₃ CH₃ Cl 2601 Cl CH₃ CH₃ OCH₃ Cl 2602 Cl CH₃ CH₃ Cl Cl 2603 Cl CH₃ CH₃Br Cl 2604 Cl CH₃ CH₃ F Cl 2605 Cl CH₃ CH₃ H Br 2606 Cl CH₃ CH₃ CH₃ Br2607 Cl CH₃ CH₃ OCH₃ Br 2608 Cl CH₃ CH₃ Cl Br 2609 Cl CH₃ CH₃ Br Br 2610Cl CH₃ CH₃ F Br 2611 Cl CH₃ CH₃ H F 2612 Cl CH₃ CH₃ CH₃ F 2613 Cl CH₃CH₃ OCH₃ F 2614 Cl CH₃ CH₃ Cl F 2615 Cl CH₃ CH₃ Br F 2616 Cl CH₃ CH₃ F F2617 Cl CH₃ OCH₃ H H 2618 Cl CH₃ OCH₃ CH₃ H 2619 Cl CH₃ OCH₃ OCH₃ H 2620Cl CH₃ OCH₃ Cl H 2621 Cl CH₃ OCH₃ Br H 2622 Cl CH₃ OCH₃ F H 2623 Cl CH₃OCH₃ H CH₃ 2624 Cl CH₃ OCH₃ CH₃ CH₃ 2625 Cl CH₃ OCH₃ OCH₃ CH₃ 2626 ClCH₃ OCH₃ Cl CH₃ 2627 Cl CH₃ OCH₃ Br CH₃ 2628 Cl CH₃ OCH₃ F CH₃ 2629 ClCH₃ OCH₃ H OCH₃ 2630 Cl CH₃ OCH₃ OCH₃ OCH₃ 2631 Cl CH₃ OCH₃ H Cl 2632 ClCH₃ OCH₃ CH₃ Cl 2633 Cl CH₃ OCH₃ OCH₃ Cl 2634 Cl CH₃ OCH₃ Cl Cl 2635 ClCH₃ OCH₃ Br Cl 2636 Cl CH₃ OCH₃ F Cl 2637 Cl CH₃ OCH₃ H Br 2638 Cl CH₃OCH₃ CH₃ Br 2639 Cl CH₃ OCH₃ OCH₃ Br 2640 Cl CH₃ OCH₃ Cl Br 2641 Cl CH₃OCH₃ Br Br 2642 Cl CH₃ OCH₃ F Br 2643 Cl CH₃ OCH₃ H F 2644 Cl CH₃ OCH₃CH₃ F 2645 Cl CH₃ OCH₃ OCH₃ F 2646 Cl CH₃ OCH₃ Cl F 2647 Cl CH₃ OCH₃ BrF 2648 Cl CH₃ OCH₃ F F 2649 Cl CH₃ Cl H H 2650 Cl CH₃ Cl CH₃ H 2651 ClCH₃ Cl OCH₃ H 2652 Cl CH₃ Cl Cl H 2653 Cl CH₃ Cl Br H 2654 Cl CH₃ Cl F H2655 Cl CH₃ Cl H CH₃ 2656 Cl CH₃ Cl CH₃ CH₃ 2657 Cl CH₃ Cl OCH₃ CH₃ 2658Cl CH₃ Cl Cl CH₃ 2659 Cl CH₃ Cl Br CH₃ 2660 Cl CH₃ Cl F CH₃ 2661 Cl CH₃Cl H OCH₃ 2662 Cl CH₃ Cl CH₃ OCH₃ 2663 Cl CH₃ Cl OCH₃ OCH₃ 2664 Cl CH₃Cl Cl OCH₃ 2665 Cl CH₃ Cl Br OCH₃ 2666 Cl CH₃ Cl F OCH₃ 2667 Cl CH₃ Cl HCl 2668 Cl CH₃ Cl Cl Cl 2669 Cl CH₃ Cl H Br 2670 Cl CH₃ Cl CH₃ Br 2671Cl CH₃ Cl OCH₃ Br 2672 Cl CH₃ Cl Cl Br 2673 Cl CH₃ Cl Br Br 2674 Cl CH₃Cl F Br 2675 Cl CH₃ Cl H F 2676 Cl CH₃ Cl CH₃ F 2677 Cl CH₃ Cl OCH₃ F2678 Cl CH₃ Cl Cl F 2679 Cl CH₃ Cl F F 2680 Cl CH₃ Br H H 2681 Cl CH₃ BrCH₃ H 2682 Cl CH₃ Br OCH₃ H 2683 Cl CH₃ Br Cl H 2684 Cl CH₃ Br Br H 2685Cl CH₃ Br F H 2686 Cl CH₃ Br H CH₃ 2687 Cl CH₃ Br CH₃ CH₃ 2688 Cl CH₃ BrOCH₃ CH₃ 2689 Cl CH₃ Br Cl CH₃ 2690 Cl CH₃ Br Br CH₃ 2691 Cl CH₃ Br FCH₃ 2692 Cl CH₃ Br H OCH₃ 2693 Cl CH₃ Br CH₃ OCH₃ 2694 Cl CH₃ Br OCH₃OCH₃ 2695 Cl CH₃ Br Cl OCH₃ 2696 Cl CH₃ Br Br OCH₃ 2697 Cl CH₃ Br F OCH₃2698 Cl CH₃ Br H Cl 2699 Cl CH₃ Br CH₃ Cl 2700 Cl CH₃ Br OCH₃ Cl 2701 ClCH₃ Br Cl Cl 2702 Cl CH₃ Br Br Cl 2703 Cl CH₃ Br F Cl 2704 Cl CH₃ Br HBr 2705 Cl CH₃ Br Br Br 2706 Cl CH₃ Br H F 2707 Cl CH₃ Br CH₃ F 2708 ClCH₃ Br OCH₃ F 2709 Cl CH₃ Br Cl F 2710 Cl CH₃ Br Br F 2711 Cl CH₃ Br F F2712 Cl CH₃ F H H 2713 Cl CH₃ F CH₃ H 2714 Cl CH₃ F OCH₃ H 2715 Cl CH₃ FCl H 2716 Cl CH₃ F Br H 2717 Cl CH₃ F F H 2718 Cl CH₃ F H CH₃ 2719 ClCH₃ F CH₃ CH₃ 2720 Cl CH₃ F OCH₃ CH₃ 2721 Cl CH₃ F Cl CH₃ 2722 Cl CH₃ FBr CH₃ 2723 Cl CH₃ F F CH₃ 2724 Cl CH₃ F H OCH₃ 2725 Cl CH₃ F CH₃ OCH₃2726 Cl CH₃ F OCH₃ OCH₃ 2727 Cl CH₃ F Cl OCH₃ 2728 Cl CH₃ F Br OCH₃ 2729Cl CH₃ F F OCH₃ 2730 Cl CH₃ F H Cl 2731 Cl CH₃ F CH₃ Cl 2732 Cl CH₃ FOCH₃ Cl 2733 Cl CH₃ F Cl Cl 2734 Cl CH₃ F Br Cl 2735 Cl CH₃ F F Cl 2736Cl CH₃ F H Br 2737 Cl CH₃ F CH₃ Br 2738 Cl CH₃ F OCH₃ Br 2739 Cl CH₃ FCl Br 2740 Cl CH₃ F Br Br 2741 Cl CH₃ F F Br 2742 Cl CH₃ F H F 2743 ClCH₃ F F F 2744 Cl OCH₃ CH₃ H H 2745 Cl OCH₃ CH₃ H CH₃ 2746 Cl OCH₃ CH₃ HOCH₃ 2747 Cl OCH₃ CH₃ H Cl 2748 Cl OCH₃ CH₃ H Br 2749 Cl OCH₃ CH₃ H F2750 Cl OCH₃ CH₃ CH₃ H 2751 Cl OCH₃ CH₃ CH₃ CH₃ 2752 Cl OCH₃ CH₃ CH₃OCH₃ 2753 Cl OCH₃ CH₃ CH₃ Cl 2754 Cl OCH₃ CH₃ CH₃ Br 2755 Cl OCH₃ CH₃CH₃ F 2756 Cl OCH₃ CH₃ OCH₃ H 2757 Cl OCH₃ CH₃ OCH₃ OCH₃ 2758 Cl OCH₃CH₃ OCH₃ Cl 2759 Cl OCH₃ CH₃ OCH₃ Br 2760 Cl OCH₃ CH₃ OCH₃ F 2761 ClOCH₃ CH₃ Cl H 2762 Cl OCH₃ CH₃ Cl OCH₃ 2763 Cl OCH₃ CH₃ Cl Cl 2764 ClOCH₃ CH₃ Cl Br 2765 Cl OCH₃ CH₃ Cl F 2766 Cl OCH₃ CH₃ Br H 2767 Cl OCH₃CH₃ Br OCH₃ 2768 Cl OCH₃ CH₃ Br Cl 2769 Cl OCH₃ CH₃ Br Br 2770 Cl OCH₃CH₃ Br F 2771 Cl OCH₃ CH₃ F H 2772 Cl OCH₃ CH₃ F OCH₃ 2773 Cl OCH₃ CH₃ FCl 2774 Cl OCH₃ CH₃ F Br 2775 Cl OCH₃ CH₃ F F 2776 Cl OCH₃ OCH₃ H H 2777Cl OCH₃ OCH₃ H CH₃ 2778 Cl OCH₃ OCH₃ H OCH₃ 2779 Cl OCH₃ OCH₃ H Cl 2780Cl OCH₃ OCH₃ H Br 2781 Cl OCH₃ OCH₃ H F 2782 Cl OCH₃ OCH₃ CH₃ H 2783 ClOCH₃ OCH₃ CH₃ CH₃ 2784 Cl OCH₃ OCH₃ CH₃ Cl 2785 Cl OCH₃ OCH₃ CH₃ Br 2786Cl OCH₃ OCH₃ CH₃ F 2787 Cl OCH₃ OCH₃ OCH₃ H 2788 Cl OCH₃ OCH₃ OCH₃ CH₃2789 Cl OCH₃ OCH₃ OCH₃ OCH₃ 2790 Cl OCH₃ OCH₃ OCH₃ Cl 2791 Cl OCH₃ OCH₃OCH₃ Br 2792 Cl OCH₃ OCH₃ OCH₃ F 2793 Cl OCH₃ OCH₃ Cl H 2794 Cl OCH₃OCH₃ Cl CH₃ 2795 Cl OCH₃ OCH₃ Cl Cl 2796 Cl OCH₃ OCH₃ Cl Br 2797 Cl OCH₃OCH₃ Cl F 2798 Cl OCH₃ OCH₃ Br H 2799 Cl OCH₃ OCH₃ Br CH₃ 2800 Cl OCH₃OCH₃ Br Cl 2801 Cl OCH₃ OCH₃ Br Br 2802 Cl OCH₃ OCH₃ Br F 2803 Cl OCH₃OCH₃ F H 2804 Cl OCH₃ OCH₃ F CH₃ 2805 Cl OCH₃ OCH₃ F Cl 2806 Cl OCH₃OCH₃ F Br 2807 Cl OCH₃ OCH₃ F F 2808 Cl OCH₃ Cl H H 2809 Cl OCH₃ Cl HCH₃ 2810 Cl OCH₃ Cl H OCH₃ 2811 Cl OCH₃ Cl H Cl 2812 Cl OCH₃ Cl H Br2813 Cl OCH₃ Cl H F 2814 Cl OCH₃ Cl CH₃ H 2815 Cl OCH₃ Cl CH₃ CH₃ 2816Cl OCH₃ Cl CH₃ OCH₃ 2817 Cl OCH₃ Cl CH₃ Br 2818 Cl OCH₃ Cl CH₃ F 2819 ClOCH₃ Cl OCH₃ H 2820 Cl OCH₃ Cl OCH₃ CH₃ 2821 Cl OCH₃ Cl OCH₃ OCH₃ 2822Cl OCH₃ Cl OCH₃ Br 2823 Cl OCH₃ Cl OCH₃ F 2824 Cl OCH₃ Cl Cl H 2825 ClOCH₃ Cl Cl CH₃ 2826 Cl OCH₃ Cl Cl OCH₃ 2827 Cl OCH₃ Cl Cl Cl 2828 ClOCH₃ Cl Cl Br 2829 Cl OCH₃ Cl Cl F 2830 Cl OCH₃ Cl Br H 2831 Cl OCH₃ ClBr CH₃ 2832 Cl OCH₃ Cl Br OCH₃ 2833 Cl OCH₃ Cl Br Br 2834 Cl OCH₃ Cl F H2835 Cl OCH₃ Cl F CH₃ 2836 Cl OCH₃ Cl F OCH₃ 2837 Cl OCH₃ Cl F Br 2838Cl OCH₃ Cl F F 2839 Cl OCH₃ Br H H 2840 Cl OCH₃ Br H CH₃ 2841 Cl OCH₃ BrH OCH₃ 2842 Cl OCH₃ Br H Cl 2843 Cl OCH₃ Br H Br 2844 Cl OCH₃ Br H F2845 Cl OCH₃ Br CH₃ H 2846 Cl OCH₃ Br CH₃ CH₃ 2847 Cl OCH₃ Br CH₃ OCH₃2848 Cl OCH₃ Br CH₃ Cl 2849 Cl OCH₃ Br CH₃ F 2850 Cl OCH₃ Br OCH₃ H 2851Cl OCH₃ Br OCH₃ CH₃ 2852 Cl OCH₃ Br OCH₃ OCH₃ 2853 Cl OCH₃ Br OCH₃ Cl2854 Cl OCH₃ Br OCH₃ F 2855 Cl OCH₃ Br Cl H 2856 Cl OCH₃ Br Cl CH₃ 2857Cl OCH₃ Br Cl OCH₃ 2858 Cl OCH₃ Br Cl Cl 2859 Cl OCH₃ Br Cl F 2860 ClOCH₃ Br Br H 2861 Cl OCH₃ Br Br CH₃ 2862 Cl OCH₃ Br Br OCH₃ 2863 Cl OCH₃Br Br Cl 2864 Cl OCH₃ Br Br Br 2865 Cl OCH₃ Br Br F 2866 Cl OCH₃ Br F H2867 Cl OCH₃ Br F CH₃ 2868 Cl OCH₃ Br F OCH₃ 2869 Cl OCH₃ Br F Cl 2870Cl OCH₃ Br F F 2871 Cl OCH₃ F H H 2872 Cl OCH₃ F H CH₃ 2873 Cl OCH₃ F HOCH₃ 2874 Cl OCH₃ F H Cl 2875 Cl OCH₃ F H Br 2876 Cl OCH₃ F H F 2877 ClOCH₃ F CH₃ H 2878 Cl OCH₃ F CH₃ CH₃ 2879 Cl OCH₃ F CH₃ OCH₃ 2880 Cl OCH₃F CH₃ Cl 2881 Cl OCH₃ F CH₃ Br 2882 Cl OCH₃ F OCH₃ H 2883 Cl OCH₃ F OCH₃CH₃ 2884 Cl OCH₃ F OCH₃ OCH₃ 2885 Cl OCH₃ F OCH₃ Cl 2886 Cl OCH₃ F OCH₃Br 2887 Cl OCH₃ F Cl H 2888 Cl OCH₃ F Cl CH₃ 2889 Cl OCH₃ F Cl OCH₃ 2890Cl OCH₃ F Cl Cl 2891 Cl OCH₃ F Cl Br 2892 Cl OCH₃ F Br H 2893 Cl OCH₃ FBr CH₃ 2894 Cl OCH₃ F Br OCH₃ 2895 Cl OCH₃ F Br Cl 2896 Cl OCH₃ F Br Br2897 Cl OCH₃ F F H 2898 Cl OCH₃ F F CH₃ 2899 Cl OCH₃ F F OCH₃ 2900 ClOCH₃ F F Cl 2901 Cl OCH₃ F F Br 2902 Cl OCH₃ F F F 2903 Cl Cl CH₃ H H2904 Cl Cl CH₃ H CH₃ 2905 Cl Cl CH₃ H OCH₃ 2906 Cl Cl CH₃ H Cl 2907 ClCl CH₃ H Br 2908 Cl Cl CH₃ H F 2909 Cl Cl CH₃ CH₃ H 2910 Cl Cl CH₃ CH₃CH₃ 2911 Cl Cl CH₃ CH₃ OCH₃ 2912 Cl Cl CH₃ CH₃ Cl 2913 Cl Cl CH₃ CH₃ Br2914 Cl Cl CH₃ CH₃ F 2915 Cl Cl CH₃ OCH₃ H 2916 Cl Cl CH₃ OCH₃ OCH₃ 2917Cl Cl CH₃ OCH₃ Cl 2918 Cl Cl CH₃ OCH₃ Br 2919 Cl Cl CH₃ OCH₃ F 2920 ClCl CH₃ Cl H 2921 Cl Cl CH₃ Cl OCH₃ 2922 Cl Cl CH₃ Cl Cl 2923 Cl Cl CH₃Cl Br 2924 Cl Cl CH₃ Cl F 2925 Cl Cl CH₃ Br H 2926 Cl Cl CH₃ Br OCH₃2927 Cl Cl CH₃ Br Cl 2928 Cl Cl CH₃ Br Br 2929 Cl Cl CH₃ Br F 2930 Cl ClCH₃ F H 2931 Cl Cl CH₃ F OCH₃ 2932 Cl Cl CH₃ F Cl 2933 Cl Cl CH₃ F Br2934 Cl Cl CH₃ F F 2935 Cl Cl OCH₃ H H 2936 Cl Cl OCH₃ H CH₃ 2937 Cl ClOCH₃ H OCH₃ 2938 Cl Cl OCH₃ H Cl 2939 Cl Cl OCH₃ H Br 2940 Cl Cl OCH₃ HF 2941 Cl Cl OCH₃ CH₃ H 2942 Cl Cl OCH₃ CH₃ CH₃ 2943 Cl Cl OCH₃ CH₃ Cl2944 Cl Cl OCH₃ CH₃ Br 2945 Cl Cl OCH₃ CH₃ F 2946 Cl Cl OCH₃ OCH₃ H 2947Cl Cl OCH₃ OCH₃ CH₃ 2948 Cl Cl OCH₃ OCH₃ OCH₃ 2949 Cl Cl OCH₃ OCH₃ Cl2950 Cl Cl OCH₃ OCH₃ Br 2951 Cl Cl OCH₃ OCH₃ F 2952 Cl Cl OCH₃ Cl H 2953Cl Cl OCH₃ Cl CH₃ 2954 Cl Cl OCH₃ Cl Cl 2955 Cl Cl OCH₃ Cl Br 2956 Cl ClOCH₃ Cl F 2957 Cl Cl OCH₃ Br H 2958 Cl Cl OCH₃ Br CH₃ 2959 Cl Cl OCH₃ BrCl 2960 Cl Cl OCH₃ Br Br 2961 Cl Cl OCH₃ Br F 2962 Cl Cl OCH₃ F H 2963Cl Cl OCH₃ F CH₃ 2964 Cl Cl OCH₃ F Cl 2965 Cl Cl OCH₃ F Br 2966 Cl ClOCH₃ F F 2967 Cl Cl Cl H H 2968 Cl Cl Cl H CH₃ 2969 Cl Cl Cl H OCH₃ 2970Cl Cl Cl H Cl 2971 Cl Cl Cl H Br 2972 Cl Cl Cl H F 2973 Cl Cl Cl CH₃ H2974 Cl Cl Cl CH₃ CH₃ 2975 Cl Cl Cl CH₃ OCH₃ 2976 Cl Cl Cl CH₃ Br 2977Cl Cl Cl CH₃ F 2978 Cl Cl Cl OCH₃ H 2979 Cl Cl Cl OCH₃ CH₃ 2980 Cl Cl ClOCH₃ OCH₃ 2981 Cl Cl Cl OCH₃ Br 2982 Cl Cl Cl OCH₃ F 2983 Cl Cl Cl Cl H2984 Cl Cl Cl Cl CH₃ 2985 Cl Cl Cl Cl OCH₃ 2986 Cl Cl Cl Cl Cl 2987 ClCl Cl Cl Br 2988 Cl Cl Cl Cl F 2989 Cl Cl Cl Br H 2990 Cl Cl Cl Br CH₃2991 Cl Cl Cl Br OCH₃ 2992 Cl Cl Cl Br Br 2993 Cl Cl Cl F H 2994 Cl ClCl F CH₃ 2995 Cl Cl Cl F OCH₃ 2996 Cl Cl Cl F Br 2997 Cl Cl Cl F F 2998Cl Cl Br H H 2999 Cl Cl Br H CH₃ 3000 Cl Cl Br H OCH₃ 3001 Cl Cl Br H Cl3002 Cl Cl Br H Br 3003 Cl Cl Br H F 3004 Cl Cl Br CH₃ H 3005 Cl Cl BrCH₃ CH₃ 3006 Cl Cl Br CH₃ OCH₃ 3007 Cl Cl Br CH₃ Cl 3008 Cl Cl Br CH₃ F3009 Cl Cl Br OCH₃ H 3010 Cl Cl Br OCH₃ CH₃ 3011 Cl Cl Br OCH₃ OCH₃ 3012Cl Cl Br OCH₃ Cl 3013 Cl Cl Br OCH₃ F 3014 Cl Cl Br Cl H 3015 Cl Cl BrCl CH₃ 3016 Cl Cl Br Cl OCH₃ 3017 Cl Cl Br Cl Cl 3018 Cl Cl Br Cl F 3019Cl Cl Br Br H 3020 Cl Cl Br Br CH₃ 3021 Cl Cl Br Br OCH₃ 3022 Cl Cl BrBr Cl 3023 Cl Cl Br Br Br 3024 Cl Cl Br Br F 3025 Cl Cl Br F H 3026 ClCl Br F CH₃ 3027 Cl Cl Br F OCH₃ 3028 Cl Cl Br F Cl 3029 Cl Cl Br F F3030 Cl Cl F H H 3031 Cl Cl F H CH₃ 3032 Cl Cl F H OCH₃ 3033 Cl Cl F HCl 3034 Cl Cl F H Br 3035 Cl Cl F H F 3036 Cl Cl F CH₃ H 3037 Cl Cl FCH₃ CH₃ 3038 Cl Cl F CH₃ OCH₃ 3039 Cl Cl F CH₃ Cl 3040 Cl Cl F CH₃ Br3041 Cl Cl F OCH₃ H 3042 Cl Cl F OCH₃ CH₃ 3043 Cl Cl F OCH₃ OCH₃ 3044 ClCl F OCH₃ Cl 3045 Cl Cl F OCH₃ Br 3046 Cl Cl F Cl H 3047 Cl Cl F Cl CH₃3048 Cl Cl F Cl OCH₃ 3049 Cl Cl F Cl Cl 3050 Cl Cl F Cl Br 3051 Cl Cl FBr H 3052 Cl Cl F Br CH₃ 3053 Cl Cl F Br OCH₃ 3054 Cl Cl F Br Cl 3055 ClCl F Br Br 3056 Cl Cl F F H 3057 Cl Cl F F CH₃ 3058 Cl Cl F F OCH₃ 3059Cl Cl F F Cl 3060 Cl Cl F F Br 3061 Cl Cl F F F 3062 Cl Br CH₃ H H 3063Cl Br CH₃ H CH₃ 3064 Cl Br CH₃ H OCH₃ 3065 Cl Br CH₃ H Cl 3066 Cl Br CH₃H Br 3067 Cl Br CH₃ H F 3068 Cl Br CH₃ CH₃ H 3069 Cl Br CH₃ CH₃ CH₃ 3070Cl Br CH₃ CH₃ OCH₃ 3071 Cl Br CH₃ CH₃ Cl 3072 Cl Br CH₃ CH₃ Br 3073 ClBr CH₃ CH₃ F 3074 Cl Br CH₃ OCH₃ H 3075 Cl Br CH₃ OCH₃ OCH₃ 3076 Cl BrCH₃ OCH₃ Cl 3077 Cl Br CH₃ OCH₃ Br 3078 Cl Br CH₃ OCH₃ F 3079 Cl Br CH₃Cl H 3080 Cl Br CH₃ Cl OCH₃ 3081 Cl Br CH₃ Cl Cl 3082 Cl Br CH₃ Cl Br3083 Cl Br CH₃ Cl F 3084 Cl Br CH₃ Br H 3085 Cl Br CH₃ Br OCH₃ 3086 ClBr CH₃ Br Cl 3087 Cl Br CH₃ Br Br 3088 Cl Br CH₃ Br F 3089 Cl Br CH₃ F H3090 Cl Br CH₃ F OCH₃ 3091 Cl Br CH₃ F Cl 3092 Cl Br CH₃ F Br 3093 Cl BrCH₃ F F 3094 Cl Br OCH₃ H H 3095 Cl Br OCH₃ H CH₃ 3096 Cl Br OCH₃ H OCH₃3097 Cl Br OCH₃ H Cl 3098 Cl Br OCH₃ H Br 3099 Cl Br OCH₃ H F 3100 Cl BrOCH₃ CH₃ H 3101 Cl Br OCH₃ CH₃ CH₃ 3102 Cl Br OCH₃ CH₃ Cl 3103 Cl BrOCH₃ CH₃ Br 3104 Cl Br OCH₃ CH₃ F 3105 Cl Br OCH₃ OCH₃ H 3106 Cl Br OCH₃OCH₃ CH₃ 3107 Cl Br OCH₃ OCH₃ OCH₃ 3108 Cl Br OCH₃ OCH₃ Cl 3109 Cl BrOCH₃ OCH₃ Br 3110 Cl Br OCH₃ OCH₃ F 3111 Cl Br OCH₃ Cl H 3112 Cl Br OCH₃Cl CH₃ 3113 Cl Br OCH₃ Cl Cl 3114 Cl Br OCH₃ Cl Br 3115 Cl Br OCH₃ Cl F3116 Cl Br OCH₃ Br H 3117 Cl Br OCH₃ Br CH₃ 3118 Cl Br OCH₃ Br Cl 3119Cl Br OCH₃ Br Br 3120 Cl Br OCH₃ Br F 3121 Cl Br OCH₃ F H 3122 Cl BrOCH₃ F CH₃ 3123 Cl Br OCH₃ F Cl 3124 Cl Br OCH₃ F Br 3125 Cl Br OCH₃ F F3126 Cl Br Cl H H 3127 Cl Br Cl H CH₃ 3128 Cl Br Cl H OCH₃ 3129 Cl Br ClH Cl 3130 Cl Br Cl H Br 3131 Cl Br Cl H F 3132 Cl Br Cl CH₃ H 3133 Cl BrCl CH₃ CH₃ 3134 Cl Br Cl CH₃ OCH₃ 3135 Cl Br Cl CH₃ Br 3136 Cl Br Cl CH₃F 3137 Cl Br Cl OCH₃ H 3138 Cl Br Cl OCH₃ CH₃ 3139 Cl Br Cl OCH₃ OCH₃3140 Cl Br Cl OCH₃ Br 3141 Cl Br Cl OCH₃ F 3142 Cl Br Cl Cl H 3143 Cl BrCl Cl CH₃ 3144 Cl Br Cl Cl OCH₃ 3145 Cl Br Cl Cl Cl 3146 Cl Br Cl Cl Br3147 Cl Br Cl Cl F 3148 Cl Br Cl Br H 3149 Cl Br Cl Br CH₃ 3150 Cl Br ClBr OCH₃ 3151 Cl Br Cl Br Br 3152 Cl Br Cl F H 3153 Cl Br Cl F CH₃ 3154Cl Br Cl F OCH₃ 3155 Cl Br Cl F Br 3156 Cl Br Cl F F 3157 Cl Br Br H H3158 Cl Br Br H CH₃ 3159 Cl Br Br H OCH₃ 3160 Cl Br Br H Cl 3161 Cl BrBr H Br 3162 Cl Br Br H F 3163 Cl Br Br CH₃ H 3164 Cl Br Br CH₃ CH₃ 3165Cl Br Br CH₃ OCH₃ 3166 Cl Br Br CH₃ Cl 3167 Cl Br Br CH₃ F 3168 Cl Br BrOCH₃ H 3169 Cl Br Br OCH₃ CH₃ 3170 Cl Br Br OCH₃ OCH₃ 3171 Cl Br Br OCH₃Cl 3172 Cl Br Br OCH₃ F 3173 Cl Br Br Cl H 3174 Cl Br Br Cl CH₃ 3175 ClBr Br Cl OCH₃ 3176 Cl Br Br Cl Cl 3177 Cl Br Br Cl F 3178 Cl Br Br Br H3179 Cl Br Br Br CH₃ 3180 Cl Br Br Br OCH₃ 3181 Cl Br Br Br Cl 3182 ClBr Br Br Br 3183 Cl Br Br Br F 3184 Cl Br Br F H 3185 Cl Br Br F CH₃3186 Cl Br Br F OCH₃ 3187 Cl Br Br F Cl 3188 Cl Br Br F F 3189 Cl Br F HH 3190 Cl Br F H CH₃ 3191 Cl Br F H OCH₃ 3192 Cl Br F H Cl 3193 Cl Br FH Br 3194 Cl Br F H F 3195 Cl Br F CH₃ H 3196 Cl Br F CH₃ CH₃ 3197 Cl BrF CH₃ OCH₃ 3198 Cl Br F CH₃ Cl 3199 Cl Br F CH₃ Br 3200 Cl Br F OCH₃ H3201 Cl Br F OCH₃ CH₃ 3202 Cl Br F OCH₃ OCH₃ 3203 Cl Br F OCH₃ Cl 3204Cl Br F OCH₃ Br 3205 Cl Br F Cl H 3206 Cl Br F Cl CH₃ 3207 Cl Br F ClOCH₃ 3208 Cl Br F Cl Cl 3209 Cl Br F Cl Br 3210 Cl Br F Br H 3211 Cl BrF Br CH₃ 3212 Cl Br F Br OCH₃ 3213 Cl Br F Br Cl 3214 Cl Br F Br Br 3215Cl Br F F H 3216 Cl Br F F CH₃ 3217 Cl Br F F OCH₃ 3218 Cl Br F F Cl3219 Cl Br F F Br 3220 Cl Br F F F 3221 Cl F CH₃ H H 3222 Cl F CH₃ H CH₃3223 Cl F CH₃ H OCH₃ 3224 Cl F CH₃ H Cl 3225 Cl F CH₃ H Br 3226 Cl F CH₃H F 3227 Cl F CH₃ CH₃ H 3228 Cl F CH₃ CH₃ CH₃ 3229 Cl F CH₃ CH₃ OCH₃3230 Cl F CH₃ CH₃ Cl 3231 Cl F CH₃ CH₃ Br 3232 Cl F CH₃ CH₃ F 3233 Cl FCH₃ OCH₃ H 3234 Cl F CH₃ OCH₃ OCH₃ 3235 Cl F CH₃ OCH₃ Cl 3236 Cl F CH₃OCH₃ Br 3237 Cl F CH₃ OCH₃ F 3238 Cl F CH₃ Cl H 3239 Cl F CH₃ Cl OCH₃3240 Cl F CH₃ Cl Cl 3241 Cl F CH₃ Cl Br 3242 Cl F CH₃ Cl F 3243 Cl F CH₃Br H 3244 Cl F CH₃ Br OCH₃ 3245 Cl F CH₃ Br Cl 3246 Cl F CH₃ Br Br 3247Cl F CH₃ Br F 3248 Cl F CH₃ F H 3249 Cl F CH₃ F OCH₃ 3250 Cl F CH₃ F Cl3251 Cl F CH₃ F Br 3252 Cl F CH₃ F F 3253 Cl F OCH₃ H H 3254 Cl F OCH₃ HCH₃ 3255 Cl F OCH₃ H OCH₃ 3256 Cl F OCH₃ H Cl 3257 Cl F OCH₃ H Br 3258Cl F OCH₃ H F 3259 Cl F OCH₃ CH₃ H 3260 Cl F OCH₃ CH₃ CH₃ 3261 Cl F OCH₃CH₃ Cl 3262 Cl F OCH₃ CH₃ Br 3263 Cl F OCH₃ CH₃ F 3264 Cl F OCH₃ OCH₃ H3265 Cl F OCH₃ OCH₃ CH₃ 3266 Cl F OCH₃ OCH₃ OCH₃ 3267 Cl F OCH₃ OCH₃ Cl3268 Cl F OCH₃ OCH₃ Br 3269 Cl F OCH₃ OCH₃ F 3270 Cl F OCH₃ Cl H 3271 ClF OCH₃ Cl CH₃ 3272 Cl F OCH₃ Cl Cl 3273 Cl F OCH₃ Cl Br 3274 Cl F OCH₃Cl F 3275 Cl F OCH₃ Br H 3276 Cl F OCH₃ Br CH₃ 3277 Cl F OCH₃ Br Cl 3278Cl F OCH₃ Br Br 3279 Cl F OCH₃ Br F 3280 Cl F OCH₃ F H 3281 Cl F OCH₃ FCH₃ 3282 Cl F OCH₃ F Cl 3283 Cl F OCH₃ F Br 3284 Cl F OCH₃ F F 3285 Cl FCl H H 3286 Cl F Cl H CH₃ 3287 Cl F Cl H OCH₃ 3288 Cl F Cl H Cl 3289 ClF Cl H Br 3290 Cl F Cl H F 3291 Cl F Cl CH₃ H 3292 Cl F Cl CH₃ CH₃ 3293Cl F Cl CH₃ OCH₃ 3294 Cl F Cl CH₃ Br 3295 Cl F Cl CH₃ F 3296 Cl F ClOCH₃ H 3297 Cl F Cl OCH₃ CH₃ 3298 Cl F Cl OCH₃ OCH₃ 3299 Cl F Cl OCH₃ Br3300 Cl F Cl OCH₃ F 3301 Cl F Cl Cl H 3302 Cl F Cl Cl CH₃ 3303 Cl F ClCl OCH₃ 3304 Cl F Cl Cl Cl 3305 Cl F Cl Cl Br 3306 Cl F Cl Cl F 3307 ClF Cl Br H 3308 Cl F Cl Br CH₃ 3309 Cl F Cl Br OCH₃ 3310 Cl F Cl Br Br3311 Cl F Cl F H 3312 Cl F Cl F CH₃ 3313 Cl F Cl F OCH₃ 3314 Cl F Cl FBr 3315 Cl F Cl F F 3316 Cl F Br H H 3317 Cl F Br H CH₃ 3318 Cl F Br HOCH₃ 3319 Cl F Br H Cl 3320 Cl F Br H Br 3321 Cl F Br H F 3322 Cl F BrCH₃ H 3323 Cl F Br CH₃ CH₃ 3324 Cl F Br CH₃ OCH₃ 3325 Cl F Br CH₃ Cl3326 Cl F Br CH₃ F 3327 Cl F Br OCH₃ H 3328 Cl F Br OCH₃ CH₃ 3329 Cl FBr OCH₃ OCH₃ 3330 Cl F Br OCH₃ Cl 3331 Cl F Br OCH₃ F 3332 Cl F Br Cl H3333 Cl F Br Cl CH₃ 3334 Cl F Br Cl OCH₃ 3335 Cl F Br Cl Cl 3336 Cl F BrCl F 3337 Cl F Br Br H 3338 Cl F Br Br CH₃ 3339 Cl F Br Br OCH₃ 3340 ClF Br Br Cl 3341 Cl F Br Br Br 3342 Cl F Br Br F 3343 Cl F Br F H 3344 ClF Br F CH₃ 3345 Cl F Br F OCH₃ 3346 Cl F Br F Cl 3347 Cl F Br F F 3348Cl F F H H 3349 Cl F F H CH₃ 3350 Cl F F H OCH₃ 3351 Cl F F H Cl 3352 ClF F H Br 3353 Cl F F H F 3354 Cl F F CH₃ H 3355 Cl F F CH₃ CH₃ 3356 Cl FF CH₃ OCH₃ 3357 Cl F F CH₃ Cl 3358 Cl F F CH₃ Br 3359 Cl F F OCH₃ H 3360Cl F F OCH₃ CH₃ 3361 Cl F F OCH₃ OCH₃ 3362 Cl F F OCH₃ Cl 3363 Cl F FOCH₃ Br 3364 Cl F F Cl H 3365 Cl F F Cl CH₃ 3366 Cl F F Cl OCH₃ 3367 ClF F Cl Cl 3368 Cl F F Cl Br 3369 Cl F F Br H 3370 Cl F F Br CH₃ 3371 ClF F Br OCH₃ 3372 Cl F F Br Cl 3373 Cl F F Br Br 3374 Cl F F F H 3375 ClF F F CH₃ 3376 Cl F F F OCH₃ 3377 Cl F F F Cl 3378 Cl F F F Br 3379 Cl FF F F 3380 Br CH₃ CH₃ H H 3381 Br CH₃ CH₃ CH₃ H 3382 Br CH₃ CH₃ OCH₃ H3383 Br CH₃ CH₃ Cl H 3384 Br CH₃ CH₃ Br H 3385 Br CH₃ CH₃ F H 3386 BrCH₃ CH₃ H CH₃ 3387 Br CH₃ CH₃ CH₃ CH₃ 3388 Br CH₃ CH₃ H OCH₃ 3389 Br CH₃CH₃ CH₃ OCH₃ 3390 Br CH₃ CH₃ OCH₃ OCH₃ 3391 Br CH₃ CH₃ Cl OCH₃ 3392 BrCH₃ CH₃ Br OCH₃ 3393 Br CH₃ CH₃ F OCH₃ 3394 Br CH₃ CH₃ H Cl 3395 Br CH₃CH₃ CH₃ Cl 3396 Br CH₃ CH₃ OCH₃ Cl 3397 Br CH₃ CH₃ Cl Cl 3398 Br CH₃ CH₃Br Cl 3399 Br CH₃ CH₃ F Cl 3400 Br CH₃ CH₃ H Br 3401 Br CH₃ CH₃ CH₃ Br3402 Br CH₃ CH₃ OCH₃ Br 3403 Br CH₃ CH₃ Cl Br 3404 Br CH₃ CH₃ Br Br 3405Br CH₃ CH₃ F Br 3406 Br CH₃ CH₃ H F 3407 Br CH₃ CH₃ CH₃ F 3408 Br CH₃CH₃ OCH₃ F 3409 Br CH₃ CH₃ Cl F 3410 Br CH₃ CH₃ Br F 3411 Br CH₃ CH₃ F F3412 Br CH₃ OCH₃ H H 3413 Br CH₃ OCH₃ CH₃ H 3414 Br CH₃ OCH₃ OCH₃ H 3415Br CH₃ OCH₃ Cl H 3416 Br CH₃ OCH₃ Br H 3417 Br CH₃ OCH₃ F H 3418 Br CH₃OCH₃ H CH₃ 3419 Br CH₃ OCH₃ CH₃ CH₃ 3420 Br CH₃ OCH₃ OCH₃ CH₃ 3421 BrCH₃ OCH₃ Cl CH₃ 3422 Br CH₃ OCH₃ Br CH₃ 3423 Br CH₃ OCH₃ F CH₃ 3424 BrCH₃ OCH₃ H OCH₃ 3425 Br CH₃ OCH₃ OCH₃ OCH₃ 3426 Br CH₃ OCH₃ H Cl 3427 BrCH₃ OCH₃ CH₃ Cl 3428 Br CH₃ OCH₃ OCH₃ Cl 3429 Br CH₃ OCH₃ Cl Cl 3430 BrCH₃ OCH₃ Br Cl 3431 Br CH₃ OCH₃ F Cl 3432 Br CH₃ OCH₃ H Br 3433 Br CH₃OCH₃ CH₃ Br 3434 Br CH₃ OCH₃ OCH₃ Br 3435 Br CH₃ OCH₃ Cl Br 3436 Br CH₃OCH₃ Br Br 3437 Br CH₃ OCH₃ F Br 3438 Br CH₃ OCH₃ H F 3439 Br CH₃ OCH₃CH₃ F 3440 Br CH₃ OCH₃ OCH₃ F 3441 Br CH₃ OCH₃ Cl F 3442 Br CH₃ OCH₃ BrF 3443 Br CH₃ OCH₃ F F 3444 Br CH₃ Cl H H 3445 Br CH₃ Cl CH₃ H 3446 BrCH₃ Cl OCH₃ H 3447 Br CH₃ Cl Cl H 3448 Br CH₃ Cl Br H 3449 Br CH₃ Cl F H3450 Br CH₃ Cl H CH₃ 3451 Br CH₃ Cl CH₃ CH₃ 3452 Br CH₃ Cl OCH₃ CH₃ 3453Br CH₃ Cl Cl CH₃ 3454 Br CH₃ Cl Br CH₃ 3455 Br CH₃ Cl F CH₃ 3456 Br CH₃Cl H OCH₃ 3457 Br CH₃ Cl CH₃ OCH₃ 3458 Br CH₃ Cl OCH₃ OCH₃ 3459 Br CH₃Cl Cl OCH₃ 3460 Br CH₃ Cl Br OCH₃ 3461 Br CH₃ Cl F OCH₃ 3462 Br CH₃ Cl HCl 3463 Br CH₃ Cl Cl Cl 3464 Br CH₃ Cl H Br 3465 Br CH₃ Cl CH₃ Br 3466Br CH₃ Cl OCH₃ Br 3467 Br CH₃ Cl Cl Br 3468 Br CH₃ Cl Br Br 3469 Br CH₃Cl F Br 3470 Br CH₃ Cl H F 3471 Br CH₃ Cl CH₃ F 3472 Br CH₃ Cl OCH₃ F3473 Br CH₃ Cl Cl F 3474 Br CH₃ Cl F F 3475 Br CH₃ Br H H 3476 Br CH₃ BrCH₃ H 3477 Br CH₃ Br OCH₃ H 3478 Br CH₃ Br Cl H 3479 Br CH₃ Br Br H 3480Br CH₃ Br F H 3481 Br CH₃ Br H CH₃ 3482 Br CH₃ Br CH₃ CH₃ 3483 Br CH₃ BrOCH₃ CH₃ 3484 Br CH₃ Br Cl CH₃ 3485 Br CH₃ Br Br CH₃ 3486 Br CH₃ Br FCH₃ 3487 Br CH₃ Br H OCH₃ 3488 Br CH₃ Br CH₃ OCH₃ 3489 Br CH₃ Br OCH₃OCH₃ 3490 Br CH₃ Br Cl OCH₃ 3491 Br CH₃ Br Br OCH₃ 3492 Br CH₃ Br F OCH₃3493 Br CH₃ Br H Cl 3494 Br CH₃ Br CH₃ Cl 3495 Br CH₃ Br OCH₃ Cl 3496 BrCH₃ Br Cl Cl 3497 Br CH₃ Br Br Cl 3498 Br CH₃ Br F Cl 3499 Br CH₃ Br HBr 3500 Br CH₃ Br Br Br 3501 Br CH₃ Br H F 3502 Br CH₃ Br CH₃ F 3503 BrCH₃ Br OCH₃ F 3504 Br CH₃ Br Cl F 3505 Br CH₃ Br Br F 3506 Br CH₃ Br F F3507 Br CH₃ F H H 3508 Br CH₃ F CH₃ H 3509 Br CH₃ F OCH₃ H 3510 Br CH₃ FCl H 3511 Br CH₃ F Br H 3512 Br CH₃ F F H 3513 Br CH₃ F H CH₃ 3514 BrCH₃ F CH₃ CH₃ 3515 Br CH₃ F OCH₃ CH₃ 3516 Br CH₃ F Cl CH₃ 3517 Br CH₃ FBr CH₃ 3518 Br CH₃ F F CH₃ 3519 Br CH₃ F H OCH₃ 3520 Br CH₃ F CH₃ OCH₃3521 Br CH₃ F OCH₃ OCH₃ 3522 Br CH₃ F Cl OCH₃ 3523 Br CH₃ F Br OCH₃ 3524Br CH₃ F F OCH₃ 3525 Br CH₃ F H Cl 3526 Br CH₃ F CH₃ Cl 3527 Br CH₃ FOCH₃ Cl 3528 Br CH₃ F Cl Cl 3529 Br CH₃ F Br Cl 3530 Br CH₃ F F Cl 3531Br CH₃ F H Br 3532 Br CH₃ F CH₃ Br 3533 Br CH₃ F OCH₃ Br 3534 Br CH₃ FCl Br 3535 Br CH₃ F Br Br 3536 Br CH₃ F F Br 3537 Br CH₃ F H F 3538 BrCH₃ F F F 3539 Br OCH₃ CH₃ H H 3540 Br OCH₃ CH₃ H CH₃ 3541 Br OCH₃ CH₃ HOCH₃ 3542 Br OCH₃ CH₃ H Cl 3543 Br OCH₃ CH₃ H Br 3544 Br OCH₃ CH₃ H F3545 Br OCH₃ CH₃ CH₃ H 3546 Br OCH₃ CH₃ CH₃ CH₃ 3547 Br OCH₃ CH₃ CH₃OCH₃ 3548 Br OCH₃ CH₃ CH₃ Cl 3549 Br OCH₃ CH₃ CH₃ Br 3550 Br OCH₃ CH₃CH₃ F 3551 Br OCH₃ CH₃ OCH₃ H 3552 Br OCH₃ CH₃ OCH₃ OCH₃ 3553 Br OCH₃CH₃ OCH₃ Cl 3554 Br OCH₃ CH₃ OCH₃ Br 3555 Br OCH₃ CH₃ OCH₃ F 3556 BrOCH₃ CH₃ Cl H 3557 Br OCH₃ CH₃ Cl OCH₃ 3558 Br OCH₃ CH₃ Cl Cl 3559 BrOCH₃ CH₃ Cl Br 3560 Br OCH₃ CH₃ Cl F 3561 Br OCH₃ CH₃ Br H 3562 Br OCH₃CH₃ Br OCH₃ 3563 Br OCH₃ CH₃ Br Cl 3564 Br OCH₃ CH₃ Br Br 3565 Br OCH₃CH₃ Br F 3566 Br OCH₃ CH₃ F H 3567 Br OCH₃ CH₃ F OCH₃ 3568 Br OCH₃ CH₃ FCl 3569 Br OCH₃ CH₃ F Br 3570 Br OCH₃ CH₃ F F 3571 Br OCH₃ OCH₃ H H 3572Br OCH₃ OCH₃ H CH₃ 3573 Br OCH₃ OCH₃ H OCH₃ 3574 Br OCH₃ OCH₃ H Cl 3575Br OCH₃ OCH₃ H Br 3576 Br OCH₃ OCH₃ H F 3577 Br OCH₃ OCH₃ CH₃ H 3578 BrOCH₃ OCH₃ CH₃ CH₃ 3579 Br OCH₃ OCH₃ CH₃ Cl 3580 Br OCH₃ OCH₃ CH₃ Br 3581Br OCH₃ OCH₃ CH₃ F 3582 Br OCH₃ OCH₃ OCH₃ H 3583 Br OCH₃ OCH₃ OCH₃ CH₃3584 Br OCH₃ OCH₃ OCH₃ OCH₃ 3585 Br OCH₃ OCH₃ OCH₃ Cl 3586 Br OCH₃ OCH₃OCH₃ Br 3587 Br OCH₃ OCH₃ OCH₃ F 3588 Br OCH₃ OCH₃ Cl H 3589 Br OCH₃OCH₃ Cl CH₃ 3590 Br OCH₃ OCH₃ Cl Cl 3591 Br OCH₃ OCH₃ Cl Br 3592 Br OCH₃OCH₃ Cl F 3593 Br OCH₃ OCH₃ Br H 3594 Br OCH₃ OCH₃ Br CH₃ 3595 Br OCH₃OCH₃ Br Cl 3596 Br OCH₃ OCH₃ Br Br 3597 Br OCH₃ OCH₃ Br F 3598 Br OCH₃OCH₃ F H 3599 Br OCH₃ OCH₃ F CH₃ 3600 Br OCH₃ OCH₃ F Cl 3601 Br OCH₃OCH₃ F Br 3602 Br OCH₃ OCH₃ F F 3603 Br OCH₃ Cl H H 3604 Br OCH₃ Cl HCH₃ 3605 Br OCH₃ Cl H OCH₃ 3606 Br OCH₃ Cl H Cl 3607 Br OCH₃ Cl H Br3608 Br OCH₃ Cl H F 3609 Br OCH₃ Cl CH₃ H 3610 Br OCH₃ Cl CH₃ CH₃ 3611Br OCH₃ Cl CH₃ OCH₃ 3612 Br OCH₃ Cl CH₃ Br 3613 Br OCH₃ Cl CH₃ F 3614 BrOCH₃ Cl OCH₃ H 3615 Br OCH₃ Cl OCH₃ CH₃ 3616 Br OCH₃ Cl OCH₃ OCH₃ 3617Br OCH₃ Cl OCH₃ Br 3618 Br OCH₃ Cl OCH₃ F 3619 Br OCH₃ Cl Cl H 3620 BrOCH₃ Cl Cl CH₃ 3621 Br OCH₃ Cl Cl OCH₃ 3622 Br OCH₃ Cl Cl Cl 3623 BrOCH₃ Cl Cl Br 3624 Br OCH₃ Cl Cl F 3625 Br OCH₃ Cl Br H 3626 Br OCH₃ ClBr CH₃ 3627 Br OCH₃ Cl Br OCH₃ 3628 Br OCH₃ Cl Br Br 3629 Br OCH₃ Cl F H3630 Br OCH₃ Cl F CH₃ 3631 Br OCH₃ Cl F OCH₃ 3632 Br OCH₃ Cl F Br 3633Br OCH₃ Cl F F 3634 Br OCH₃ Br H H 3635 Br OCH₃ Br H CH₃ 3636 Br OCH₃ BrH OCH₃ 3637 Br OCH₃ Br H Cl 3638 Br OCH₃ Br H Br 3639 Br OCH₃ Br H F3640 Br OCH₃ Br CH₃ H 3641 Br OCH₃ Br CH₃ CH₃ 3642 Br OCH₃ Br CH₃ OCH₃3643 Br OCH₃ Br CH₃ Cl 3644 Br OCH₃ Br CH₃ F 3645 Br OCH₃ Br OCH₃ H 3646Br OCH₃ Br OCH₃ CH₃ 3647 Br OCH₃ Br OCH₃ OCH₃ 3648 Br OCH₃ Br OCH₃ Cl3649 Br OCH₃ Br OCH₃ F 3650 Br OCH₃ Br Cl H 3651 Br OCH₃ Br Cl CH₃ 3652Br OCH₃ Br Cl OCH₃ 3653 Br OCH₃ Br Cl Cl 3654 Br OCH₃ Br Cl F 3655 BrOCH₃ Br Br H 3656 Br OCH₃ Br Br CH₃ 3657 Br OCH₃ Br Br OCH₃ 3658 Br OCH₃Br Br Cl 3659 Br OCH₃ Br Br Br 3660 Br OCH₃ Br Br F 3661 Br OCH₃ Br F H3662 Br OCH₃ Br F CH₃ 3663 Br OCH₃ Br F OCH₃ 3664 Br OCH₃ Br F Cl 3665Br OCH₃ Br F F 3666 Br OCH₃ F H H 3667 Br OCH₃ F H CH₃ 3668 Br OCH₃ F HOCH₃ 3669 Br OCH₃ F H Cl 3670 Br OCH₃ F H Br 3671 Br OCH₃ F H F 3672 BrOCH₃ F CH₃ H 3673 Br OCH₃ F CH₃ CH₃ 3674 Br OCH₃ F CH₃ OCH₃ 3675 Br OCH₃F CH₃ Cl 3676 Br OCH₃ F CH₃ Br 3677 Br OCH₃ F OCH₃ H 3678 Br OCH₃ F OCH₃CH₃ 3679 Br OCH₃ F OCH₃ OCH₃ 3680 Br OCH₃ F OCH₃ Cl 3681 Br OCH₃ F OCH₃Br 3682 Br OCH₃ F Cl H 3683 Br OCH₃ F Cl CH₃ 3684 Br OCH₃ F Cl OCH₃ 3685Br OCH₃ F Cl Cl 3686 Br OCH₃ F Cl Br 3687 Br OCH₃ F Br H 3688 Br OCH₃ FBr CH₃ 3689 Br OCH₃ F Br OCH₃ 3690 Br OCH₃ F Br Cl 3691 Br OCH₃ F Br Br3692 Br OCH₃ F F H 3693 Br OCH₃ F F CH₃ 3694 Br OCH₃ F F OCH₃ 3695 BrOCH₃ F F Cl 3696 Br OCH₃ F F Br 3697 Br OCH₃ F F F 3698 Br Cl CH₃ H H3699 Br Cl CH₃ H CH₃ 3700 Br Cl CH₃ H OCH₃ 3701 Br Cl CH₃ H Cl 3702 BrCl CH₃ H Br 3703 Br Cl CH₃ H F 3704 Br Cl CH₃ CH₃ H 3705 Br Cl CH₃ CH₃CH₃ 3706 Br Cl CH₃ CH₃ OCH₃ 3707 Br Cl CH₃ CH₃ Cl 3708 Br Cl CH₃ CH₃ Br3709 Br Cl CH₃ CH₃ F 3710 Br Cl CH₃ OCH₃ H 3711 Br Cl CH₃ OCH₃ OCH₃ 3712Br Cl CH₃ OCH₃ Cl 3713 Br Cl CH₃ OCH₃ Br 3714 Br Cl CH₃ OCH₃ F 3715 BrCl CH₃ Cl H 3716 Br Cl CH₃ Cl OCH₃ 3717 Br Cl CH₃ Cl Cl 3718 Br Cl CH₃Cl Br 3719 Br Cl CH₃ Cl F 3720 Br Cl CH₃ Br H 3721 Br Cl CH₃ Br OCH₃3722 Br Cl CH₃ Br Cl 3723 Br Cl CH₃ Br Br 3724 Br Cl CH₃ Br F 3725 Br ClCH₃ F H 3726 Br Cl CH₃ F OCH₃ 3727 Br Cl CH₃ F Cl 3728 Br Cl CH₃ F Br3729 Br Cl CH₃ F F 3730 Br Cl OCH₃ H H 3731 Br Cl OCH₃ H CH₃ 3732 Br ClOCH₃ H OCH₃ 3733 Br Cl OCH₃ H Cl 3734 Br Cl OCH₃ H Br 3735 Br Cl OCH₃ HF 3736 Br Cl OCH₃ CH₃ H 3737 Br Cl OCH₃ CH₃ CH₃ 3738 Br Cl OCH₃ CH₃ Cl3739 Br Cl OCH₃ CH₃ Br 3740 Br Cl OCH₃ CH₃ F 3741 Br Cl OCH₃ OCH₃ H 3742Br Cl OCH₃ OCH₃ CH₃ 3743 Br Cl OCH₃ OCH₃ OCH₃ 3744 Br Cl OCH₃ OCH₃ Cl3745 Br Cl OCH₃ OCH₃ Br 3746 Br Cl OCH₃ OCH₃ F 3747 Br Cl OCH₃ Cl H 3748Br Cl OCH₃ Cl CH₃ 3749 Br Cl OCH₃ Cl Cl 3750 Br Cl OCH₃ Cl Br 3751 Br ClOCH₃ Cl F 3752 Br Cl OCH₃ Br H 3753 Br Cl OCH₃ Br CH₃ 3754 Br Cl OCH₃ BrCl 3755 Br Cl OCH₃ Br Br 3756 Br Cl OCH₃ Br F 3757 Br Cl OCH₃ F H 3758Br Cl OCH₃ F CH₃ 3759 Br Cl OCH₃ F Cl 3760 Br Cl OCH₃ F Br 3761 Br ClOCH₃ F F 3762 Br Cl Cl H H 3763 Br Cl Cl H CH₃ 3764 Br Cl Cl H OCH₃ 3765Br Cl Cl H Cl 3766 Br Cl Cl H Br 3767 Br Cl Cl H F 3768 Br Cl Cl CH₃ H3769 Br Cl Cl CH₃ CH₃ 3770 Br Cl Cl CH₃ OCH₃ 3771 Br Cl Cl CH₃ Br 3772Br Cl Cl CH₃ F 3773 Br Cl Cl OCH₃ H 3774 Br Cl Cl OCH₃ CH₃ 3775 Br Cl ClOCH₃ OCH₃ 3776 Br Cl Cl OCH₃ Br 3777 Br Cl Cl OCH₃ F 3778 Br Cl Cl Cl H3779 Br Cl Cl Cl CH₃ 3780 Br Cl Cl Cl OCH₃ 3781 Br Cl Cl Cl Cl 3782 BrCl Cl Cl Br 3783 Br Cl Cl Cl F 3784 Br Cl Cl Br H 3785 Br Cl Cl Br CH₃3786 Br Cl Cl Br OCH₃ 3787 Br Cl Cl Br Br 3788 Br Cl Cl F H 3789 Br ClCl F CH₃ 3790 Br Cl Cl F OCH₃ 3791 Br Cl Cl F Br 3792 Br Cl Cl F F 3793Br Cl Br H H 3794 Br Cl Br H CH₃ 3795 Br Cl Br H OCH₃ 3796 Br Cl Br H Cl3797 Br Cl Br H Br 3798 Br Cl Br H F 3799 Br Cl Br CH₃ H 3800 Br Cl BrCH₃ CH₃ 3801 Br Cl Br CH₃ OCH₃ 3802 Br Cl Br CH₃ Cl 3803 Br Cl Br CH₃ F3804 Br Cl Br OCH₃ H 3805 Br Cl Br OCH₃ CH₃ 3806 Br Cl Br OCH₃ OCH₃ 3807Br Cl Br OCH₃ Cl 3808 Br Cl Br OCH₃ F 3809 Br Cl Br Cl H 3810 Br Cl BrCl CH₃ 3811 Br Cl Br Cl OCH₃ 3812 Br Cl Br Cl Cl 3813 Br Cl Br Cl F 3814Br Cl Br Br H 3815 Br Cl Br Br CH₃ 3816 Br Cl Br Br OCH₃ 3817 Br Cl BrBr Cl 3818 Br Cl Br Br Br 3819 Br Cl Br Br F 3820 Br Cl Br F H 3821 BrCl Br F CH₃ 3822 Br Cl Br F OCH₃ 3823 Br Cl Br F Cl 3824 Br Cl Br F F3825 Br Cl F H H 3826 Br Cl F H CH₃ 3827 Br Cl F H OCH₃ 3828 Br Cl F HCl 3829 Br Cl F H Br 3830 Br Cl F H F 3831 Br Cl F CH₃ H 3832 Br Cl FCH₃ CH₃ 3833 Br Cl F CH₃ OCH₃ 3834 Br Cl F CH₃ Cl 3835 Br Cl F CH₃ Br3836 Br Cl F OCH₃ H 3837 Br Cl F OCH₃ CH₃ 3838 Br Cl F OCH₃ OCH₃ 3839 BrCl F OCH₃ Cl 3840 Br Cl F OCH₃ Br 3841 Br Cl F Cl H 3842 Br Cl F Cl CH₃3843 Br Cl F Cl OCH₃ 3844 Br Cl F Cl Cl 3845 Br Cl F Cl Br 3846 Br Cl FBr H 3847 Br Cl F Br CH₃ 3848 Br Cl F Br OCH₃ 3849 Br Cl F Br Cl 3850 BrCl F Br Br 3851 Br Cl F F H 3852 Br Cl F F CH₃ 3853 Br Cl F F OCH₃ 3854Br Cl F F Cl 3855 Br Cl F F Br 3856 Br Cl F F F 3857 Br Br CH₃ H H 3858Br Br CH₃ H CH₃ 3859 Br Br CH₃ H OCH₃ 3860 Br Br CH₃ H Cl 3861 Br Br CH₃H Br 3862 Br Br CH₃ H F 3863 Br Br CH₃ CH₃ H 3864 Br Br CH₃ CH₃ CH₃ 3865Br Br CH₃ CH₃ OCH₃ 3866 Br Br CH₃ CH₃ Cl 3867 Br Br CH₃ CH₃ Br 3868 BrBr CH₃ CH₃ F 3869 Br Br CH₃ OCH₃ H 3870 Br Br CH₃ OCH₃ OCH₃ 3871 Br BrCH₃ OCH₃ Cl 3872 Br Br CH₃ OCH₃ Br 3873 Br Br CH₃ OCH₃ F 3874 Br Br CH₃Cl H 3875 Br Br CH₃ Cl OCH₃ 3876 Br Br CH₃ Cl Cl 3877 Br Br CH₃ Cl Br3878 Br Br CH₃ Cl F 3879 Br Br CH₃ Br H 3880 Br Br CH₃ Br OCH₃ 3881 BrBr CH₃ Br Cl 3882 Br Br CH₃ Br Br 3883 Br Br CH₃ Br F 3884 Br Br CH₃ F H3885 Br Br CH₃ F OCH₃ 3886 Br Br CH₃ F Cl 3887 Br Br CH₃ F Br 3888 Br BrCH₃ F F 3889 Br Br OCH₃ H H 3890 Br Br OCH₃ H CH₃ 3891 Br Br OCH₃ H OCH₃3892 Br Br OCH₃ H Cl 3893 Br Br OCH₃ H Br 3894 Br Br OCH₃ H F 3895 Br BrOCH₃ CH₃ H 3896 Br Br OCH₃ CH₃ CH₃ 3897 Br Br OCH₃ CH₃ Cl 3898 Br BrOCH₃ CH₃ Br 3899 Br Br OCH₃ CH₃ F 3900 Br Br OCH₃ OCH₃ H 3901 Br Br OCH₃OCH₃ CH₃ 3902 Br Br OCH₃ OCH₃ OCH₃ 3903 Br Br OCH₃ OCH₃ Cl 3904 Br BrOCH₃ OCH₃ Br 3905 Br Br OCH₃ OCH₃ F 3906 Br Br OCH₃ Cl H 3907 Br Br OCH₃Cl CH₃ 3908 Br Br OCH₃ Cl Cl 3909 Br Br OCH₃ Cl Br 3910 Br Br OCH₃ Cl F3911 Br Br OCH₃ Br H 3912 Br Br OCH₃ Br CH₃ 3913 Br Br OCH₃ Br Cl 3914Br Br OCH₃ Br Br 3915 Br Br OCH₃ Br F 3916 Br Br OCH₃ F H 3917 Br BrOCH₃ F CH₃ 3918 Br Br OCH₃ F Cl 3919 Br Br OCH₃ F Br 3920 Br Br OCH₃ F F3921 Br Br Cl H H 3922 Br Br Cl H CH₃ 3923 Br Br Cl H OCH₃ 3924 Br Br ClH Cl 3925 Br Br Cl H Br 3926 Br Br Cl H F 3927 Br Br Cl CH₃ H 3928 Br BrCl CH₃ CH₃ 3929 Br Br Cl CH₃ OCH₃ 3930 Br Br Cl CH₃ Br 3931 Br Br Cl CH₃F 3932 Br Br Cl OCH₃ H 3933 Br Br Cl OCH₃ CH₃ 3934 Br Br Cl OCH₃ OCH₃3935 Br Br Cl OCH₃ Br 3936 Br Br Cl OCH₃ F 3937 Br Br Cl Cl H 3938 Br BrCl Cl CH₃ 3939 Br Br Cl Cl OCH₃ 3940 Br Br Cl Cl Cl 3941 Br Br Cl Cl Br3942 Br Br Cl Cl F 3943 Br Br Cl Br H 3944 Br Br Cl Br CH₃ 3945 Br Br ClBr OCH₃ 3946 Br Br Cl Br Br 3947 Br Br Cl F H 3948 Br Br Cl F CH₃ 3949Br Br Cl F OCH₃ 3950 Br Br Cl F Br 3951 Br Br Cl F F 3952 Br Br Br H H3953 Br Br Br H CH₃ 3954 Br Br Br H OCH₃ 3955 Br Br Br H Cl 3956 Br BrBr H Br 3957 Br Br Br H F 3958 Br Br Br CH₃ H 3959 Br Br Br CH₃ CH₃ 3960Br Br Br CH₃ OCH₃ 3961 Br Br Br CH₃ Cl 3962 Br Br Br CH₃ F 3963 Br Br BrOCH₃ H 3964 Br Br Br OCH₃ CH₃ 3965 Br Br Br OCH₃ OCH₃ 3966 Br Br Br OCH₃Cl 3967 Br Br Br OCH₃ F 3968 Br Br Br Cl H 3969 Br Br Br Cl CH₃ 3970 BrBr Br Cl OCH₃ 3971 Br Br Br Cl Cl 3972 Br Br Br Cl F 3973 Br Br Br Br H3974 Br Br Br Br CH₃ 3975 Br Br Br Br OCH₃ 3976 Br Br Br Br Cl 3977 BrBr Br Br Br 3978 Br Br Br Br F 3979 Br Br Br F H 3980 Br Br Br F CH₃3981 Br Br Br F OCH₃ 3982 Br Br Br F Cl 3983 Br Br Br F F 3984 Br Br F HH 3985 Br Br F H CH₃ 3986 Br Br F H OCH₃ 3987 Br Br F H Cl 3988 Br Br FH Br 3989 Br Br F H F 3990 Br Br F CH₃ H 3991 Br Br F CH₃ CH₃ 3992 Br BrF CH₃ OCH₃ 3993 Br Br F CH₃ Cl 3994 Br Br F CH₃ Br 3995 Br Br F OCH₃ H3996 Br Br F OCH₃ CH₃ 3997 Br Br F OCH₃ OCH₃ 3998 Br Br F OCH₃ Cl 3999Br Br F OCH₃ Br 4000 Br Br F Cl H 4001 Br Br F Cl CH₃ 4002 Br Br F ClOCH₃ 4003 Br Br F Cl Cl 4004 Br Br F Cl Br 4005 Br Br F Br H 4006 Br BrF Br CH₃ 4007 Br Br F Br OCH₃ 4008 Br Br F Br Cl 4009 Br Br F Br Br 4010Br Br F F H 4011 Br Br F F CH₃ 4012 Br Br F F OCH₃ 4013 Br Br F F Cl4014 Br Br F F Br 4015 Br Br F F F 4016 Br F CH₃ H H 4017 Br F CH₃ H CH₃4018 Br F CH₃ H OCH₃ 4019 Br F CH₃ H Cl 4020 Br F CH₃ H Br 4021 Br F CH₃H F 4022 Br F CH₃ CH₃ H 4023 Br F CH₃ CH₃ CH₃ 4024 Br F CH₃ CH₃ OCH₃4025 Br F CH₃ CH₃ Cl 4026 Br F CH₃ CH₃ Br 4027 Br F CH₃ CH₃ F 4028 Br FCH₃ OCH₃ H 4029 Br F CH₃ OCH₃ OCH₃ 4030 Br F CH₃ OCH₃ Cl 4031 Br F CH₃OCH₃ Br 4032 Br F CH₃ OCH₃ F 4033 Br F CH₃ Cl H 4034 Br F CH₃ Cl OCH₃4035 Br F CH₃ Cl Cl 4036 Br F CH₃ Cl Br 4037 Br F CH₃ Cl F 4038 Br F CH₃Br H 4039 Br F CH₃ Br OCH₃ 4040 Br F CH₃ Br Cl 4041 Br F CH₃ Br Br 4042Br F CH₃ Br F 4043 Br F CH₃ F H 4044 Br F CH₃ F OCH₃ 4045 Br F CH₃ F Cl4046 Br F CH₃ F Br 4047 Br F CH₃ F F 4048 Br F OCH₃ H H 4049 Br F OCH₃ HCH₃ 4050 Br F OCH₃ H OCH₃ 4051 Br F OCH₃ H Cl 4052 Br F OCH₃ H Br 4053Br F OCH₃ H F 4054 Br F OCH₃ CH₃ H 4055 Br F OCH₃ CH₃ CH₃ 4056 Br F OCH₃CH₃ Cl 4057 Br F OCH₃ CH₃ Br 4058 Br F OCH₃ CH₃ F 4059 Br F OCH₃ OCH₃ H4060 Br F OCH₃ OCH₃ CH₃ 4061 Br F OCH₃ OCH₃ OCH₃ 4062 Br F OCH₃ OCH₃ Cl4063 Br F OCH₃ OCH₃ Br 4064 Br F OCH₃ OCH₃ F 4065 Br F OCH₃ Cl H 4066 BrF OCH₃ Cl CH₃ 4067 Br F OCH₃ Cl Cl 4068 Br F OCH₃ Cl Br 4069 Br F OCH₃Cl F 4070 Br F OCH₃ Br H 4071 Br F OCH₃ Br CH₃ 4072 Br F OCH₃ Br Cl 4073Br F OCH₃ Br Br 4074 Br F OCH₃ Br F 4075 Br F OCH₃ F H 4076 Br F OCH₃ FCH₃ 4077 Br F OCH₃ F Cl 4078 Br F OCH₃ F Br 4079 Br F OCH₃ F F 4080 Br FCl H H 4081 Br F Cl H CH₃ 4082 Br F Cl H OCH₃ 4083 Br F Cl H Cl 4084 BrF Cl H Br 4085 Br F Cl H F 4086 Br F Cl CH₃ H 4087 Br F Cl CH₃ CH₃ 4088Br F Cl CH₃ OCH₃ 4089 Br F Cl CH₃ Br 4090 Br F Cl CH₃ F 4091 Br F ClOCH₃ H 4092 Br F Cl OCH₃ CH₃ 4093 Br F Cl OCH₃ OCH₃ 4094 Br F Cl OCH₃ Br4095 Br F Cl OCH₃ F 4096 Br F Cl Cl H 4097 Br F Cl Cl CH₃ 4098 Br F ClCl OCH₃ 4099 Br F Cl Cl Cl 4100 Br F Cl Cl Br 4101 Br F Cl Cl F 4102 BrF Cl Br H 4103 Br F Cl Br CH₃ 4104 Br F Cl Br OCH₃ 4105 Br F Cl Br Br4106 Br F Cl F H 4107 Br F Cl F CH₃ 4108 Br F Cl F OCH₃ 4109 Br F Cl FBr 4110 Br F Cl F F 4111 Br F Br H H 4112 Br F Br H CH₃ 4113 Br F Br HOCH₃ 4114 Br F Br H Cl 4115 Br F Br H Br 4116 Br F Br H F 4117 Br F BrCH₃ H 4118 Br F Br CH₃ CH₃ 4119 Br F Br CH₃ OCH₃ 4120 Br F Br CH₃ Cl4121 Br F Br CH₃ F 4122 Br F Br OCH₃ H 4123 Br F Br OCH₃ CH₃ 4124 Br FBr OCH₃ OCH₃ 4125 Br F Br OCH₃ Cl 4126 Br F Br OCH₃ F 4127 Br F Br Cl H4128 Br F Br Cl CH₃ 4129 Br F Br Cl OCH₃ 4130 Br F Br Cl Cl 4131 Br F BrCl F 4132 Br F Br Br H 4133 Br F Br Br CH₃ 4134 Br F Br Br OCH₃ 4135 BrF Br Br Cl 4136 Br F Br Br Br 4137 Br F Br Br F 4138 Br F Br F H 4139 BrF Br F CH₃ 4140 Br F Br F OCH₃ 4141 Br F Br F Cl 4142 Br F Br F F 4143Br F F H H 4144 Br F F H CH₃ 4145 Br F F H OCH₃ 4146 Br F F H Cl 4147 BrF F H Br 4148 Br F F H F 4149 Br F F CH₃ H 4150 Br F F CH₃ CH₃ 4151 Br FF CH₃ OCH₃ 4152 Br F F CH₃ Cl 4153 Br F F CH₃ Br 4154 Br F F OCH₃ H 4155Br F F OCH₃ CH₃ 4156 Br F F OCH₃ OCH₃ 4157 Br F F OCH₃ Cl 4158 Br F FOCH₃ Br 4159 Br F F Cl H 4160 Br F F Cl CH₃ 4161 Br F F Cl OCH₃ 4162 BrF F Cl Cl 4163 Br F F Cl Br 4164 Br F F Br H 4165 Br F F Br CH₃ 4166 BrF F Br OCH₃ 4167 Br F F Br Cl 4168 Br F F Br Br 4169 Br F F F H 4170 BrF F F CH₃ 4171 Br F F F OCH₃ 4172 Br F F F Cl 4173 Br F F F Br 4174 Br FF F F 4175 F CH₃ CH₃ H H 4176 F CH₃ CH₃ CH₃ H 4177 F CH₃ CH₃ OCH₃ H 4178F CH₃ CH₃ Cl H 4179 F CH₃ CH₃ Br H 4180 F CH₃ CH₃ F H 4181 F CH₃ CH₃ HCH₃ 4182 F CH₃ CH₃ CH₃ CH₃ 4183 F CH₃ CH₃ H OCH₃ 4184 F CH₃ CH₃ CH₃ OCH₃4185 F CH₃ CH₃ OCH₃ OCH₃ 4186 F CH₃ CH₃ Cl OCH₃ 4187 F CH₃ CH₃ Br OCH₃4188 F CH₃ CH₃ F OCH₃ 4189 F CH₃ CH₃ H Cl 4190 F CH₃ CH₃ CH₃ Cl 4191 FCH₃ CH₃ OCH₃ Cl 4192 F CH₃ CH₃ Cl Cl 4193 F CH₃ CH₃ Br Cl 4194 F CH₃ CH₃F Cl 4195 F CH₃ CH₃ H Br 4196 F CH₃ CH₃ CH₃ Br 4197 F CH₃ CH₃ OCH₃ Br4198 F CH₃ CH₃ Cl Br 4199 F CH₃ CH₃ Br Br 4200 F CH₃ CH₃ F Br 4201 F CH₃CH₃ H F 4202 F CH₃ CH₃ CH₃ F 4203 F CH₃ CH₃ OCH₃ F 4204 F CH₃ CH₃ Cl F4205 F CH₃ CH₃ Br F 4206 F CH₃ CH₃ F F 4207 F CH₃ OCH₃ H H 4208 F CH₃OCH₃ CH₃ H 4209 F CH₃ OCH₃ OCH₃ H 4210 F CH₃ OCH₃ Cl H 4211 F CH₃ OCH₃Br H 4212 F CH₃ OCH₃ F H 4213 F CH₃ OCH₃ H CH₃ 4214 F CH₃ OCH₃ CH₃ CH₃4215 F CH₃ OCH₃ OCH₃ CH₃ 4216 F CH₃ OCH₃ Cl CH₃ 4217 F CH₃ OCH₃ Br CH₃4218 F CH₃ OCH₃ F CH₃ 4219 F CH₃ OCH₃ H OCH₃ 4220 F CH₃ OCH₃ OCH₃ OCH₃4221 F CH₃ OCH₃ H Cl 4222 F CH₃ OCH₃ CH₃ Cl 4223 F CH₃ OCH₃ OCH₃ Cl 4224F CH₃ OCH₃ Cl Cl 4225 F CH₃ OCH₃ Br Cl 4226 F CH₃ OCH₃ F Cl 4227 F CH₃OCH₃ H Br 4228 F CH₃ OCH₃ CH₃ Br 4229 F CH₃ OCH₃ OCH₃ Br 4230 F CH₃ OCH₃Cl Br 4231 F CH₃ OCH₃ Br Br 4232 F CH₃ OCH₃ F Br 4233 F CH₃ OCH₃ H F4234 F CH₃ OCH₃ CH₃ F 4235 F CH₃ OCH₃ OCH₃ F 4236 F CH₃ OCH₃ Cl F 4237 FCH₃ OCH₃ Br F 4238 F CH₃ OCH₃ F F 4239 F CH₃ Cl H H 4240 F CH₃ Cl CH₃ H4241 F CH₃ Cl OCH₃ H 4242 F CH₃ Cl Cl H 4243 F CH₃ Cl Br H 4244 F CH₃ ClF H 4245 F CH₃ Cl H CH₃ 4246 F CH₃ Cl CH₃ CH₃ 4247 F CH₃ Cl OCH₃ CH₃4248 F CH₃ Cl Cl CH₃ 4249 F CH₃ Cl Br CH₃ 4250 F CH₃ Cl F CH₃ 4251 F CH₃Cl H OCH₃ 4252 F CH₃ Cl CH₃ OCH₃ 4253 F CH₃ Cl OCH₃ OCH₃ 4254 F CH₃ ClCl OCH₃ 4255 F CH₃ Cl Br OCH₃ 4256 F CH₃ Cl F OCH₃ 4257 F CH₃ Cl H Cl4258 F CH₃ Cl Cl Cl 4259 F CH₃ Cl H Br 4260 F CH₃ Cl CH₃ Br 4261 F CH₃Cl OCH₃ Br 4262 F CH₃ Cl Cl Br 4263 F CH₃ Cl Br Br 4264 F CH₃ Cl F Br4265 F CH₃ Cl H F 4266 F CH₃ Cl CH₃ F 4267 F CH₃ Cl OCH₃ F 4268 F CH₃ ClCl F 4269 F CH₃ Cl F F 4270 F CH₃ Br H H 4271 F CH₃ Br CH₃ H 4272 F CH₃Br OCH₃ H 4273 F CH₃ Br Cl H 4274 F CH₃ Br Br H 4275 F CH₃ Br F H 4276 FCH₃ Br H CH₃ 4277 F CH₃ Br CH₃ CH₃ 4278 F CH₃ Br OCH₃ CH₃ 4279 F CH₃ BrCl CH₃ 4280 F CH₃ Br Br CH₃ 4281 F CH₃ Br F CH₃ 4282 F CH₃ Br H OCH₃4283 F CH₃ Br CH₃ OCH₃ 4284 F CH₃ Br OCH₃ OCH₃ 4285 F CH₃ Br Cl OCH₃4286 F CH₃ Br Br OCH₃ 4287 F CH₃ Br F OCH₃ 4288 F CH₃ Br H Cl 4289 F CH₃Br CH₃ Cl 4290 F CH₃ Br OCH₃ Cl 4291 F CH₃ Br Cl Cl 4292 F CH₃ Br Br Cl4293 F CH₃ Br F Cl 4294 F CH₃ Br H Br 4295 F CH₃ Br Br Br 4296 F CH₃ BrH F 4297 F CH₃ Br CH₃ F 4298 F CH₃ Br OCH₃ F 4299 F CH₃ Br Cl F 4300 FCH₃ Br Br F 4301 F CH₃ Br F F 4302 F CH₃ F H H 4303 F CH₃ F CH₃ H 4304 FCH₃ F OCH₃ H 4305 F CH₃ F Cl H 4306 F CH₃ F Br H 4307 F CH₃ F F H 4308 FCH₃ F H CH₃ 4309 F CH₃ F CH₃ CH₃ 4310 F CH₃ F OCH₃ CH₃ 4311 F CH₃ F ClCH₃ 4312 F CH₃ F Br CH₃ 4313 F CH₃ F F CH₃ 4314 F CH₃ F H OCH₃ 4315 FCH₃ F CH₃ OCH₃ 4316 F CH₃ F OCH₃ OCH₃ 4317 F CH₃ F Cl OCH₃ 4318 F CH₃ FBr OCH₃ 4319 F CH₃ F F OCH₃ 4320 F CH₃ F H Cl 4321 F CH₃ F CH₃ Cl 4322 FCH₃ F OCH₃ Cl 4323 F CH₃ F Cl Cl 4324 F CH₃ F Br Cl 4325 F CH₃ F F Cl4326 F CH₃ F H Br 4327 F CH₃ F CH₃ Br 4328 F CH₃ F OCH₃ Br 4329 F CH₃ FCl Br 4330 F CH₃ F Br Br 4331 F CH₃ F F Br 4332 F CH₃ F H F 4333 F CH₃ FF F 4334 F OCH₃ CH₃ H H 4335 F OCH₃ CH₃ H CH₃ 4336 F OCH₃ CH₃ H OCH₃4337 F OCH₃ CH₃ H Cl 4338 F OCH₃ CH₃ H Br 4339 F OCH₃ CH₃ H F 4340 FOCH₃ CH₃ CH₃ H 4341 F OCH₃ CH₃ CH₃ CH₃ 4342 F OCH₃ CH₃ CH₃ OCH₃ 4343 FOCH₃ CH₃ CH₃ Cl 4344 F OCH₃ CH₃ CH₃ Br 4345 F OCH₃ CH₃ CH₃ F 4346 F OCH₃CH₃ OCH₃ H 4347 F OCH₃ CH₃ OCH₃ OCH₃ 4348 F OCH₃ CH₃ OCH₃ Cl 4349 F OCH₃CH₃ OCH₃ Br 4350 F OCH₃ CH₃ OCH₃ F 4351 F OCH₃ CH₃ Cl H 4352 F OCH₃ CH₃Cl OCH₃ 4353 F OCH₃ CH₃ Cl Cl 4354 F OCH₃ CH₃ Cl Br 4355 F OCH₃ CH₃ Cl F4356 F OCH₃ CH₃ Br H 4357 F OCH₃ CH₃ Br OCH₃ 4358 F OCH₃ CH₃ Br Cl 4359F OCH₃ CH₃ Br Br 4360 F OCH₃ CH₃ Br F 4361 F OCH₃ CH₃ F H 4362 F OCH₃CH₃ F OCH₃ 4363 F OCH₃ CH₃ F Cl 4364 F OCH₃ CH₃ F Br 4365 F OCH₃ CH₃ F F4366 F OCH₃ OCH₃ H H 4367 F OCH₃ OCH₃ H CH₃ 4368 F OCH₃ OCH₃ H OCH₃ 4369F OCH₃ OCH₃ H Cl 4370 F OCH₃ OCH₃ H Br 4371 F OCH₃ OCH₃ H F 4372 F OCH₃OCH₃ CH₃ H 4373 F OCH₃ OCH₃ CH₃ CH₃ 4374 F OCH₃ OCH₃ CH₃ Cl 4375 F OCH₃OCH₃ CH₃ Br 4376 F OCH₃ OCH₃ CH₃ F 4377 F OCH₃ OCH₃ OCH₃ H 4378 F OCH₃OCH₃ OCH₃ CH₃ 4379 F OCH₃ OCH₃ OCH₃ OCH₃ 4380 F OCH₃ OCH₃ OCH₃ Cl 4381 FOCH₃ OCH₃ OCH₃ Br 4382 F OCH₃ OCH₃ OCH₃ F 4383 F OCH₃ OCH₃ Cl H 4384 FOCH₃ OCH₃ Cl CH₃ 4385 F OCH₃ OCH₃ Cl Cl 4386 F OCH₃ OCH₃ Cl Br 4387 FOCH₃ OCH₃ Cl F 4388 F OCH₃ OCH₃ Br H 4389 F OCH₃ OCH₃ Br CH₃ 4390 F OCH₃OCH₃ Br Cl 4391 F OCH₃ OCH₃ Br Br 4392 F OCH₃ OCH₃ Br F 4393 F OCH₃ OCH₃F H 4394 F OCH₃ OCH₃ F CH₃ 4395 F OCH₃ OCH₃ F Cl 4396 F OCH₃ OCH₃ F Br4397 F OCH₃ OCH₃ F F 4398 F OCH₃ Cl H H 4399 F OCH₃ Cl H CH₃ 4400 F OCH₃Cl H OCH₃ 4401 F OCH₃ Cl H Cl 4402 F OCH₃ Cl H Br 4403 F OCH₃ Cl H F4404 F OCH₃ Cl CH₃ H 4405 F OCH₃ Cl CH₃ CH₃ 4406 F OCH₃ Cl CH₃ OCH₃ 4407F OCH₃ Cl CH₃ Br 4408 F OCH₃ Cl CH₃ F 4409 F OCH₃ Cl OCH₃ H 4410 F OCH₃Cl OCH₃ CH₃ 4411 F OCH₃ Cl OCH₃ OCH₃ 4412 F OCH₃ Cl OCH₃ Br 4413 F OCH₃Cl OCH₃ F 4414 F OCH₃ Cl Cl H 4415 F OCH₃ Cl Cl CH₃ 4416 F OCH₃ Cl ClOCH₃ 4417 F OCH₃ Cl Cl Cl 4418 F OCH₃ Cl Cl Br 4419 F OCH₃ Cl Cl F 4420F OCH₃ Cl Br H 4421 F OCH₃ Cl Br CH₃ 4422 F OCH₃ Cl Br OCH₃ 4423 F OCH₃Cl Br Br 4424 F OCH₃ Cl F H 4425 F OCH₃ Cl F CH₃ 4426 F OCH₃ Cl F OCH₃4427 F OCH₃ Cl F Br 4428 F OCH₃ Cl F F 4429 F OCH₃ Br H H 4430 F OCH₃ BrH CH₃ 4431 F OCH₃ Br H OCH₃ 4432 F OCH₃ Br H Cl 4433 F OCH₃ Br H Br 4434F OCH₃ Br H F 4435 F OCH₃ Br CH₃ H 4436 F OCH₃ Br CH₃ CH₃ 4437 F OCH₃ BrCH₃ OCH₃ 4438 F OCH₃ Br CH₃ Cl 4439 F OCH₃ Br CH₃ F 4440 F OCH₃ Br OCH₃H 4441 F OCH₃ Br OCH₃ CH₃ 4442 F OCH₃ Br OCH₃ OCH₃ 4443 F OCH₃ Br OCH₃Cl 4444 F OCH₃ Br OCH₃ F 4445 F OCH₃ Br Cl H 4446 F OCH₃ Br Cl CH₃ 4447F OCH₃ Br Cl OCH₃ 4448 F OCH₃ Br Cl Cl 4449 F OCH₃ Br Cl F 4450 F OCH₃Br Br H 4451 F OCH₃ Br Br CH₃ 4452 F OCH₃ Br Br OCH₃ 4453 F OCH₃ Br BrCl 4454 F OCH₃ Br Br Br 4455 F OCH₃ Br Br F 4456 F OCH₃ Br F H 4457 FOCH₃ Br F CH₃ 4458 F OCH₃ Br F OCH₃ 4459 F OCH₃ Br F Cl 4460 F OCH₃ Br FF 4461 F OCH₃ F H H 4462 F OCH₃ F H CH₃ 4463 F OCH₃ F H OCH₃ 4464 F OCH₃F H Cl 4465 F OCH₃ F H Br 4466 F OCH₃ F H F 4467 F OCH₃ F CH₃ H 4468 FOCH₃ F CH₃ CH₃ 4469 F OCH₃ F CH₃ OCH₃ 4470 F OCH₃ F CH₃ Cl 4471 F OCH₃ FCH₃ Br 4472 F OCH₃ F OCH₃ H 4473 F OCH₃ F OCH₃ CH₃ 4474 F OCH₃ F OCH₃OCH₃ 4475 F OCH₃ F OCH₃ Cl 4476 F OCH₃ F OCH₃ Br 4477 F OCH₃ F Cl H 4478F OCH₃ F Cl CH₃ 4479 F OCH₃ F Cl OCH₃ 4480 F OCH₃ F Cl Cl 4481 F OCH₃ FCl Br 4482 F OCH₃ F Br H 4483 F OCH₃ F Br CH₃ 4484 F OCH₃ F Br OCH₃ 4485F OCH₃ F Br Cl 4486 F OCH₃ F Br Br 4487 F OCH₃ F F H 4488 F OCH₃ F F CH₃4489 F OCH₃ F F OCH₃ 4490 F OCH₃ F F Cl 4491 F OCH₃ F F Br 4492 F OCH₃ FF F 4493 F Cl CH₃ H H 4494 F Cl CH₃ H CH₃ 4495 F Cl CH₃ H OCH₃ 4496 F ClCH₃ H Cl 4497 F Cl CH₃ H Br 4498 F Cl CH₃ H F 4499 F Cl CH₃ CH₃ H 4500 FCl CH₃ CH₃ CH₃ 4501 F Cl CH₃ CH₃ OCH₃ 4502 F Cl CH₃ CH₃ Cl 4503 F Cl CH₃CH₃ Br 4504 F Cl CH₃ CH₃ F 4505 F Cl CH₃ OCH₃ H 4506 F Cl CH₃ OCH₃ OCH₃4507 F Cl CH₃ OCH₃ Cl 4508 F Cl CH₃ OCH₃ Br 4509 F Cl CH₃ OCH₃ F 4510 FCl CH₃ Cl H 4511 F Cl CH₃ Cl OCH₃ 4512 F Cl CH₃ Cl Cl 4513 F Cl CH₃ ClBr 4514 F Cl CH₃ Cl F 4515 F Cl CH₃ Br H 4516 F Cl CH₃ Br OCH₃ 4517 F ClCH₃ Br Cl 4518 F Cl CH₃ Br Br 4519 F Cl CH₃ Br F 4520 F Cl CH₃ F H 4521F Cl CH₃ F OCH₃ 4522 F Cl CH₃ F Cl 4523 F Cl CH₃ F Br 4524 F Cl CH₃ F F4525 F Cl OCH₃ H H 4526 F Cl OCH₃ H CH₃ 4527 F Cl OCH₃ H OCH₃ 4528 F ClOCH₃ H Cl 4529 F Cl OCH₃ H Br 4530 F Cl OCH₃ H F 4531 F Cl OCH₃ CH₃ H4532 F Cl OCH₃ CH₃ CH₃ 4533 F Cl OCH₃ CH₃ Cl 4534 F Cl OCH₃ CH₃ Br 4535F Cl OCH₃ CH₃ F 4536 F Cl OCH₃ OCH₃ H 4537 F Cl OCH₃ OCH₃ CH₃ 4538 F ClOCH₃ OCH₃ OCH₃ 4539 F Cl OCH₃ OCH₃ Cl 4540 F Cl OCH₃ OCH₃ Br 4541 F ClOCH₃ OCH₃ F 4542 F Cl OCH₃ Cl H 4543 F Cl OCH₃ Cl CH₃ 4544 F Cl OCH₃ ClCl 4545 F Cl OCH₃ Cl Br 4546 F Cl OCH₃ Cl F 4547 F Cl OCH₃ Br H 4548 FCl OCH₃ Br CH₃ 4549 F Cl OCH₃ Br Cl 4550 F Cl OCH₃ Br Br 4551 F Cl OCH₃Br F 4552 F Cl OCH₃ F H 4553 F Cl OCH₃ F CH₃ 4554 F Cl OCH₃ F Cl 4555 FCl OCH₃ F Br 4556 F Cl OCH₃ F F 4557 F Cl Cl H H 4558 F Cl Cl H CH₃ 4559F Cl Cl H OCH₃ 4560 F Cl Cl H Cl 4561 F Cl Cl H Br 4562 F Cl Cl H F 4563F Cl Cl CH₃ H 4564 F Cl Cl CH₃ CH₃ 4565 F Cl Cl CH₃ OCH₃ 4566 F Cl ClCH₃ Br 4567 F Cl Cl CH₃ F 4568 F Cl Cl OCH₃ H 4569 F Cl Cl OCH₃ CH₃ 4570F Cl Cl OCH₃ OCH₃ 4571 F Cl Cl OCH₃ Br 4572 F Cl Cl OCH₃ F 4573 F Cl ClCl H 4574 F Cl Cl Cl CH₃ 4575 F Cl Cl Cl OCH₃ 4576 F Cl Cl Cl Cl 4577 FCl Cl Cl Br 4578 F Cl Cl Cl F 4579 F Cl Cl Br H 4580 F Cl Cl Br CH₃ 4581F Cl Cl Br OCH₃ 4582 F Cl Cl Br Br 4583 F Cl Cl F H 4584 F Cl Cl F CH₃4585 F Cl Cl F OCH₃ 4586 F Cl Cl F Br 4587 F Cl Cl F F 4588 F Cl Br H H4589 F Cl Br H CH₃ 4590 F Cl Br H OCH₃ 4591 F Cl Br H Cl 4592 F Cl Br HBr 4593 F Cl Br H F 4594 F Cl Br CH₃ H 4595 F Cl Br CH₃ CH₃ 4596 F Cl BrCH₃ OCH₃ 4597 F Cl Br CH₃ Cl 4598 F Cl Br CH₃ F 4599 F Cl Br OCH₃ H 4600F Cl Br OCH₃ CH₃ 4601 F Cl Br OCH₃ OCH₃ 4602 F Cl Br OCH₃ Cl 4603 F ClBr OCH₃ F 4604 F Cl Br Cl H 4605 F Cl Br Cl CH₃ 4606 F Cl Br Cl OCH₃4607 F Cl Br Cl Cl 4608 F Cl Br Cl F 4609 F Cl Br Br H 4610 F Cl Br BrCH₃ 4611 F Cl Br Br OCH₃ 4612 F Cl Br Br Cl 4613 F Cl Br Br Br 4614 F ClBr Br F 4615 F Cl Br F H 4616 F Cl Br F CH₃ 4617 F Cl Br F OCH₃ 4618 FCl Br F Cl 4619 F Cl Br F F 4620 F Cl F H H 4621 F Cl F H CH₃ 4622 F ClF H OCH₃ 4623 F Cl F H Cl 4624 F Cl F H Br 4625 F Cl F H F 4626 F Cl FCH₃ H 4627 F Cl F CH₃ CH₃ 4628 F Cl F CH₃ OCH₃ 4629 F Cl F CH₃ Cl 4630 FCl F CH₃ Br 4631 F Cl F OCH₃ H 4632 F Cl F OCH₃ CH₃ 4633 F Cl F OCH₃OCH₃ 4634 F Cl F OCH₃ Cl 4635 F Cl F OCH₃ Br 4636 F Cl F Cl H 4637 F ClF Cl CH₃ 4638 F Cl F Cl OCH₃ 4639 F Cl F Cl Cl 4640 F Cl F Cl Br 4641 FCl F Br H 4642 F Cl F Br CH₃ 4643 F Cl F Br OCH₃ 4644 F Cl F Br Cl 4645F Cl F Br Br 4646 F Cl F F H 4647 F Cl F F CH₃ 4648 F Cl F F OCH₃ 4649 FCl F F Cl 4650 F Cl F F Br 4651 F Cl F F F 4652 F Br CH₃ H H 4653 F BrCH₃ H CH₃ 4654 F Br CH₃ H OCH₃ 4655 F Br CH₃ H Cl 4656 F Br CH₃ H Br4657 F Br CH₃ H F 4658 F Br CH₃ CH₃ H 4659 F Br CH₃ CH₃ CH₃ 4660 F BrCH₃ CH₃ OCH₃ 4661 F Br CH₃ CH₃ Cl 4662 F Br CH₃ CH₃ Br 4663 F Br CH₃ CH₃F 4664 F Br CH₃ OCH₃ H 4665 F Br CH₃ OCH₃ OCH₃ 4666 F Br CH₃ OCH₃ Cl4667 F Br CH₃ OCH₃ Br 4668 F Br CH₃ OCH₃ F 4669 F Br CH₃ Cl H 4670 F BrCH₃ Cl OCH₃ 4671 F Br CH₃ Cl Cl 4672 F Br CH₃ Cl Br 4673 F Br CH₃ Cl F4674 F Br CH₃ Br H 4675 F Br CH₃ Br OCH₃ 4676 F Br CH₃ Br Cl 4677 F BrCH₃ Br Br 4678 F Br CH₃ Br F 4679 F Br CH₃ F H 4680 F Br CH₃ F OCH₃ 4681F Br CH₃ F Cl 4682 F Br CH₃ F Br 4683 F Br CH₃ F F 4684 F Br OCH₃ H H4685 F Br OCH₃ H CH₃ 4686 F Br OCH₃ H OCH₃ 4687 F Br OCH₃ H Cl 4688 F BrOCH₃ H Br 4689 F Br OCH₃ H F 4690 F Br OCH₃ CH₃ H 4691 F Br OCH₃ CH₃ CH₃4692 F Br OCH₃ CH₃ Cl 4693 F Br OCH₃ CH₃ Br 4694 F Br OCH₃ CH₃ F 4695 FBr OCH₃ OCH₃ H 4696 F Br OCH₃ OCH₃ CH₃ 4697 F Br OCH₃ OCH₃ OCH₃ 4698 FBr OCH₃ OCH₃ Cl 4699 F Br OCH₃ OCH₃ Br 4700 F Br OCH₃ OCH₃ F 4701 F BrOCH₃ Cl H 4702 F Br OCH₃ Cl CH₃ 4703 F Br OCH₃ Cl Cl 4704 F Br OCH₃ ClBr 4705 F Br OCH₃ Cl F 4706 F Br OCH₃ Br H 4707 F Br OCH₃ Br CH₃ 4708 FBr OCH₃ Br Cl 4709 F Br OCH₃ Br Br 4710 F Br OCH₃ Br F 4711 F Br OCH₃ FH 4712 F Br OCH₃ F CH₃ 4713 F Br OCH₃ F Cl 4714 F Br OCH₃ F Br 4715 F BrOCH₃ F F 4716 F Br Cl H H 4717 F Br Cl H CH₃ 4718 F Br Cl H OCH₃ 4719 FBr Cl H Cl 4720 F Br Cl H Br 4721 F Br Cl H F 4722 F Br Cl CH₃ H 4723 FBr Cl CH₃ CH₃ 4724 F Br Cl CH₃ OCH₃ 4725 F Br Cl CH₃ Br 4726 F Br Cl CH₃F 4727 F Br Cl OCH₃ H 4728 F Br Cl OCH₃ CH₃ 4729 F Br Cl OCH₃ OCH₃ 4730F Br Cl OCH₃ Br 4731 F Br Cl OCH₃ F 4732 F Br Cl Cl H 4733 F Br Cl ClCH₃ 4734 F Br Cl Cl OCH₃ 4735 F Br Cl Cl Cl 4736 F Br Cl Cl Br 4737 F BrCl Cl F 4738 F Br Cl Br H 4739 F Br Cl Br CH₃ 4740 F Br Cl Br OCH₃ 4741F Br Cl Br Br 4742 F Br Cl F H 4743 F Br Cl F CH₃ 4744 F Br Cl F OCH₃4745 F Br Cl F Br 4746 F Br Cl F F 4747 F Br Br H H 4748 F Br Br H CH₃4749 F Br Br H OCH₃ 4750 F Br Br H Cl 4751 F Br Br H Br 4752 F Br Br H F4753 F Br Br CH₃ H 4754 F Br Br CH₃ CH₃ 4755 F Br Br CH₃ OCH₃ 4756 F BrBr CH₃ Cl 4757 F Br Br CH₃ F 4758 F Br Br OCH₃ H 4759 F Br Br OCH₃ CH₃4760 F Br Br OCH₃ OCH₃ 4761 F Br Br OCH₃ Cl 4762 F Br Br OCH₃ F 4763 FBr Br Cl H 4764 F Br Br Cl CH₃ 4765 F Br Br Cl OCH₃ 4766 F Br Br Cl Cl4767 F Br Br Cl F 4768 F Br Br Br H 4769 F Br Br Br CH₃ 4770 F Br Br BrOCH₃ 4771 F Br Br Br Cl 4772 F Br Br Br Br 4773 F Br Br Br F 4774 F BrBr F H 4775 F Br Br F CH₃ 4776 F Br Br F OCH₃ 4777 F Br Br F Cl 4778 FBr Br F F 4779 F Br F H H 4780 F Br F H CH₃ 4781 F Br F H OCH₃ 4782 F BrF H Cl 4783 F Br F H Br 4784 F Br F H F 4785 F Br F CH₃ H 4786 F Br FCH₃ CH₃ 4787 F Br F CH₃ OCH₃ 4788 F Br F CH₃ Cl 4789 F Br F CH₃ Br 4790F Br F OCH₃ H 4791 F Br F OCH₃ CH₃ 4792 F Br F OCH₃ OCH₃ 4793 F Br FOCH₃ Cl 4794 F Br F OCH₃ Br 4795 F Br F Cl H 4796 F Br F Cl CH₃ 4797 FBr F Cl OCH₃ 4798 F Br F Cl Cl 4799 F Br F Cl Br 4800 F Br F Br H 4801 FBr F Br CH₃ 4802 F Br F Br OCH₃ 4803 F Br F Br Cl 4804 F Br F Br Br 4805F Br F F H 4806 F Br F F CH₃ 4807 F Br F F OCH₃ 4808 F Br F F Cl 4809 FBr F F Br 4810 F Br F F F 4811 F F CH₃ H H 4812 F F CH₃ H CH₃ 4813 F FCH₃ H OCH₃ 4814 F F CH₃ H Cl 4815 F F CH₃ H Br 4816 F F CH₃ H F 4817 F FCH₃ CH₃ H 4818 F F CH₃ CH₃ CH₃ 4819 F F CH₃ CH₃ OCH₃ 4820 F F CH₃ CH₃ Cl4821 F F CH₃ CH₃ Br 4822 F F CH₃ CH₃ F 4823 F F CH₃ OCH₃ H 4824 F F CH₃OCH₃ OCH₃ 4825 F F CH₃ OCH₃ Cl 4826 F F CH₃ OCH₃ Br 4827 F F CH₃ OCH₃ F4828 F F CH₃ Cl H 4829 F F CH₃ Cl OCH₃ 4830 F F CH₃ Cl Cl 4831 F F CH₃Cl Br 4832 F F CH₃ Cl F 4833 F F CH₃ Br H 4834 F F CH₃ Br OCH₃ 4835 F FCH₃ Br Cl 4836 F F CH₃ Br Br 4837 F F CH₃ Br F 4838 F F CH₃ F H 4839 F FCH₃ F OCH₃ 4840 F F CH₃ F Cl 4841 F F CH₃ F Br 4842 F F CH₃ F F 4843 F FOCH₃ H H 4844 F F OCH₃ H CH₃ 4845 F F OCH₃ H OCH₃ 4846 F F OCH₃ H Cl4847 F F OCH₃ H Br 4848 F F OCH₃ H F 4849 F F OCH₃ CH₃ H 4850 F F OCH₃CH₃ CH₃ 4851 F F OCH₃ CH₃ Cl 4852 F F OCH₃ CH₃ Br 4853 F F OCH₃ CH₃ F4854 F F OCH₃ OCH₃ H 4855 F F OCH₃ OCH₃ CH₃ 4856 F F OCH₃ OCH₃ OCH₃ 4857F F OCH₃ OCH₃ Cl 4858 F F OCH₃ OCH₃ Br 4859 F F OCH₃ OCH₃ F 4860 F FOCH₃ Cl H 4861 F F OCH₃ Cl CH₃ 4862 F F OCH₃ Cl Cl 4863 F F OCH₃ Cl Br4864 F F OCH₃ Cl F 4865 F F OCH₃ Br H 4866 F F OCH₃ Br CH₃ 4867 F F OCH₃Br Cl 4868 F F OCH₃ Br Br 4869 F F OCH₃ Br F 4870 F F OCH₃ F H 4871 F FOCH₃ F CH₃ 4872 F F OCH₃ F Cl 4873 F F OCH₃ F Br 4874 F F OCH₃ F F 4875F F Cl H H 4876 F F Cl H CH₃ 4877 F F Cl H OCH₃ 4878 F F Cl H Cl 4879 FF Cl H Br 4880 F F Cl H F 4881 F F Cl CH₃ H 4882 F F Cl CH₃ CH₃ 4883 F FCl CH₃ OCH₃ 4884 F F Cl CH₃ Br 4885 F F Cl CH₃ F 4886 F F Cl OCH₃ H 4887F F Cl OCH₃ CH₃ 4888 F F Cl OCH₃ OCH₃ 4889 F F Cl OCH₃ Br 4890 F F ClOCH₃ F 4891 F F Cl Cl H 4892 F F Cl Cl CH₃ 4893 F F Cl Cl OCH₃ 4894 F FCl Cl Cl 4895 F F Cl Cl Br 4896 F F Cl Cl F 4897 F F Cl Br H 4898 F F ClBr CH₃ 4899 F F Cl Br OCH₃ 4900 F F Cl Br Br 4901 F F Cl F H 4902 F F ClF CH₃ 4903 F F Cl F OCH₃ 4904 F F Cl F Br 4905 F F Cl F F 4906 F F Br HH 4907 F F Br H CH₃ 4908 F F Br H OCH₃ 4909 F F Br H Cl 4910 F F Br H Br4911 F F Br H F 4912 F F Br CH₃ H 4913 F F Br CH₃ CH₃ 4914 F F Br CH₃OCH₃ 4915 F F Br CH₃ Cl 4916 F F Br CH₃ F 4917 F F Br OCH₃ H 4918 F F BrOCH₃ CH₃ 4919 F F Br OCH₃ OCH₃ 4920 F F Br OCH₃ Cl 4921 F F Br OCH₃ F4922 F F Br Cl H 4923 F F Br Cl CH₃ 4924 F F Br Cl OCH₃ 4925 F F Br ClCl 4926 F F Br Cl F 4927 F F Br Br H 4928 F F Br Br CH₃ 4929 F F Br BrOCH₃ 4930 F F Br Br Cl 4931 F F Br Br Br 4932 F F Br Br F 4933 F F Br FH 4934 F F Br F CH₃ 4935 F F Br F OCH₃ 4936 F F Br F Cl 4937 F F Br F F4938 F F F H H 4939 F F F H CH₃ 4940 F F F H OCH₃ 4941 F F F H Cl 4942 FF F H Br 4943 F F F H F 4944 F F F CH₃ H 4945 F F F CH₃ CH₃ 4946 F F FCH₃ OCH₃ 4947 F F F CH₃ Cl 4948 F F F CH₃ Br 4949 F F F OCH₃ H 4950 F FF OCH₃ CH₃ 4951 F F F OCH₃ OCH₃ 4952 F F F OCH₃ Cl 4953 F F F OCH₃ Br4954 F F F Cl H 4955 F F F Cl CH₃ 4956 F F F Cl OCH₃ 4957 F F F Cl Cl4958 F F F Cl Br 4959 F F F Br H 4960 F F F Br CH₃ 4961 F F F Br OCH₃4962 F F F Br Cl 4963 F F F Br Br 4964 F F F F H 4965 F F F F CH₃ 4966 FF F F OCH₃ 4967 F F F F Cl 4968 F F F F Br 4969 F F F F F

The compounds of Formulas I, II, III, IV, and V are MCH receptorantagonists, as demonstrated by the ligand binding assays describedhereinbelow. MCH receptor antagonist activity has been correlated withpharmaceutical activity for the treatment of eating disorders such asobesity and hyperphagia, and diabetes. Compounds of Formula I exhibitgood activity in standard in vitro MCH calcium mobilization assaysand/or receptor binding assays, specifically in the assays describedhereinbelow, see Examples 6 and 7. Generally, compounds of Formula Ihave a K_(i) of about 10 μM or less, preferably about 1 μM or less, morepreferably about 100 nM or less, or even more preferably about 10 nM orless, as determined by a standard in vitro MCH receptor mediated calciummobilization assay as exemplified by Example 6, hereinbelow. Generallycompounds of Formula I are MCH receptor antagonists and exhibit IC₅₀values of about 10 μM or less, preferably about 1 μM or less, morepreferably about 100 nM or less, or even more preferably about 10 nM orless, as determined by a standard in vitro MCH receptor binding assaysuch as is described hereinbelow in Example 7.

Preferably, the MCH receptor antagonists of Formula I bind specifically,and still more preferably with high affinity, to MCH receptors.

General Synthetic Procedures

The compounds described herein may be synthesized according to thefollowing procedures of Schemes 1-3, wherein A, W, X, Z, and R¹-R⁸ areas defined for Formulas I-V, above.

Compounds of Formula I can be prepared by the methods of genericscheme 1. Coupling of carbonyl compounds such as aldehydes or ketones 1with amines 2 and compounds 3 (where A′ is a ring precursor) forms anintermediate precursor that is then cyclized to form the compounds 4 ofFormula I.

Compounds of Formula II-V can be prepared by general scheme 2. Using amodified Ugi synthesis, [(a) Ugi, I., Angew. Chem. Int. Ed. Engl. 1962,1, 8; (b) Ugi, I. and Steinbruckner, C., Chem Ber. 1961, 94, 734; (c)Ugi, I. et al., Endeavor 1994, 18, 115; (d) Domling, A., CombinatorialChemistry & High Throughput Screening 1998, 1, 1] carbonyl compoundssuch as aldehydes or ketones 1 with piperazines 5 and isocyanides 6forms an intermediate precursor that is cyclized, such as with TMSN₃, toform tetrazoles 7.

Isoxazoles compounds can be prepared by general scheme 3. Cycloadditionreactions of substituted propynyl piperazines 8, such as with nitrileoxide, form isoxazoles 9.

The following examples illustrate the invention.

EXAMPLE 1

Benzaldehyde (102 mL, 1 mmol), trans-cinnamylpiperazine (202 mg, 1mmol), 2,6-dimethylphenylisocyanide (131 mg, 1 mmol), and TMSN₃ (132 mL,1 mmol) were added to 40 mL methanol in order of their participation inthe Ugi reaction. After 18 hours the solution was concentrated to yielda colorless oil. The product was purified by FCC (2% MeOH/CHCl₃) toyield a colorless oil.

EXAMPLE 2

Biphenylcarboxaldehyde (182 mg, 1 mmol), TMSN₃ (132 mL, 1 mmol),2,6-dimethylphenylisocyanide (131 mg, 1 mmol) andtrans-cinnamylpiperazine (202 mg, 1 mmol) were added to 40 mL methanolin order of their participation in the Ugi reaction. After 18 hours, thesolution was concentrated to yield a colorless oil, which was purifiedby FCC (1% MeOH/CHCl₃). Because of rapid elution of product in 1%MeOH/CHCl₃, only one fraction was pure. Other fractions were combinedand evaporated. The product was a light yellow oil, which was briefly awhite solid during evaporation.

EXAMPLE 3

The compound of Example 2 (168 mg, 0.359 mmol) was dissolved in 5 mL DCMand 1.0 M HCl/ether (0.72 mL) was added. After 1 hour, the resultingwhite precipitate was filtered.

EXAMPLE 4

Amine (0.93 g, 5 mmol), aldehyde (0.51 mL, 5 mmol), TMSN₃ (0.66 mL, 5mmol) and isocyanide (0.66 g, 5 mmol) were dissolved in 200 mL MeOH inorder of participation in the Ugi reaction. After 4 days, the reactionsolution was about 75% evaporated, and the white precipitate wasfiltered, washed with cold MeOH, and air dried.

EXAMPLE 5

The compound of Example 4 (37 mg) and 2 mL 10% TFA/DCE were shaken for18 hours and concentrated to give a colorless oil. The product waspurified by LC.

EXAMPLE 6 Functional Assays

Human embryonic kidney cells (293 total) expressing either human, rat,or mouse MCH receptor were harvested from 150 mm culture dishes usingPBS. Spinning at 1500 rpm for 2 minutes initially pelleted cells. Theresulting pellet was then homogenized in 15 mL ice cold sucrose buffer(25 mM HEPES, 0.3 M sucrose, pH 7.4) with a motorized, glass fitted,Teflon® homogenizer. The homogenate was centrifuged at 48,000×g at 4° C.for 10 minutes, resuspended in 15 mL assay buffer (25 mM HEPES, 10 mMmgCl₂, 0.2% BSA, 0.1 mg/mL STI, 0.1 mg/mL Pefabloc®, 1 μMPhosphoramidon, pH 7.4) with a Tissue-Tearor® (Biospec Products) andcentrifuged again at 48,000×g for 10 minutes. The pellet was homogenizedfor a third time in 15 mL assay buffer using the Tissue-Tearor® andagain centrifuged at 48,000×g for 10 minutes. The resulting pellet wasresuspended in assay buffer at a wet weight concentration of 10-20mg/mL.

Pharmacological analyses were conducted using either a HT-PS100 device(Axiom Biotechnologies, San Diego, Calif.), which provideshigh-resolution dose-response fluorometric measurements of [Ca⁺⁺]_(i)mobilization, or using a FLIPR® device (Molecular Devices, Sunnyvale,Calif.).

HT-PS100 Protocol:

Materials: HEK 293 cells were stably transfected with the rat MCH1receptor and maintained under G418 antibiotic pressure. HT-PS100 assaybuffer consisted of Physiological Saline Solution (145 mM NaCl, 5.4 mMKCL, 1.0 mM NaH₂PO₄, 1.8 mM CaCl₂, 0.8 mM mgSO₄, 15.0 mM HEPES, pH 7.4,11.2 mM glucose)+50 μM Pluronic-F127. MCH peptide (Amgen, Inc.) wasreconstituted in assay buffer and served as the positive agonist controlfor all experiments. Test compounds were prepared as 10 mM stocks in100% DMSO and diluted to a top end working concentration of 100 μM in 96well plates.

Methods: HEK 293 stably expressing MCH1R were maintained in Dulbeco'smodified Eagle's medium (GIBCO/Life Technologies, Rockville, Md.)supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum(HyClone, Logan, Utah) at 37° C., 5% CO₂. Cells were harvested by 10′treatment with Versene (GIBCO/Life Technologies) followed bytrituration, washing twice with cold (4° C.) hybridoma medium(Serum/Protein free, with L-glutamine, sodium bicarbonate, MOPS buffer)(Sigma-Aldrich Corp, St. Louis, Mo.) and resuspended at 2×10⁶ cells/mLin the same medium. The resuspended cells were loaded with thefluorescent calcium indicator Fura-2 by incubating with Fura-2AM(Molecular Probes, Eugene, Oreg.) at 1.6 μM for 60′ at room temperature.The loaded cells were then washed twice with hybridoma medium, adjustedto 2×10⁵ cells/mL and kept at ambient temperature in a spinner flaskunder gentle stirring for up to 6 hours during the experiment.

Receptor-stimulated intracellular calcium responses were detected in theflow-through detector cuvette of the HT-PS100 by monitoring increases inthe ratio of Fura-2 fluorescence intensities R_(340/380) measured atalternating 340/380 nm excitation and 510 nm emission.

Preliminary static experiments, conducted to determine the kinetics ofMCH1R's dose response to MCH peptide, indicated the optimum time pointto capture the maximum Ca⁺⁺ transients was 30 s. No interference withDMSO was seen up to 1%. Based on these observations, subsequentexperiments were conducted on the HT-PS100 to generate high resolutiondose response curves, characterize agonist/antagonist properties, andevaluate antagonist potencies via Schild experiments. During HT-PS100validation, reproducible EC₅₀s for MCH of 10 nM were generated within abroad range of cell passage and harvest density. HT-PS100 gradientgeneration was calibrated with a standardized stock of fluorescein.

Test compounds were screened for MCH1R activity in the HT-PS100 for bothagonist and antagonist action. Agonist mode challenges were conducted ata maximum gradient concentration of 100 μM. Antagonist activity wastested by 30 s pre-incubation of cells at a compound concentration of100 μM, with subsequent introduction of MCH at a concentration 5-fold ofEC₅₀ as determined in preliminary experiments. Compounds that showedinhibition of the MCH-induced Ca⁺⁺ response were automatically taggedfor re-interrogation, IC₅₀ generation, and Schild analysis.

Schild experiments were conducted on the HT-PS100 for selected compoundsby 30 s pre-incubation of cells with antagonist compounds prior toadministering MCH peptide. Several fixed concentrations of antagonistcompounds were prepared in 10-fold increments, and presented to thecells 30 s before introducing a gradient of increasing MCHconcentration. Values for compound pA₂ were calculated by linearregression of Log(DR−1) MCH EC₅₀ as a function of Log(antagonistconcentration), where DR is the dose ratio of MCH EC₅₀ values determinedin the presence and absence of antagonist.

The following compounds had K_(i) values of 100 nM or less in theHT-PS100 assay: Compound Nos. 1, 4, 48, 53, 55, 56, 57, 60, 61, 62, 64,70, 76, 77, 78, 79, 82, 83, and 84.

FLIPR® Protocol:

Materials: Pharmacological analysis was conducted using a FLIPR® device(Molecular Devices, Sunnyvale, Calif.). CHOK1-Gqi cells were stablytransfected with the rat MCH1 receptor and maintained under G418antibiotic pressure. FLIPR® assay buffer consisted of phenol red-freeDMEM+2.5 mM probenecid. MCH peptide (Amgen, Inc.) was reconstituted inassay buffer and served as the positive agonist control for allexperiments. Test compounds were prepared as 10 mM stocks in 100% DMSOand diluted to a top end working concentration of 10 μM in 96 wellblack, flat bottom, collagen-I coated plates (Becton Dickinson, Bedford,Mass.).

Methods: CHOK1-Gqi cells stably expressing MCH1R were maintained inDulbeco's modified Eagle's medium (GIBCO/Life Technologies, Rockville,Md.) supplemented with 2 mM glutamine and 10% dialyzed fetal bovineserum (HyCLone, Logan, Utah) at 37° C., 5% CO₂. Cells were harvested by10′ treatment with Versene (GIBCO/Life Technologies) followed bytrituration, washing twice with cold (4° C.) hybridoma medium(Serum/Protein free, with L-glutamine, sodium bicarbonate, MOPS buffer)(Sigma-Aldrich Corp, St. Louis, Mo.) and replated onto 96 well black,flat bottom, collagen-I coated plates to a density of 10,000 cells/well.The cells were then loaded with the fluorescent calcium indicator Fura-2(Molecular Probes, Eugene, Oreg.) at 1.6 μM for 60′ at room temperature.The loaded cells were then washed twice with 90 μl/well of wash buffer(1×HBSS, 20 mM HEPES, 2.5 mM probenecid).

Receptor-stimulated intracellular calcium responses were detected usingFLIPR® by monitoring increases in the Fura-2 fluorescence response.

Test compounds were screened for MCH1R activity in the FLIPR® for bothagonist and antagonist action. Agonist mode challenges were conducted ata maximum gradient concentration of 1 μM. Antagonist activity was testedby 10 min pre-incubation of cells at a compound concentration of definedto be 300× the EC₅₀ of MCH (typically 1 μM), with subsequentintroduction of MCH at a concentration 5-fold of EC₅₀ as determined inpreliminary experiments. Compounds that showed inhibition of MCH inducedMCH1R dependant Ca⁺⁺ responses were automatically tagged forre-interogation, IC₅₀ generation, and Schild analysis.

Schild experiments were conducted on the FLIPR® for selected compoundsby co-administering antagonist compounds together with MCH peptide.Several fixed concentrations of antagonist compounds were prepared in10-fold increments, and presented to the cells in a gradient ofincreasing MCH concentration. Values for compound pA₂ were calculated bylinear regression of MCH EC₅₀s as a function of antagonistconcentration.

The following compounds had K_(i) values of 100 μM or less in the rMCHFLIPR® assay: Compound Nos. 1, 4, 11, 12, 20, 48, 53, 55, 56, 57, 60,61, 62, 64, 70, 76, 77, 78, 79, 82, 83, 84, 86, 87, 92, 133, 134, 135,143, 144, 145, 145, 147, 148, 150, and 151. Of these, Compound Nos. 11and 56 had K_(i) values of 100 nM or less in this assay.

The following compounds had K_(i) values of 100 μM or less in the hMCHFLIPR® assay: Compound Nos. 1, 4, 20, 48, 53, 55, 56, 57, 60, 61, 62,70, 77, 78, 79, 82, 83, 84, 86, 87, 133, 134, 135, 143, 144, 145, 147,148, 150, and 151. Of these, Compound Nos. 4, 48, 53, 55, 56, 70, 79,and 82 had K_(i) values of 100 nM or less in this assay.

EXAMPLE 7 Ligand Binding Assay

Binding assays were determined as described below using mouse, rat orhuman MCH 1 receptors (mMCH1R, rMCH1R, and hMCH1R, respectively)expressed in HEK 293; IC₅₀ values were calculated.

Binding assays were performed in 96-well U-bottom plates. Membranes (100μg tissue) were incubated at 30° C. for 90 minutes in assay buffer withvarious peptides in the presence of 0.2 nM ¹²⁵I native-MCH (Perkin-ElmerLife Sciences, Boston, Mass.) in 100 μL total volume. Non-specificbinding was assessed in the presence of 1 μM cold native-MCH. Thereaction was terminated by rapid filtration through Unfilter-96 GF/Cglass fiber filter plates (FilterMate® 196 Harvester, Packard InstrumentCo., Meriden, Conn.) pre-soaked in PBS/0.5% BSA, followed by threewashes with 300 μL ice-cold water. Bound radioactivity was determinedusing a TopCount® microplate scintillation and luminescence counter(Packard Instrument Co., Meriden, Conn.). Nonlinear regression analysesof drug concentration curves were performed using GraphPad Prism®(GraphPad Software, Inc., San Diego, Calif.).

The following compounds had IC₅₀ values of 100 μM or less in the rMCHassay: Compound Nos. 1, 4, 11, 12, 14, 15, 19, 20, 21, 22, 24, 26, 27,28, 29, 29, 30, 31, 33, 35, 36, 37, 38, 39, 46, 48, 52, 53, 55, 56, 57,58, 60, 61, 62, 63, 64, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79,80, 81, 82, 83, 84, 92, 99, 118, 122, 123, 124, 125, 126, 127, 128, 129,130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 142, 143, 144, 145,147, 148, 150, 151, 154, 156, 162, 163, and 164. Of these, Compound Nos.1, 11, 56, 70, 79, 84, 129, 134, 136, 137, 138, 139, 140, 142, 144, and163 had IC₅₀ values of 100 nM or less in the rMCH assay.

The following compounds had IC₅₀ values of 100 μM or less in the hMCHassay: Compound Nos. 1, 4, 11, 12, 14, 15, 16, 17, 19, 20, 21, 22, 26,29, 30, 31, 33, 35, 36, 37, 38, 39, 42, 46, 48, 52, 53, 55, 56, 57, 58,60, 61, 62, 63, 64, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 77, 78, 79,80, 81, 82, 83, 84, 85, 86, 87, 91, 92, 133, 134, 135, 142, 143, 144,145, 147, 148, 150, 151, and 164. Of these, Compound Nos. 1, 4, 20, 55,56, 62, 64, 70, 76, 77, 78, 84, 134, 142, and 144 had IC₅₀ values of 100nM or less in the hMCH assay.

In view of the above, it will be seen that the several objects of theinvention are achieved.

The above description of the embodiments and examples are intended onlyto acquaint others skilled in the art with the invention, itsprinciples, and its practical application, so that others skilled in theart may adapt and apply the invention in its numerous forms, as may bebest suited to the requirements of a particular use. The presentinvention, therefore, is not limited to the above embodiments, and maybe variously modified.

With reference to the use of the word(s) “comprise” or “comprises” or“comprising” or “including” or “having” in the above description and/orin the following claims, it should be noted that unless the contextrequires otherwise, those words are used on the basis and clearunderstanding that they are to be interpreted inclusively, rather thanexclusively, and that each of those words is to be so interpreted inconstruing the above description and/or the following claims. Whenintroducing elements of the present invention or the preferredembodiment(s) thereof, the articles “a,” “an,” “the,” and “said” areintended to mean that there are one or more of the elements.

In view of the above, it will be seen that the several objects of theinvention are achieved and other advantageous results attained.

As various changes could be made in the above compounds and methodswithout departing from the scope of the invention, it is intended thatall matter contained in the above description shall be interpreted asillustrative and not in a limiting sense.

The entire texts of all U.S. Patents and other references cited hereinare hereby incorporated by reference into this patent.

1. A compound, pharmaceutically-acceptable salt or tautomer of acompound of Formula IV

wherein Z is selected from the group consisting of a bond, methyl,ethyl, propyl, t-butyl, phenyl, tetrahydronaphthyl, biphenyl, naphthyl,phenylpropyl, indolylethyl, and piperidyl; R¹ is selected from the groupconsisting of methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl,isopropyl, n-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, benzyl, phenyl, tetrahydronaphthyl, indolyl,tetrahydrofuryl, pyrrolidinyl, and morpholinyl, wherein R¹ is optionallysubstituted by one or more substituents selected from the groupconsisting of methyl, ethyl, propyl, bromo, fluoro, chloro, and keto; R²is selected from the group consisting of methyl, phenyl, biphenyl,naphthyl, tetrahydrofuryl, pyrrolidinyl, morpholinyl, piperidyl,thienyl, pyrrolyl, and pyridyl, or R² and R⁸ together with the atom towhich they are both attached form a piperidyl or cyclohexyl group,wherein R² or the piperidyl or cycohexyl group formed with R⁸ isoptionally substituted by one or more substituents selected from thegroup consisting of methoxy, ethoxy, methyl, ethyl, isopropyl, isobutyl,methylphenoxy, methylthio, phenylethenyl, benzyloxy, phenylethoxy,benzyl, phenoxy, cyano, fluoro, chloro, bromo, trifluoromethyl,trifluoromethylphenyl, dichlorophenoxy, imidazole, benzodioxole,hydroxy, hydroxyethoxy, N-(methylcarbonyl)amino, and nitro; R⁴, R⁵, R⁶,and R⁷ are independently selected from the group consisting of hydrogen,methyl, ethyl, n-propyl, isopropyl, fluoro, chloro, and bromo; R⁸ ishydrogen or alkyl; and R^(10a), R^(10b), R^(10c), R^(10d), and R^(10e)are independently selected from the group consisting of hydrogen,methyl, hydroxy, and methoxy.
 2. The compound,pharmaceutically-acceptable salt or tautomer of a compound of Formula V

wherein Z is selected from the group consisting of a bond, methyl,ethyl, propyl, t-butyl, phenylpropyl, indolylethyl, and piperidyl; R¹ isselected from the group consisting of methoxycarbonyl, ethoxycarbonyl,t-butoxycarbonyl, isopropyl, n-butyl, t-butyl, benzyl, phenyl,tetrahydronaphthyl, indolyl, tetrahydrofuryl, pyrrolidinyl, andmorpholinyl, wherein R¹ is optionally substituted by one or moresubstituents selected from the group consisting of methyl, chloro, andketo; R² is selected from the group consisting of methyl, phenyl,biphenyl, naphthyl, thienyl, pyrrolyl, and pyridyl, or R² and R⁸together with the atom to which they are both attached form a piperidylor cyclohexyl group, wherein R² or the piperidyl or cyclohexyl groupformed with R⁸ is optionally substituted by one or more substituentsselected from the group consisting of methoxy, ethoxy, methyl, ethyl,isopropyl, isobutyl, methylphenoxy, methylthio, phenylethenyl,benzyloxy, phenylethoxy, benzyl, phenoxy, cyano, fluoro, chloro, bromo,trifluoromethyl, trifluoromethylphenyl, dichlorophenoxy, imidazole,benzodioxole, hydroxy, hydroxyethoxy, N-(methylcarbonyl)amino, andnitro; R⁸ is hydrogen or alkyl; and R^(10a), R^(10b), R^(10c), R^(10d),and R^(10e) are independently selected from the group consisting ofhydrogen, methyl, hydroxy, and methoxy.
 3. The compound,pharmaceutically-acceptable salt or tautomer of claim 2, wherein thecompound is selected from the group consisting of1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine,1-{biphenyl-4-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-phenoxyphenyl)methyl]-4-(3-phenylallyl)piperazine,1-[(1-tert-butyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine,1-[(1-benzyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine,(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)aceticacid methyl ester,1-[(1-butyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine,1-[(1-isopropyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine,5-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)-1H-indole,(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)aceticacid ethyl ester,1-(3-phenylallyl)-4-{phenyl-[1-(1,1,3,3-tetramethylbutyl)-1H-tetrazol-5-yl]methyl}piperazine,(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)aceticacid tert-butyl ester,1-{[1-(3,3-diphenylpropyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine,1-{[1-(1-benzylpiperidin-4-yl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine,3-[2-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)ethyl]-1H-indole,1-{[1-(3,4-dichlorobenzyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine,3-(1H-indol-3-yl)-2-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)propionicacid methyl ester,1-(3-phenylallyl)-4-{phenyl-[1-(tetrahydrofuran-2-ylmethyl)-1H-tetrazol-5-yl]methyl}piperazine,1-[(1-phenethyl-1H-tetrazol-5-yl)phenylmethyl]-4-(3-phenylallyl)piperazine,1-[3-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)propyl]pyrrolidin-2-one,1-({1-[2-(1-methyl-pyrrolidin-2-yl)ethyl]-1H-tetrazol-5-yl}phenylmethyl)-4-(3-phenylallyl)piperazine,1-(3-phenylallyl)-4-{phenyl-[1-(5,6,7,8-tetrahydronaphthalen-1-yl)-1H-tetrazol-5-yl]methyl}piperazine,1-({1-[2-(4-chlorophenyl)ethyl]-1H-tetrazol-5-yl}phenylmethyl)-4-(3-phenylallyl)piperazine,4-[3-(5-{phenyl-[4-(3-phenylallyl)piperazin-1-yl]methyl}tetrazol-1-yl)propyl]morpholine,1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]naphthalen-1-ylmethyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-fluorophenyl)methyl]-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-styrylphenyl)methyl]-4-(3-phenylallyl)piperazine,1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]thiophen-2-ylmethyl}-4-(3-phenylallyl)piperazine,1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-p-tolylmethyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3-phenylallyl)piperazine,1-{(4-chlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-fluorophenyl)methyl]-4-(3-phenylallyl)piperazine,1-{(3,4-dichlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-m-tolylmethyl}-4-(3-phenylallyl)piperazine,1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]naphthalen-2-ylmethyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-trifluoromethylphenyl)methyl]-4-(3-phenylallyl)piperazine,1-{biphenyl-4-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(1-methyl-1H-pyrrol-2-yl)methyl]-4-(3-phenylallyl)piperazine,1-{(2-benzyloxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-{2-benzyloxy-1-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]ethyl}-4-(3-phenylallyl)piperazine,1-{(4-benzyloxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(6-methylpyridin-2-yl)methyl]-4-(3-phenylallyl)piperazine,1-{[3-(3,4-dichlorophenoxy)phenyl]-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-p-tolyloxyphenyl)methyl]-4-(3-phenylallyl)piperazine,1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]pyridin-3-ylmethyl}-4-(3-phenylallyl)piperazine,1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]pyridin-2-ylmethyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-phenoxyphenyl)methyl]-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-imidazol-1-ylphenyl)methyl]-4-(3-phenylallyl)piperazine,3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}benzonitrile,2-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}benzonitrile,3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}phenol,2-(3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}phenoxy)ethanol,1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]pyridin-4-ylmethyl}-4-(3-phenylallyl)piperazine,1-{[3-(3,5-dichloro-phenoxy)-phenyl]-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-{1-benzyl-4-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]piperidin-4-yl}-4-(3-phenylallyl)piperazine,1-{1-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]cyclohexyl}-4-(3-phenylallyl)piperazine,1-{4-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-1-methylpiperidin-4-yl}-4-(3-phenylallyl)piperazine,1-{(4-bromophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-{(4-chlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-(3-phenylallyl)-4-[phenyl-(1-phenyl-1H-tetrazol-5-yl)methyl]piperazine,1-[(4-imidazol-1-ylphenyl)-(1-phenyl-1H-tetrazol-5-yl)methyl]-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-methoxyphenyl)methyl]-4-(3-phenylallyl)piperazine,1-{(3,4-dimethylphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-{(3,4-difluorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-isopropylphenyl)methyl]-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-methylsulfanylphenyl)methyl]-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-ethylphenyl)methyl]-4-(3-phenylallyl)piperazine,1-{(3,4-dimethoxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-{(4-benzyloxy-3-methoxyphenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-isobutylphenyl)methyl]-4-(3-phenylallyl)piperazine,N-(4-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}phenyl)acetamide,3-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-[4-(3-phenylallyl)piperazin-1-yl]methyl}benzonitrile,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-imidazol-1-ylphenyl)methyl]-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(4-ethoxyphenyl)methyl]-4-(3-phenylallyl)piperazine,1-{(3,5-dichlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-nitrophenyl)methyl]-4-(3-phenylallyl)piperazine,1-{(3-bromophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-{(3-chlorophenyl)-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3-phenylallyl)piperazine,1-{biphenyl-3-yl-[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]methyl}-4-(3-phenylallyl)piperazine,1-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-[3-(4-methoxyphenyl)allyl]piperazine,2-(3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1-yl}propenyl)phenol,4-(3-{4-[[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]piperazin-1-yl}propenyl)-2-methoxyphenol,and1-[[1-(2,6-dichlorophenyl)-1H-tetrazol-5-yl]-(3-trifluoromethylphenyl)methyl]-4-(3-phenylallyl)piperazine.4. A compound, or a pharmaceutically-acceptable salt or tautomerthereof, wherein the compound corresponds to Formula

wherein R^(1a) is independently selected from the group consisting ofhydrogen, methyl, methoxy, chloro, bromo, and fluoro; R^(1b) isindependently selected from the group consisting of methyl, methoxy,chloro, bromo, and fluoro; R^(2a) is independently selected from thegroup consisting of methyl, methoxy, chloro, bromo, and fluoro; R^(2b)is independently selected from the group consisting of hydrogen, methyl,methoxy, chloro, bromo, and fluoro; and R^(2c) is independently selectedfrom the group consisting of hydrogen, methyl, methoxy, chloro, bromo,and fluoro.
 5. A pharmaceutical composition comprising a compound,pharmaceutically-acceptable salt or tautomer according to any one ofclaims 1, 2, 3, and 4 and a pharmaceutically acceptable carrier,adjuvant, or diluent.
 6. The compound, pharmaceutically-acceptable saltor tautomer of claim 4, wherein R^(1a) is methyl; and R^(1b) is methyl.7. The compound, pharmaceutically-acceptable salt or tautomer of claim 4wherein R^(2b) is selected from the group consisting of chloro, bromo,and fluoro.
 8. The compound, pharmaceutically-acceptable salt ortautomer of claim 6 wherein R^(2b) is selected from the group consistingof chloro, bromo, and fluoro.
 9. The compound of claim 3 comprising1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine.